
<html lang="en"     class="pb-page"  data-request-id="5b124479-57ca-41de-8c6c-2652801c7b21"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b01751;issue:issue:10.1021/jmcmar.2018.61.issue-6;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="4-Amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure–Activity Relationships" /></meta><meta name="dc.Creator" content="Richard S.  Roberts" /></meta><meta name="dc.Creator" content="Sara  Sevilla" /></meta><meta name="dc.Creator" content="Manel  Ferrer" /></meta><meta name="dc.Creator" content="Joan  Taltavull" /></meta><meta name="dc.Creator" content="Begoña  Hernández" /></meta><meta name="dc.Creator" content="Victor  Segarra" /></meta><meta name="dc.Creator" content="Jordi  Gràcia" /></meta><meta name="dc.Creator" content="Martin D.  Lehner" /></meta><meta name="dc.Creator" content="Amadeu  Gavaldà" /></meta><meta name="dc.Creator" content="Miriam  Andrés" /></meta><meta name="dc.Creator" content="Judit  Cabedo" /></meta><meta name="dc.Creator" content="Dolors  Vilella" /></meta><meta name="dc.Creator" content="Peter  Eichhorn" /></meta><meta name="dc.Creator" content="Elena  Calama" /></meta><meta name="dc.Creator" content="Carla  Carcasona" /></meta><meta name="dc.Creator" content="Montserrat  Miralpeix" /></meta><meta name="dc.Description" content="Rational design of a novel template of naphthyridinones rapidly led to PDE4 inhibitors with subnanomolar enzymatic potencies. X-ray crystallography confirmed the binding mode of this novel template..." /></meta><meta name="Description" content="Rational design of a novel template of naphthyridinones rapidly led to PDE4 inhibitors with subnanomolar enzymatic potencies. X-ray crystallography confirmed the binding mode of this novel template..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 5, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01751" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01751" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01751" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01751" /></link>
        
    
    

<title>4-Amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure–Activity Relationships | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01751" /></meta><meta property="og:title" content="4-Amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure–Activity Relationships" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0024.jpeg" /></meta><meta property="og:description" content="Rational design of a novel template of naphthyridinones rapidly led to PDE4 inhibitors with subnanomolar enzymatic potencies. X-ray crystallography confirmed the binding mode of this novel template. We achieved compounds with double-digit picomolar enzymatic potencies through further structure-based design by targeting both the PDE4 enzyme metal-binding pocket and occupying the solvent-filled pocket. A strategy for lung retention and long duration of action based on low aqueous solubility was followed. In vivo efficacies were measured in a rat lung neutrophilia model by suspension microspray and dry powder administration. Suspension microspray of potent compounds showed in vivo efficacy with a clear dose–response. Despite sustained lung levels, dry powder administration performed much less well and without proper dose–response, highlighting clear differences between the two formulations. This indicates a deficiency in the low aqueous solubility strategy for long duration lung efficacy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01751"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01751">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01751&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01751&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01751&amp;href=/doi/10.1021/acs.jmedchem.7b01751" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2472-2489</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01648" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01752" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">4-Amino-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure–Activity Relationships</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Richard S. Roberts</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard S. Roberts</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#582a313b33762b762a373a3d2a2c2b183f35393134763b3735"><span class="__cf_email__" data-cfemail="b8cad1dbd396cb96cad7daddcacccbf8dfd5d9d1d496dbd7d5">[email protected]</span></a>. Tel: +34 699 420 353.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+S.++Roberts">Richard S. Roberts</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2343-6301" title="Orcid link">http://orcid.org/0000-0003-2343-6301</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sara Sevilla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sara Sevilla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sara++Sevilla">Sara Sevilla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manel Ferrer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manel Ferrer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manel++Ferrer">Manel Ferrer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joan Taltavull</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joan Taltavull</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joan++Taltavull">Joan Taltavull</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5199-5349" title="Orcid link">http://orcid.org/0000-0002-5199-5349</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Begoña Hernández</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Begoña Hernández</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bego%C3%B1a++Hern%C3%A1ndez">Begoña Hernández</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Victor Segarra</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Victor Segarra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Victor++Segarra">Victor Segarra</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jordi Gràcia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jordi Gràcia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jordi++Gr%C3%A0cia">Jordi Gràcia</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7470-6933" title="Orcid link">http://orcid.org/0000-0002-7470-6933</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin D. Lehner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin D. Lehner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bionorica SE, Kerschensteinerstraße 11-15, 92318 Neumarkt, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin+D.++Lehner">Martin D. Lehner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amadeu Gavaldà</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amadeu Gavaldà</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Dermatology†, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amadeu++Gavald%C3%A0">Amadeu Gavaldà</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Miriam Andrés</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Miriam Andrés</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Miriam++Andr%C3%A9s">Miriam Andrés</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Judit Cabedo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Judit Cabedo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Judit++Cabedo">Judit Cabedo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dolors Vilella</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dolors Vilella</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dolors++Vilella">Dolors Vilella</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Eichhorn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Eichhorn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacokinetics & Metabolism†, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Eichhorn">Peter Eichhorn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elena Calama</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elena Calama</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Dermatology†, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Calama">Elena Calama</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carla Carcasona</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carla Carcasona</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Dermatology†, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carla++Carcasona">Carla Carcasona</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Montserrat Miralpeix</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Montserrat Miralpeix</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry & Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Montserrat++Miralpeix">Montserrat Miralpeix</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01751&amp;href=/doi/10.1021%2Facs.jmedchem.7b01751" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2472–2489</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 5, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 December 2017</li><li><span class="item_label"><b>Published</b> online</span>5 March 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 March 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01751" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01751</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2472%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRichard%2BS.%2BRoberts%252C%2BSara%2BSevilla%252C%2BManel%2BFerrer%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D6%26contentID%3Dacs.jmedchem.7b01751%26title%3D4-Amino-7%252C8-dihydro-1%252C6-naphthyridin-5%25286H%2529-ones%2Bas%2BInhaled%2BPhosphodiesterase%2BType%2B4%2B%2528PDE4%2529%2BInhibitors%253A%2BStructural%2BBiology%2Band%2BStructure%25E2%2580%2593Activity%2BRelationships%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2489%26publicationDate%3DMarch%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01751"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1654</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01751" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;4-Amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure–Activity Relationships&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;S. Roberts&quot;},{&quot;first_name&quot;:&quot;Sara&quot;,&quot;last_name&quot;:&quot;Sevilla&quot;},{&quot;first_name&quot;:&quot;Manel&quot;,&quot;last_name&quot;:&quot;Ferrer&quot;},{&quot;first_name&quot;:&quot;Joan&quot;,&quot;last_name&quot;:&quot;Taltavull&quot;},{&quot;first_name&quot;:&quot;Begoña&quot;,&quot;last_name&quot;:&quot;Hernández&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;Segarra&quot;},{&quot;first_name&quot;:&quot;Jordi&quot;,&quot;last_name&quot;:&quot;Gràcia&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;D. Lehner&quot;},{&quot;first_name&quot;:&quot;Amadeu&quot;,&quot;last_name&quot;:&quot;Gavaldà&quot;},{&quot;first_name&quot;:&quot;Miriam&quot;,&quot;last_name&quot;:&quot;Andrés&quot;},{&quot;first_name&quot;:&quot;Judit&quot;,&quot;last_name&quot;:&quot;Cabedo&quot;},{&quot;first_name&quot;:&quot;Dolors&quot;,&quot;last_name&quot;:&quot;Vilella&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Eichhorn&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Calama&quot;},{&quot;first_name&quot;:&quot;Carla&quot;,&quot;last_name&quot;:&quot;Carcasona&quot;},{&quot;first_name&quot;:&quot;Montserrat&quot;,&quot;last_name&quot;:&quot;Miralpeix&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;2472-2489&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01751&quot;},&quot;abstract&quot;:&quot;Rational design of a novel template of naphthyridinones rapidly led to PDE4 inhibitors with subnanomolar enzymatic potencies. X-ray crystallography confirmed the binding mode of this novel template. We achieved compounds with double-digit picomolar enzymatic potencies through further structure-based design by targeting both the PDE4 enzyme metal-binding pocket and occupying the solvent-filled pocket. A strategy for lung retention and long duration of action based on low aqueous solubility was followed. In vivo efficacies were measured in a rat lung neutrophilia model by suspension microspray and dry powder administration. Suspension microspray of potent compounds showed in vivo efficacy with a clear dose–response. Despite sustained lung levels, dry powder administration performed much less well and without proper dose–response, highlighting clear differences between the two formulations. This indicates a deficiency in the low aqueous solubility strategy for long duration lung efficacy.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01751&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01751" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01751&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01751" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01751&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01751" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01751&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01751&amp;href=/doi/10.1021/acs.jmedchem.7b01751" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01751" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01751" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01751%26sid%3Dliteratum%253Aachs%26pmid%3D29502405%26genre%3Darticle%26aulast%3DRoberts%26date%3D2018%26atitle%3D4-Amino-7%252C8-dihydro-1%252C6-naphthyridin-5%25286H%2529-ones%2Bas%2BInhaled%2BPhosphodiesterase%2BType%2B4%2B%2528PDE4%2529%2BInhibitors%253A%2BStructural%2BBiology%2Band%2BStructure%25E2%2580%2593Activity%2BRelationships%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D6%26spage%3D2472%26epage%3D2489%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=290797" title="Metals">Metals</a>,</li><li><a href="/action/doSearch?ConceptID=291465" title="Structure activity relationship">Structure activity relationship</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/jmcmar.2018.61.issue-6/20180322/jmcmar.2018.61.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Rational design of a novel template of naphthyridinones rapidly led to PDE4 inhibitors with subnanomolar enzymatic potencies. X-ray crystallography confirmed the binding mode of this novel template. We achieved compounds with double-digit picomolar enzymatic potencies through further structure-based design by targeting both the PDE4 enzyme metal-binding pocket and occupying the solvent-filled pocket. A strategy for lung retention and long duration of action based on low aqueous solubility was followed. <i>In vivo</i> efficacies were measured in a rat lung neutrophilia model by suspension microspray and dry powder administration. Suspension microspray of potent compounds showed <i>in vivo</i> efficacy with a clear dose–response. Despite sustained lung levels, dry powder administration performed much less well and without proper dose–response, highlighting clear differences between the two formulations. This indicates a deficiency in the low aqueous solubility strategy for long duration lung efficacy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cyclic nucleotide adenosine monophosphate (cAMP) is a ubiquitous secondary messenger involved in a range of cellular responses to biological agents brought about through activation of adenylyl cyclase. Intracellular levels of cAMP are tightly controlled by a family of cyclic nucleotide degrading enzymes, the phosphodiesterases (PDEs). The PDEs are therefore implicated in the control of many biological processes.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> We were particularly interested in the inflammatory responses modulated by PDE4, especially with respect to chronic obstructive pulmonary disease (COPD). Research into PDE4 inhibitors is decades old, and the recent successful launches of the inhibitors roflumilast (Daliresp <b>1</b>) for the oral treatment of COPD and apremilast (Otezla <b>2</b>) for the oral treatment of psoriasis have been long-awaited in the field (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). PDE4 is therefore still an active target for research, and several reviews on the development of PDE4 inhibitor clinical candidates are available.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9">(5−9)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures and affinities<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> of approved oral drugs roflumilast <b>1</b> and apremilast <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite these successes, cardiac and emetic side effects are prevalent. PDE4 has four isotypes, PDE4A–D. PDE4B is linked to the anti-inflammatory effects,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> while the side effects are attributed to PDE4D.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> X-ray crystallography has facilitated the understanding of the catalytic domains of PDE4A–D.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> It has also revealed that the four isoforms show little difference in their active sites, and as a result, few isoform-selective compounds exist.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Therefore, to minimize the potential systemic side effects of PDE4, and with special relevant to respiratory diseases, we and many others have turned to inhaled delivery to the lung.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p last">The molecular design of compounds for inhaled delivery has advanced significantly over the past few years.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The lung is a highly perfused organ, and so, highly soluble and permeable compounds, properties that desirable for oral administration, are readily absorbed systemically and therefore of little use as compounds to target the lungs. Inhaled compounds need to stay localized in the lungs and respiratory tract, and so, strategies of reduced aqueous solubility and/or increased tissue binding are common.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> Reducing systemic exposure through high clearance can help improve the safety profile of compounds: “soft-drugs” incorporate metabolically labile groups, susceptible to either plasma hydrolysis or hepatic oxidative phase I or conjugative phase II metabolism.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> A further approach is to incorporate slow binding kinetics and to dissociate the pharmacodynamics (PD) effect from the pharmacokinetic (PK) profile.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> Finally, since the dose of compound that can be administered to the lung is limited, often to a milligram or less in humans,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> compounds should be as potent as possible. Molecular properties addressing these issues can, and probably should, therefore, deviate from properties that are desirable for oral compounds. Since PDE4 is an intracellular target, molecular properties should still be controlled to some degree as cellular permeability is necessary for efficacy, and whole-cell assays should be employed to detect any such deficiencies in permeation and target access.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85672" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85672" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design of the Inhibitors</h3><div class="NLM_p">Here, we describe our efforts to discover novel, highly potent (subnanomolar), inhaled inhibitors of PDE4 for the treatment of COPD. We were drawn to the series of quinolines from GSK, which showed extremely high potency and had physicochemical properties aligned with inhaled delivery. Quinoline <b>3</b> (GSK256066) reached phase II clinical trials for the inhaled treatment of respiratory disorders.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In addition, the crystal structure of <b>3</b> bound to the catalytic site of PDE4B2B has been published (pdb code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwt">3gwt</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> From our own extensive oral PDE4 program we also had obtained crystal structure data for a series of pyridazinone compounds such as <b>4</b> (bound to PDE4D, pdb code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k1i">5k1i</a>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of the X-ray structures of <b>4</b> (colored by element, pdb code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5kli">5kli</a>) and inhaled clinical candidate GSK256066 <b>3</b> (in blue, pdb code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwt">3gwt</a>). Only glutamine-369 and the two metal ions (magnesium in green, zinc in gray) of the PDE4D enzyme are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">So, once we overlaid the crystal structure of <b>4</b> with that published for the quinoline <b>3</b>, we could design a new chemical family, the naphthyridinones (NAPs) <b>5</b>. We envisaged rapid entry to a new series, taking advantage of the precedent for inhaled delivery of <b>3</b> and the known structure–activity relationship (SAR) from both families but in an unexploited chemical space with fast synthetic access to compounds with widespread physicochemical properties as desired (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Conceptual design and interactions of the naphthyridinone (NAP) series. Active site regions are defined as follows with respect to the cartoon view above: [1] The pi-clamp region (between Phe-372 and Phe-340). [2] The “glutamine switch” glutamine-369.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> [3] The small lipophilic pocket. [4] The large lipophilic pocket. [5] The metal binding zone containing the zinc and magnesium ions responsible for the catalytic activity. [6] The solvent exposed pocket; in the full PDE4 isoenzyme, the helices of the upstream conserved region (UCR2), a negative regulator of cAMP hydrolysis, partially fill this area.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In truncated protein sequences, coding only for the PDE4 active site, this zone is exposed to the bulk solvent, hence the name.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In our design, the aryl-amino-heteroaryl motif (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, in green) was conserved across the three families. The rigid core of the NAPs would slot into the pi-clamp region [1] with the 4-aminopyridine motif acting as a powerful H-bond acceptor for the glutamine switch [2]. The lactam portion of the NAP would both fill the small lipophilic pocket [3] and be a H-bond donor to interact with Asn-321 in the floor of the active site, as for the quinoline <b>3</b>. We could also take advantage of our own internal SAR of the pyridazinone series: first for the metal binding zone [5] and second for the substitution in the NAP 2-position, filling the large lipophilic pocket [4] and allowing access to the solvent-filled pocket [6].</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthesis of the Inhibitors</h3><div class="NLM_p">The synthesis of the NAPs has been described previously, as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Briefly, beta-amino acids <b>6</b> were condensed with Meldrum’s acid, and the resulting tricarbonyl compounds <b>7</b> were thermally cyclized to give Boc-protected piperidinediones <b>8</b>. Condensation with carbon disulfide and trapping with methyl iodide gave the ketene dithioacetals <b>9</b>. The key sequence of the synthesis was the Michael addition of an acetophenone enolate (<b>9</b> → <b>10</b>) and subsequent condensation–cyclization with ammonia to form the core of the NAP <b>11</b> and with a functionalized handle to introduce the 4-amino substituent. Yields were at best 50% in this sequence <b>9</b> → <b>11</b>: the two methylthio groups of <b>9</b> were of equal reactivity, but only displacement of the methylthiol group <i>cis</i> to the piperidinedione ketone carbonyl (<b>9</b> → <b>10</b>) led to correct cyclization and pyridine formation. Nevertheless, the route was sufficiently robust to allow large quantities of sulfides <b>11</b> to be synthesized. The sulfides <b>11</b> were oxidized to the sulfones <b>12</b> to increase the reactivity of the leaving group. Finalization of the synthesis to the desired NAPs <b>5</b> could be carried out in one of two ways. In the first case, the sulfones were thermally displaced directly with the appropriate amine or aniline. When the displacement was carried out in refluxing ethanol, the Boc protecting group remained largely intact, so this was removed under acidic conditions with a final treatment with trifluoroacetic acid (TFA) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>f). Alternatively, the Boc group could be removed thermally, under microwave irradiation at 160 °C (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>g). Despite liberating carbon dioxide under sealed tube conditions, the increase in pressure was well within the tolerability of the microwave apparatus. For poorly reactive amines, we moved directly to microwave irradiation to carry out the amide displacement and Boc deprotection in one step (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>h). In the second route, Boc deprotection of sulfone <b>12</b> and displacement of the sulfone with ammonia gave versatile intermediate <b>13</b>, which allowed introduction of a range of R<sup>2</sup>-substituents via palladium-catalyzed <i>N</i>-arylations (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>i–k). Despite the moderate-to-low yields of the key cyclization sequence <b>9</b> → <b>11</b>, the modular synthesis allowed us rapid access to a range of substituents to systematically probe the SAR of each position in turn.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route to Naphthyridinones <b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DCC, DMAP, DCM, 5 °C, 94% yield; (b) EtOAc, reflux, 83% yield; (c) CS<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt then MeI, DMF, 70% yield; (d) R<sup>1</sup>COMe, <i>t</i>BuOK, DMSO, THF, rt, 3 h, then NH<sub>4</sub>OAc, AcOH, 90 °C, 6–55% yield; (e) mCPBA, DCM, 5 °C, 77–100% yield; (f) R<sup>2</sup>NH<sub>2</sub>, EtOH, reflux, then TFA, DCM, rt if necessary, 20–62% yield; (g) R<sup>2</sup>NH<sub>2</sub>, EtOH, reflux, then 160 °C (microwave), 0.5 h, 14–51% yield; (h) R<sup>2</sup>NH<sub>2</sub>, EtOH, 160 °C (microwave), 0.5–18 h, 7–83% yield; (i) TFA, DCM, rt; (j) NH<sub>3</sub> (7 N MeOH), 140 °C (microwave), 67–97% yield over two steps; (k) R<sup>2</sup>Hal, Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, dioxane, 90 °C, 28–41% yield.</p></p></figure><div class="NLM_p">A biaryl substitution pattern in the NAP R<sup>1</sup> position was of particular interest. These compounds <b>17</b> were synthesized according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. 3-Bromo-NAPs <b>14</b> were simply extended via Suzuki reaction to give biphenyls <b>17</b>. Thioethers were also accessible from the same intermediate <b>14</b>. Alternatively, intermediate <b>15</b> was first coupled via Suzuki reaction, and the resulting amines <b>16</b> were <i>N</i>-arylated as before.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Route to R<sup>3</sup>-Aryl Substituted Naphthyridinones <b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) R<sup>3</sup>Hal, Cs<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, dioxane, 90 °C, 4–80% yield from <b>14</b>, 41–95% yield from <b>15</b>; (b) thiol, Pd(PPh<sub>3</sub>)<sub>4</sub>, Bu<sub>3</sub>SnOMe, xylene, reflux, 64% yield; (c) R<sup>2</sup>Hal, Cs<sub>1k</sub>O<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, dioxane, 90 °C, 9–64% yield.</p></p></figure><div class="NLM_p">Deep-reaching NAPs, to study the binding interactions with the floor of the active site, were synthesized as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. NAP compounds <b>5</b> were converted to their corresponding thiolactams <b>18</b> with phosphorus pentasulfide. <i>S</i>-Alkylation with methyl iodide (<b>19</b>) and displacement with hydroxylamine or cyanamide gave access to the desired amidoximes and cyanoamidates <b>20</b>, respectively.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthetic Route to Carbonyl-Variant Naphthyridinones <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) P<sub>4</sub>S<sub>10</sub>, iPrNEt<sub>2</sub>, dioxane, 90 °C, 18 h, 58–99% yield; (b) NaH, MeI, DMF, 60 °C, 3 h, 81–82% yield; (c) NH<sub>2</sub>OH·HCl, K<sub>2</sub>CO<sub>3</sub>, EtOH, 70 °C, 18 h, 23% yield; (d) NH<sub>2</sub>CN, EtOH or THF, 70 °C, 1–2 h, 26–51% yield.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> X-ray Binding Mode of Naphthyridinones</h3><div class="NLM_p">Following the synthetic routes outlined above, the first simple NAP <b>21</b> was synthesized and was highly potent with an IC<sub>50</sub> of 1.6 nM against PDE4B1, corresponding to a high ligand efficiency<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (LE) of 0.46.</div><div class="NLM_p">The proposed binding mode of NAP <b>21</b>, as outlined in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, was confirmed by X-ray crystallography (pdb code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k32">5k32</a>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In addition to the expected interactions, the 3-methoxyaniline substituent was held in place by an intramolecular hydrogen bond between the aniline NH and the lactam carbonyl. The NAP lactam N–H formed a hydrogen bond directly to the side chain of Asn-321 (at 2.7 Å) in the floor of the binding pocket. The lactam also took part in a hydrogen-bonding network with the floor of the binding pocket via a water molecule at 2.5 Å from the lactam carbonyl. In the metal-binding zone, the 3-methoxy group hydrogen bonded (at 3.1 Å) with one of the water molecules in the outer coordination shell of the magnesium ion.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray structure of first synthesized NAP <b>21</b> bound to the active site of PDE4D (magnesium, green sphere; zinc, gray; pdb code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k32">5k32</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> PDE4 Inhibitory Activity and Structure–Activity Relationships</h3><div class="NLM_p">With the molecular design of the NAPs validated, we expanded the SAR in both the metal binding zone and the large lipophilic/solvent-exposed pocket (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). Compounds were typically tested in two assays. In the first assay, we measured enzyme binding potency through the inhibition of radiolabeled [<sup>3</sup>H]-cAMP hydrolysis from the human PDE4B1 construct. As PDE4 is an intracellular target, for many compounds we also measured functional inhibition in the production of tumor necrosis factor alpha (TNFα) from peripheral blood mononucleated cells (PBMCs).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. R<sup>1</sup> Ring Substituent SAR in the Large Lipophilic Pocket<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0010.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0011.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">n.d., not determined. All experimental data <i>n</i> ≥ 2. pIC<sub>50</sub> SD ± < 0.2. Data shown to two significant figures.</p></div></div><div></div></div><div class="NLM_p">We first varied the monocyclic ring in the R<sup>1</sup> position in the large lipophilic pocket with simple substitutions available from acetophenone building blocks (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In general, little difference was observed in the potency but with two exceptions: the 2-methoxy group (<b>24</b>) lost over 10-fold potency, undoubtedly due to a greater twist in the biaryl bond. Pyridyl (<b>25</b>) was well-tolerated; however, the <i>N</i>-oxide <b>26</b> (a synthetic byproduct formed during the sulfide to sulfone oxidation step) was not. Clearly, the large lipophilic pocket craves lipophilic groups. Cyclopropyl (<b>27</b>) was also tolerated, but other aliphatic R<sup>1</sup> groups were not followed up. Since the R<sup>1</sup> group was introduced from a methyl ketone (see <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, step (d)), enolization of aliphatic methyl ketones would occur in both directions, and mixtures of two regioisomers would occur. Both compounds <b>21</b> and <b>25</b> displayed similar potencies in the enzymatic assay and the functional cellular assay, indicative of an effective cell permeability. The permeability of compound <b>21</b> was measured at 2 × 10<sup>–6</sup> cm/s by parallel artificial membrane permeability assay (PAMPA).</div><div class="NLM_p">We also extended the R<sup>1</sup> monocycle to a series of biphenyl groups (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Here the intention was often 2-fold: access the solvent filled pocket with hydrophilic groups and use these groups as metabolic handles for glucuronidation. We derived the meta-substitution pattern from known SAR of our internal PYR series.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Biaryl-substituted NAP <b>28</b> had a potency of 0.35 nM, further validating our design hypothesis and confirming a close analogy between the PYR and the NAP series.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. R<sup>3</sup> Biaryl Substituent SAR Towards the Solvent Exposed Pocket<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0012.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0013.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">All experimental data <i>n</i> ≥ 2. pIC<sub>50</sub> SD ± < 0.2. Data shown to two significant figures.</p></div></div><div></div></div><div class="NLM_p">Biaryl substituted compound acid <b>28</b> was subnanomolar in the enzymatic assay. However, this compound showed a 16-fold loss of potency in the cellular assay. Compound <b>28</b> showed an acceptable permeability of 3.5 × 10<sup>–6</sup> cm/s as measured by the PAMPA assay. Another acid compound, <b>30</b>, also displayed this loss of potency between the enzymatic and cellular assays. Other factors could be responsible for the loss of activity, for example, active transport, not contemplated in the PAMPA assay. This was not investigated further, but we took the shift in potencies as a warning not to proceed with acidic compounds. This shift could be avoided by using the esters <b>29</b> and <b>31</b>, respectively. However, to avoid the complications associated with pharmacologically active prodrugs, we dropped this line of research. A series of amides also gave potent compounds. Amide <b>34</b> demonstrated that large groups could be introduced while maintaining enzymatic potency and could be applicable to the modulation of physical chemical properties at a later date. Cyclopropylamide <b>33</b> was particularly effective and showed subnanomolar cellular potency. Phenol (<b>35</b>) and thioether (<b>36</b>) could also be introduced but with no impact on potency compared to <b>28</b>.</div><div class="NLM_p">The X-ray structure of NAP <b>21</b> showed the 3-methoxyphenyl R<sup>2</sup> substituent was directed toward the metal binding zone of PDE4, making a hydrogen bond to one of the water molecules in the outer coordination sphere of the magnesium ion. A similar interaction was observed from the benzoic acid group of our pyridazinone <b>4</b> (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k1i">5k1i</a>). Many enzymes, particularly the hydrolase family, possess metal ions in their active sites. Metal binding groups, such as thiols, hydroxamic acids, and other bidentate ligands are often used to obtain high affinity inhibitors. However, the common mechanism of metal chelation of these compounds can also lead to a lack of selectivity across this family of enzymes. Through our NAP ligand design, we were not especially troubled by this possibility: first, the metal-binding group was designed to target either the outer or inner hydration sphere of the metals, not the metal atoms themselves. Second, a large proportion of the binding affinity of our ligands came from the NAP core structure (see zones [1]–[4], <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Nonselective interactions with other metal-containing enzymes not possessing this specific recognition pattern would therefore be much less potent.</div><div class="NLM_p">With plenty of opportunity to vary the strength and direction of the hydrogen bonds in that zone, we synthesized a series of analogues. The SAR was reasonably flat (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), with no significant increase of affinity over <b>21</b>. An aromatic ring was at least necessary, as demonstrated by the poor activity of truncated amine <b>37</b>. Interestingly, despite the drop in potency this compound still maintained a ligand efficiency (LE) of 0.43, little changed from the LE of 0.46 for <b>21</b>. Compound <b>37</b> could therefore be considered as an efficient fragment for PDE4 and validation that the NAP core provided much of the binding energy of the whole compound. For the remainder of the changes, small substituents <b>38</b>–<b>39</b>, alcohols <b>40</b>–<b>42</b>, acid <b>43</b>, amides <b>44</b>–<b>45</b>, and pyridines <b>46</b>–<b>48</b> in general showed potencies within an order of magnitude of the first NAP <b>21</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. R<sup>2</sup> Monocyclic Amine SAR in the Metal Binding Zone<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0014.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0015.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">n.d., not determined. All experimental data <i>n</i> ≥ 2. pIC<sub>50</sub> SD ± < 0.2. Data shown to two significant figures.</p></div></div><div></div></div><div class="NLM_p">We also synthesized bicyclic metal binding groups (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Plain naphthyl (<b>49</b>) lost potency, showing that at least some kind of polar substituent was beneficial. The series of quinoline analogues <b>50</b>–<b>52</b> showed that the location of this polarity did have some impact. Quinoline <b>50</b> was the first compound with subnanomolar potency for both the enzymatic and the cellular assays. Pyrazolopyridines <b>53</b>–<b>55</b>, designed to maintain the same interaction as quinoline <b>50</b>, lost potency. Finally, quinoline <i>N</i>-oxide <b>56</b> provided a final small increase of potency in both enzymatic and cellular assays. Ligand efficiency of <b>56</b> was still high at 0.44.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. R<sup>2</sup> Bicyclic Amine SAR in the Metal Binding Zone<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0016.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0017.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">n.d., not determined. All experimental data <i>n</i> ≥ 2. pIC<sub>50</sub> SD ± < 0.2. Data shown to two significant figures.</p></div></div><div></div></div><div class="NLM_p">Two other areas were briefly explored: the 3-position of the NAP core and the small lipophilic pocket (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Pyrimidine analogue <b>57</b> was synthesized in a variation of <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, replacing the acetophenone enolate of step (d) with phenylamidine. Nitrogen at the 3-position of the NAP core lost potency, possibly because of the weaker hydrogen bonding potential of a 4-aminopyrimidine versus a 4-aminopyridine. Similar structures have been reported with potencies also generally in the double-digit nanomolar range.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In the small lipophilic pocket, the role of the C7–C8 ethylene unit of the NAP core was identified. 7-Methyl (<b>58</b>) and 8-methyl (<b>59</b>) analogues of <b>21</b> were synthesized from the appropriate beta-amino acids according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> (in 4% and 15% overall yield, respectively). Methyl substitution of these positions resulted in a 70- and 400-fold drop in potency, respectively, indicating a close fit to the small lipophilic pocket in the initial design. The lipophilic nature of the ethylene unit to fill the small lipophilic pocket was also evident: open amide structures <b>60</b> and <b>61</b> lost between 30- and 150-fold potency with respect to their NAP counterparts (<b>60</b> ↔ <b>21</b> and <b>61</b> ↔ <b>50</b>, respectively).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The methyl amide <b>62</b> essentially lost all potency; the favored conformation of the amide would direct the methyl group into the floor of the binding site, thus dislodging the rest of the structure from its ideal fitting position. Hence, the initial NAP core design was optimal.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Core Variations<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0018.gif" alt="" id="fx9" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>No</b></th><th class="colsep0 rowsep0" align="center"><b>PDE4B IC</b><sub><b>50</b></sub><b>(nM)</b></th><th class="colsep0 rowsep0" align="center"><b>TNFα IC</b><sub><b>50</b></sub><b>(nM)</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="center">1.6</td><td class="colsep0 rowsep0" align="center">5.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="center">52</td><td class="colsep0 rowsep0" align="center">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="center">120</td><td class="colsep0 rowsep0" align="center">270</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="center">640</td><td class="colsep0 rowsep0" align="center">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="center">240</td><td class="colsep0 rowsep0" align="center">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="center">5800</td><td class="colsep0 rowsep0" align="center">n.d.</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">n.d., not determined. All experimental data <i>n</i> ≥ 2. pIC<sub>50</sub> SD ± < 0.2. Data shown to two significant figures.</p></div></div></div><div class="NLM_p">We also extended the NAP lactam group down to the floor of the PDE4 binding site. Displacement of energetically unfavored water molecules from binding sites can add significant binging affinity, although our approach was done empirically, without applying any of the sophisticated methods for analyzing water molecules.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The X-ray crystal structure of NAP <b>21</b> showed just a single water molecule between the NAP and the wall of the large lipophilic region, indicating an already close fit (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). However, this water molecule forms a stable H-bonded network between an NH of Gln-369 and the backbone carbonyl of Val-365. We instead targeted the water molecule located at 2.5 Å from the NAP carbonyl (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Our approach was to extend the structure down from the NAP carbonyl to leave a polar atom where the water molecule should be.</div><div class="NLM_p">Some example lactam-containing NAPs were converted to their extended analogues following the steps of <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> (<b>24</b> → <b>63</b> and <b>64</b>, <b>65</b> → <b>66</b>, respectively). NAP Hydroxyamidine <b>63</b> (N–O bond length typically 1.3 Å) was, as expected, a bond too short and, whether by a steric clash with the trapped water molecule or by leaving a high-energy gap between its hydroxyl group and Asn-321, lost three orders of magnitude of potency with respect to the parent NAP <b>24</b>. The NAP cyanoamidines <b>64</b> and <b>66</b> were much more promising (N–C≡N typically 2.5 Å long). While they effectively maintained the enzymatic potency of their NAP lactam analogues, <b>66</b> showed some cellular drop-off, so these compounds were not explored further (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Carbonyl-Variant NAPs To Displace a Deep Water Molecule<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0020.gif" alt="" id="fx10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0021.gif" alt="" id="fx11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">n.d., not determined. All experimental data <i>n</i> ≥ 2. pIC<sub>50</sub> SD ± < 0.2. Data shown to two significant figures.</p></div></div><div></div></div><div class="NLM_p">Finally, some of the best groups of the R<sup>2</sup> and R<sup>3</sup> substituents were combined, and the SAR was suitably additive (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Many of the compounds showed subnanomolar potencies in both enzymatic and cellular assays. Of particular interest, quinoline <b>72</b> and its <i>N</i>-oxide <b>73</b> combined the best R<sup>2</sup> and R<sup>3</sup> substituents from <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Quinoline <b>72</b> was 170 pM in enzymatic and 120 pM in the cellular assay. <i>N</i>-Oxide <b>73</b> was the most potent compound of the series with IC<sub>50</sub> 45 pM in the enzymatic and 75 pM in the cellular assay. This <i>in vitro</i> activity is comparable to the best compounds of our previous PYR series,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> from which the selection of the R<sup>2</sup> and R<sup>3</sup> groups of the NAPs were derived.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. SAR with Combinations of R<sup>2</sup> and R<sup>3</sup><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0022.gif" alt="" id="fx12" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0023.gif" alt="" id="fx13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">All experimental data <i>n</i> ≥ 2. pIC<sub>50</sub> SD ± < 0.2. Data shown to two significant figures.</p></div></div><div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Lung PK and <i>in Vivo</i> Neutrophilia in Rats</h3><div class="NLM_p">From the series of NAPs, compound <b>72</b> was selected for further profiling, both <i>in vitro</i> and <i>in vivo</i>, due to its excellent cellular potency in the TNFα assay and to allow like-for-like comparison with other in-house compounds from the PYR series (unpublished results). Permeability of <b>72</b> was modest (PAMPA P<sub>app</sub> 0.15 × 10<sup>–6</sup> cm/s). Following our strategy for low aqueous solubility, thermodynamic solubility for <b>72</b> was low (4 μg/mL at 37 °C) but comparable to GSK compound <b>3</b> (19 μg/mL at 37 °C) and higher than that published for roflumilast (0.52 μg/mL at 22 °C).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Compound <b>72</b> was selective against several other phosphodiesterases and in a counter-screen of 30 kinases (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01751/suppl_file/jm7b01751_si_001.pdf" class="ext-link">Supporting Information Table S2</a>). Pharmacokinetic data is shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Intravenous rat PK at 500 μg/kg showed a moderate-to-high volume of distribution (3.9 L/kg) and a desirably high systemic clearance of around hepatic blood flow (79 mL/min/kg). Intratracheal PK in rats using dry powder at 1000 μg/kg (5% w/w with lactose) showed a prolonged exposure. The percentage of the total administered dose present in the lungs reached a maximum of 36% and dropped to 15% over a 24 h period, based on compound recovered from lung biopsies. Corresponding plasma levels measured after intratracheal dosing were around or below the level of quantification (<5 ng/mL) up to 1 h postdose, and undetectable after that (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PK profiles of compound <b>72</b> in rat. (a) i.v. dose = 500 μg/kg. (b) i.t. dose of dry powder = 1000 μg/kg, as a 5% w/w mixture with lactose. Percentages in the i.t. PK graph refer to the percentage of the total dose (250 μg compound/animal) recovered from the lungs by methanol extraction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>72</b> was tested in a rat lipopolysaccharide (LPS)-induced neutrophilia model, measuring the inhibition of increase of neutrophils in the bronchoalveolar lavage (BAL) fluid. Compounds were prepared in aqueous suspension and administered intratracheally by microspray using the Penn–Century device. Animals were challenged 1 h later with nebulized LPS, with the neutrophilia readout 4 h later, i.e., a total of 5 h after test compound administration. Roflumilast <b>1</b> was used as a control, showing a clear dose–response and reaching 80% inhibition at 1000 μg/kg. Compound <b>72</b> also showed a clear dose–response; however, it only reached an inhibition of 58% at 1000 μg/kg (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a). Other compounds were also tested at single doses but showed lower efficacies than <b>72</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01751/suppl_file/jm7b01751_si_001.pdf" class="ext-link">Supporting Information Table S3</a>).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Dose–responses of roflumilast <b>1</b> and compound <b>72</b> in a LPS-induced rat neutrophilia model. Compounds were administered in suspension by intratracheal microspray delivery. (b) Time-course inhibition of LPS-induced rat neutrophilia. Roflumilast <b>1</b> and compound <b>72</b> were given by i.t. administration of dry powder comixed with lactose. n.t.: not tested.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Clinical delivery of inhaled compounds is almost always carried out using a dry powder formulation of active ingredient mixed with a lactose carrier. We also measured inhibition of lung neutrophilia after dry powder i.t. administration of compound <b>72</b> with roflumilast <b>1</b> as control (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b). Both compounds were micronized before comixing with lactose to enhance their kinetic solubility and lung deposition. Compounds were administered with a dry powder insufflator. Animals were again challenged with nebulized LPS 1 or 18 h later, with the neutrophilia readout 4 h later, i.e., a total of 5 or 22 h after test compound administration. Roflumilast again performed well 5 h after dosing, with the inhibition dropping off 22 h postadministration. Compound <b>72</b> showed much more erratic results: a moderate but sustained efficacy at 100 μg/kg, moderate efficacy but short duration at 1000 μg/kg, and a slight improvement of efficacy at 3000 μg/kg at the only tested time of 22 h postdose. Despite extended lung levels of compound <b>72</b>, a maximum of 35% inhibition was seen across this range of doses. The absence of clear dose–responses, either for different doses or at different time-points, shows that other factors are impeding the efficacy of <b>72</b> in the dry powder formulation.</div><div class="NLM_p">The low lung neutrophilia efficacy of compound <b>72</b> after inhaled delivery is probably related to its solubility (thermodynamic solubility 4 μg/mL at 37 °C). Compound <b>72</b> was micronized from its amorphous solid/crystalline state without detailed crystallization experiments and so should represent a more soluble solid form. The separation between lung and plasma levels after i.t. administration is evident of dissolution rate-driven PK (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). Despite the apparently long lung PK profile, the lung levels observed were possibly misleading in that they represent the total amount of compound in the lung. A low solubility may well mean that most of the compound remained undissolved in solid microparticles, or even phagocytosed by macrophages within the lung, and with little of the total compound dissolved and available to inhibit the PDE4 enzymes present. Lung free fraction or <i>ex vivo</i> target engagement studies could have shed more light on this situation.</div><div class="NLM_p">Nondissolving particles in the lung can often lead to irritation and a proinflammatory response. Compound <b>72</b> itself was not proinflammatory; dry powder administration of 1000 or 3000 μg/kg to the lung did not result in an increase in neutrophils in BAL (0.7- and 1.3-fold increase on basal levels observed, respectively, <i>n</i> = 4). However, the sustained PK profile of <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b is not characteristic of an effective dissolution in the lung.</div><div class="NLM_p">Ultimately, in a preliminary safety assay, compound <b>72</b> also produced emesis in ferrets in a dose-dependent manner (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Emetic Events Observed in Ferrets for Compound <b>72</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Dose</b><b>(μg/kg)</b></th><th class="colsep0 rowsep0" align="center"><b>Emesis</b><b>observed</b><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center">0/4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">1/4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">300</td><td class="colsep0 rowsep0" align="center">3/4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Number of animals with emesis/number of animals in study. Compound <b>72</b> was administered intertracheally to ferrets as a dry-powder comixture with lactose. Observation lasted 1 h. The first emetic event in each group occurred within 20 min.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02235" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02235" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We used rational design based on X-ray crystallography to conceive a novel chemical series of PDE4 inhibitors, the naphthyridoinones (NAPs). The first synthesized example <b>21</b> was highly potent at 1.6 nM. A modular chemical synthesis allowed rapid SAR expansion of all substitution positions around the central core. Several examples with subnanomolar potencies both in enzymatic assays and inhibition of TNF-α production in whole cells were found. Compound <b>72</b> was advanced to the <i>in vivo</i> LPS-induced lung neutrophilia in rats. This compound demonstrated a moderate efficacy; however, physicochemical properties seemed to restrict its full potential, especially when dosed as a dry powder formulation. In our other PDE4 series, the pyridazinones,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> we observed superior <i>in vivo</i> results for more soluble compounds, incorporating basic groups to facilitate a long lung duration. We conclude that the low solubility strategy of the NAPs was not ideal: <i>in vivo</i> efficacy was compromised for highly potent <i>in vitro</i> molecules, and erratic kinetic solubility rates can lead to unpredictable or irreproducible results. The NAP series was abandoned at this stage.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45550" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45550" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Chemistry Methods</h3><div class="NLM_p">Reaction products were purified, when necessary, by flash chromatography on silica gel (40–63 μm) with the solvent system indicated. Purifications in reverse phase were made in a Biotage SP1 automated purification system equipped with a C18 column and using a gradient of, unless otherwise stated, water–acetonitrile/MeOH (1:1) (0.1% v/v ammonium formate both phases) from 0% to 100% acetonitrile/MeOH (1:1) in 80 column volumes. Preparative HPLC–MS was performed on a Waters instrument equipped with a 2767 injector/collector, a 2525 binary gradient pump, a 2996 PDA detector, a 515 pump as a makeup pump, and a ZQ4000 Mass spectrometer detector. All test compounds were purified to >95% purity by HPLC UV trace unless otherwise stated.</div><div class="NLM_p"><sup>1</sup>H Nuclear magnetic resonance spectra were recorded on a Gemini 200 MHz spectrometer or a Varian Mercury plus operating at a frequency of 400 MHz. Tetramethylsilane was used as reference. Chemical shifts (δ) are given in ppm to two decimal places. Coupling constants (<i>J</i> values) are given in ppm to one decimal place. The following abbreviations are used: singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin), double doublet (dd), double triplet (dt), triple doublet (td), multiplet (m), broad signal (br. s), apparent (app). Partial refers to spectra where a peak or peaks are obscured under solvent peaks and cannot be assigned. Signals of protons attached to heteroatoms may or may not be present according to solvent conditions. Mass spectra (<i>m</i>/<i>z</i>) were recorded on a Micromass ZMD or in a Waters ZQ mass spectrometer using ESI ionization.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>tert</i>-Butyl [3-(2,2-Dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-3-oxopropyl]carbamate (<b>7</b>)</h4><div class="NLM_p last">Boc-beta alanine (<b>6</b>) (83 g, 0.44 mol) was dissolved in 2.7 L of dichloromethane, which had been previously cooled to 5 °C in the fridge. Meldrum’s acid (66.6 g, 0.46 mol) was added and the mixture shaken to dissolve. 4,4-Dimethylaminopyridine (75 g, 0.61 mol) was added and shaken to dissolve. The solution was left in the fridge for 1 h to cool to approx 5 °C. Dicyclohexylcarbodiimide (100 g, 0.48 mol) was added, the mixture shaken to dissolve, and then left to stand in the fridge (5 °C) for 2 d. The mixture was filtered and the solid washed twice with cold dichloromethane. The combined filtrates were evaporated to approx 700 mL volume. The organics were washed three times with 10% w/v potassium hydrogen sulfate solution, once with brine, and were dried over sodium sulfate. Filtration, evaporation of the filtrate, and re-evaporation from ether gave <b>7</b> as a white solid (136 g, 0.41 mol, 94% yield), HPLC purity 99%. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.43 (s, 9H), 1.75 (s, 6H), 3.30 (t, <i>J</i> = 6.4 Hz, 2H), 3.55 (q, <i>J</i> = 5.9 Hz, 2H), 4.85 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 316 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>tert</i>-Butyl 2,4-Dioxopiperidine-1-carboxylate (<b>8</b>)</h4><div class="NLM_p last">A suspension of <b>7</b> (136 g, 0.41 mol) in 250 mL of ethyl acetate was heated at reflux (bath temperature 120 °C) for 2.5 h. The mixture was allowed to cool and was filtered. The filtrate was evaporated, giving an orange semisolid residue. The residue was dissolved in 200 mL of diisopropyl ether. The volume of solvent was then reduced to around 40 mL, precipitating a yellow solid. The solid was collected by filtration, washed twice with diisopropyl ether, and dried in a stream of air to give <b>8</b> as a pale yellow solid (6.4 g, 30.0 mmol, 62% yield), HPLC purity 100%. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.56 (s, 9H), 2.63 (t, <i>J</i> = 6.1 Hz, 2H), 3.52 (s, 2H), 4.11 (t, <i>J</i> = 5.9 Hz, 2H); MS(ESI) <i>m</i>/<i>z</i> 212 [M – H]<sup>−</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>tert</i>-Butyl 3-[Bis(methylthio)methylene]-2,4-dioxopiperidine-1-carboxylate (<b>9</b>)</h4><div class="NLM_p last">A mixture of <b>8</b> (22.7 g, 106 mmol) and carbon disulfide (14.0 mL, 232 mmol) were dissolved in 180 mL of dry dimethylformamide. Potassium carbonate (31 g, 224 mmol, previously powdered in a mortar) was added and the mixture stirred for 2 h at room temperature, rapidly turning a deep red color. Methyl iodide (14.0 mL, 225 mmol) dissolved in 50 mL of dry dimethylformamide was added to the mixture dropwise and with stirring over 1 h. The solution was cooled during addition using a water bath. Upon addition the mixture was stirred for a further 1 h at room temperature. Four hundred milliliters of water and 200 mL of 4% w/v sodium carbonate solution were added, and the mixture was extracted four times with ether. The combined bright red ether layer was washed with 5% w/v sodium thiosulfate solution and brine and then dried over sodium sulfate. Evaporation of the mixture gave a residue that solidified. The solid was broken up in a little diisopropyl ether and was collected by filtration. The solid was washed with a little diisopropyl ether and was dried in a stream of air to give <b>9</b> as a pale yellow solid (21.2 g, 67 mmol, 63% yield), HPLC purity 99%. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.54 (s, 9H), 2.53 (s, 6H), 2.60 (t, <i>J</i> = 6.1 Hz, 2H), 3.90 (t, <i>J</i> = 6.1 Hz, 2H); MS(ESI) <i>m</i>/<i>z</i> 318 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>tert</i>-Butyl 4-(Methylthio)-5-oxo-2-phenyl-7,8-dihydro-1,6-naphthyridine-6(5<i>H</i>)-carboxylate (<b>11</b>)</h4><div class="NLM_p last">R<sup>1</sup> = Ph. Typical procedure for Michael addition of acetophenone/ammonia condensation sequence (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, conditions d). Method 1d. A mixture of <b>9</b> (9.95 g, 31.3 mmol) and acetophenone (7.6 g, 63.3 mmol) was dissolved in 250 mL of dimethyl sulfoxide and 200 mL of tetrahydrofuran. Potassium <i>tert</i>-butoxide (10.5 g, 93.6 mmol) was added in three equal portions at 30 min intervals, giving a dark red solution. After addition, the mixture was stirred for 2 h. Ammonium acetate (25 g, 324 mmol) was added followed by 200 mL of acetic acid. The solution warmed and paled slightly. The mixture was heated at 90 °C for 2 h, allowed to cool to room temperature, and diluted with 200 mL water. The mixture was then cooled in an ice–water bath and was carefully neutralized with slow addition of approx 400 mL of 8 N sodium hydroxide solution. Solid sodium carbonate was then carefully added to basify the solution to pH 11. The mixture was extracted four times with ether. The combined ether layers were washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue was purified by column chromatography (ethyl acetate–hexane, 20:80) to give <b>11</b> (R<sup>1</sup> = Ph) as a pale yellow solid (4.02 g, 10.7 mmol, 37% yield), HPLC purity 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.60 (s, 9H), 2.51 (s, 3H), 3.23 (t, <i>J</i> = 6.3 Hz, 2H), 4.03 (t, <i>J</i> = 6.3 Hz, 2H), 7.45–7.55 (m, 4H), 8.01 (d, <i>J</i> = 6.7 Hz, 2H); MS(ESI) <i>m</i>/<i>z</i> 371 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>tert</i>-Butyl 4-(Methylsulfonyl)-5-oxo-2-phenyl-7,8-dihydro-1,6-naphthyridine-6(5<i>H</i>)-carboxylate (<b>12</b>)</h4><div class="NLM_p last">R<sup>1</sup> = Ph. Typical procedure for oxidation of sulfide to sulfone (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, conditions e). Method 1e. A solution of <b>11</b> (R<sup>1</sup> = Ph, 4.02 g, 10.8 mmol) dissolved in 150 mL of dichloromethane was cooled to 5 °C in an ice bath. <i>meta</i>-Chloroperbenzoic acid (max purity 77%, 7.25 g, 32.4 mmol) was added, and the mixture was stirred for 30 min at 5 °C. The mixture was then stirred at room temperature for 2 h. The organics were washed three times with 4% w/v sodium carbonate solution, once with brine, and dried over sodium sulfate. Filtration and evaporation gave <b>12</b> (R<sup>1</sup> = Ph) as a white solid (4.40 g, 10.7 mmol, 99% yield), HPLC purity 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.60 (s, 9H), 3.33 (t, <i>J</i> = 6.1 Hz, 2H), 3.69 (s, 3H), 4.10 (t, <i>J</i> = 6.1 Hz, 2H), 7.50–7.57 (m, 3H), 8.14 (dd, <i>J</i> = 6.5, 2.9 Hz, 2H), 8.50 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 420 [M + NH<sub>4</sub>]<sup>+</sup>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-Amino-2-(3-bromophenyl)-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>15</b>)</h4><div class="NLM_p last">Method 1ij (see compound <b>37</b>). Tan solid. Yield of 88% over two steps from <b>12</b> (R<sup>1</sup> = 3-BrPh), HPLC purity 96%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.12 (t, <i>J</i> = 6.8 Hz, 2H), 3.59 (td, <i>J</i> = 6.7, 2.5 Hz, 2H), 5.71 (br. s., 2H), 6.79 (s, 1H), 7.31 (t, <i>J</i> = 7.8 Hz, 1H), 7.53 (d, <i>J</i> = 7.8 Hz, 1H), 7.84 (d, <i>J</i> = 7.8 Hz, 1H), 8.11 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 318, 320 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-[(3-Methoxyphenyl)amino]-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>21</b>)</h4><div class="NLM_p">Typical procedure for sulfide displacement with amines and anilines under conventional heating and subsequent Boc-deprotection under acidic conditions (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, conditions f). Method 1f. Step 1. A mixture of <b>12</b> (R<sup>1</sup> = Ph, 50 mg, 0.124 mmol) and 3-methoxyaniline (74 mg, 0.60 mmol) was suspended in 1 mL of ethanol and agitated at 70 °C overnight in a capped vial. The mixture was allowed to cool and was partitioned between saturated sodium carbonate solution and ether. The aqueous was extracted twice with ether, and the combined organics were washed with brine and dried over sodium sulfate, filtered, and evaporated to give a residue. The residue was purified by column chromatography (ethyl acetate–hexane, 50:50) to give <i>tert</i>-butyl 4-[(3-methoxyphenyl)amino]-5-oxo-2-phenyl-7,8-dihydro-1,6-naphthyridine-6(5<i>H</i>)-carboxylate.</div><div class="NLM_p last">Step 2. This compound was dissolved directly in 0.3 mL of dichloromethane, and 0.5 mL of trifluoroacetic acid was added. After 10 min at room temperature, the mixture was reduced in volume in a stream of nitrogen and was partitioned between saturated sodium carbonate solution and ether. The aqueous was extracted twice with ether. The combined organics were washed with brine and dried over sodium sulfate. Filtration and evaporation gave a residue that was purified by column chromatography (ethyl acetate–hexane, gradient) to give <b>21</b> as a pale yellow solid (26 mg, 0.075 mmol, 60% yield), HPLC purity 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.18 (t, <i>J</i> = 6.7 Hz, 2H), 3.64 (td, <i>J</i> = 6.7, 2.7 Hz, 2H), 3.82 (s, 3H), 5.80 (br. s., 1H), 6.76 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 6.84 (s, 1H), 6.92 (d, <i>J</i> = 7.8 Hz, 1H), 7.31 (t, <i>J</i> = 8.2 Hz, 1H), 7.36 (s, 1H), 7.38–7.46 (m, 3H), 7.87 (d, <i>J</i> = 7.5 Hz, 2H), 10.77 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 346 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-(3-Bromophenyl)-4-[(3-methoxyphenyl)amino]-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>22</b>)</h4><div class="NLM_p last">Typical procedure for direct sulfide displacement with amines and anilines under microwave heating (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, conditions h). Method 1h. A mixture of <b>12</b> (R<sup>1</sup> = 3-BrPh, 224 mg, 0.47 mmol) and 3-methoxyaniline (0.30 g mg, 2.45 mmol) were suspended in 10 mL of ethanol and were heated at 160 °C (max pressure 12 bar) for 9 h under microwave irradiation. The mixture was allowed to cool and evaporated under reduced pressure. The residue was taken up in dichloromethane, and the organics washed three times with 4% w/v sodium carbonate solution, once with brine, and dried over sodium sulfate. Filtration and evaporation gave a residue that was purified by column chromatography (ethyl acetate–hexane, gradient) to give <b>22</b> as a white solid (150 mg, 0.35 mmol, 76% yield), HPLC purity 99%. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.17 (t, <i>J</i> = 6.7 Hz, 2H), 3.64 (td, <i>J</i> = 6.7, 2.5 Hz, 2H), 3.83 (s, 3H), 5.82 (br. s., 1H), 6.78 (d, <i>J</i> = 8.2 Hz, 1H), 6.83 (s, 1H), 6.91 (d, <i>J</i> = 8.2 Hz, 1H), 7.21–7.39 (m, 3H), 7.52 (d, <i>J</i> = 8.2 Hz, 1H), 7.74 (d, <i>J</i> = 7.8 Hz, 1H), 8.08 (s, 1H), 10.80 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 424, 426 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-(3-Methoxyphenyl)-4-[(3-methoxyphenyl)amino]-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>23</b>)</h4><div class="NLM_p last">Method 1h. Pale brown solid, HPLC purity 98%. Yield of 51% from <b>12</b> (R<sup>1</sup> = 3-MeOPh) and 3-methoxyaniline. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.17 (t, <i>J</i> = 6.8 Hz, 2H), 3.63 (td, <i>J</i> = 6.5, 2.5 Hz, 2H), 3.82 (s, 3H), 3.86 (s, 3H), 6.02 (br. s., 1H), 6.75 (d, <i>J</i> = 8.2 Hz, 1H), 6.83 (s, 1H), 6.86–6.99 (m, 2H), 7.27–7.51 (m, 5H), 10.76 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 376 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-(2-Methoxyphenyl)-4-[(3-methoxyphenyl)amino]-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>24</b>)</h4><div class="NLM_p last">Method 1h. Pale brown solid, HPLC purity 96%. Yield of 71% from <b>12</b> (R<sup>1</sup> = 2-MeOPh) and 3-methoxyaniline. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.15 (t, <i>J</i> = 6.6 Hz, 2H), 3.61 (td, <i>J</i> = 6.6, 2.5 Hz, 2H), 3.81 (s, 3H), 3.84 (s, 3H), 6.07 (br. s., 1H), 6.69 (d, <i>J</i> = 7.4 Hz, 1H), 6.83–6.98 (m, 3H), 7.03 (t, <i>J</i> = 7.4 Hz, 1H), 7.19–7.41 (m, 2H), 7.58 (s, 1H), 7.78 (d, <i>J</i> = 7.4 Hz, 1H), 10.72 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 376 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-[(3-Methoxyphenyl)amino]-2-pyridin-4-yl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>25</b>) and 4-[(3-Methoxyphenyl)amino]-2-(1-oxidopyridin-4-yl)-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>26</b>)</h4><div class="NLM_p last">Thiol oxidation (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, step e) of 11 (R<sup>1</sup> = 4-pyr) gave intermediate <b>12</b> as a mixture of pyridine and pyridine <i>N</i>-oxide. This mixture was treated using method 1h and separated chromatographically at that point. Compound <b>25</b>: Off-white solid, HPLC purity 97%. Yield of 39% from <b>12</b> (R<sup>1</sup> = 4-Pyr/4-Pyr <i>N</i>-oxide mixture) and 3-methoxyaniline. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.18 (t, <i>J</i> = 6.6 Hz, 2H), 3.65 (td, <i>J</i> = 6.5, 2.5 Hz, 2H), 3.83 (s, 3H), 5.80 (br. s., 1H), 6.69–6.99 (m, 3H), 7.17–7.36 (m, 1H), 7.40 (s, 1H), 7.76 (d, <i>J</i> = 5.9 Hz, 2H), 8.67 (d, <i>J</i> = 5.5 Hz, 2H), 10.83 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 347 [M + H]<sup>+</sup>. Compound <b>26</b>: Yellow solid, HPLC purity 100%. Yield of 9% from <b>12</b> (R<sup>1</sup> = 4-Pyr/4-Pyr <i>N</i>-oxide mixture) and 3-methoxyaniline. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.14 (t, <i>J</i> = 6.6 Hz, 2H), 3.64 (td, <i>J</i> = 6.6, 2.5, Hz, 2H), 3.83 (s, 3H), 5.92 (br. s., 1H), 6.73–6.85 (m, 2H), 6.89 (d, <i>J</i> = 8.2 Hz, 1H), 7.28–7.42 (m, 2H), 7.84 (d, <i>J</i> = 7.0 Hz, 2H), 8.22 (d, <i>J</i> = 7.0 Hz, 2H), 10.83 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 363 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-Cyclopropyl-4-[(3-methoxyphenyl)amino]-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>27</b>)</h4><div class="NLM_p last">Method 1h. Off-white solid, HPLC purity 97%. Yield of 31% from <b>12</b> (R<sup>1</sup> = cPr) and 3-methoxyaniline: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 0.75–1.05 (m, 4H), 1.96–2.12 (m, 1H), 3.15 (t, <i>J</i> = 6.6 Hz, 2H), 3.58 (td, <i>J</i> = 6.6, 2.3 Hz, 2H), 3.83 (s, 3H), 5.75 (br. s., 1H), 6.64 (s, 1H), 6.71–6.80 (m, 2H), 6.84 (d, <i>J</i> = 8.2 Hz, 1H), 7.29–7.37 (m, 1H), 10.82 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 310 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3′-{4-[(3-Methoxyphenyl)amino]-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl}biphenyl-4-carboxylic Acid (<b>28</b>)</h4><div class="NLM_p last">Typical procedure for Suzuki reaction (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, conditions a). Method 2a. A mixture of <b>22</b> (80 mg, 0.19 mmol), 4-carboxyphenylboronic acid (47 mg, 0.28 mmol), and 2 M cesium carbonate (0.28 mL, 0.57 mmol) was suspended in 2 mL of degassed dioxane in a sealed tube. The mixture was subjected to three cycles of evacuation-backfilling with argon. 1′-Bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (8 mg, 0.01 mmol) was added, and the mixture was subjected again to three cycles of evacuation–backfilling with argon and then heated at 90 °C for 3 h. The mixture was allowed to cool to room temperature, and the solvent was evaporated. The crude was purified by column chromatography using the SP1 Purification system (ethyl acetate–hexane gradient) to give <b>28</b> as a beige solid (58 mg, 0.12 mmol, 66% yield), HPLC purity 100%. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.03 (t, <i>J</i> = 6.4 Hz, 2H), 3.51–3.67 (m, 2H), 3.79 (s, 3H), 6.77 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 6.89–7.01 (m, 2H), 7.35 (t, <i>J</i> = 8.0 Hz, 1H), 7.50 (s, 1H), 7.58 (t, <i>J</i> = 7.8 Hz, 1H), 7.67–7.83 (m, 3H), 7.89 (d, <i>J</i> = 7.8 Hz, 1H), 8.03 (d, <i>J</i> = 8.2 Hz, 2H), 8.17–8.28 (m, 2H), 11.13 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 466 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Ethyl 3′-{4-[(3-Methoxyphenyl)amino]-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl}biphenyl-4-carboxylate (<b>29</b>)</h4><div class="NLM_p last">Method 2a. White solid, HPLC purity 96%. Yield of 22% from <b>22</b> and 4-(ethoxycarbonyl)phenylboronic acid: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.42 (t, <i>J</i> = 7.0 Hz, 3H), 3.19 (t, <i>J</i> = 6.8 Hz, 2H), 3.65 (td, <i>J</i> = 6.8, 2.3 Hz, 2H), 3.82 (s, 3H), 4.41 (q, <i>J</i> = 7.3 Hz, 2H), 5.77 (br. s., 1H), 6.76 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 6.85 (s, 1H), 6.92 (d, <i>J</i> = 7.8 Hz, 1H), 7.29–7.38 (m, 1H), 7.41 (s, 1H), 7.51 (t, <i>J</i> = 7.6 Hz, 1H), 7.59–7.65 (m, 1H), 7.70 (d, <i>J</i> = 8.2 Hz, 2H), 7.83 (d, <i>J</i> = 7.8 Hz, 1H), 8.12 (d, <i>J</i> = 8.2 Hz, 2H), 8.17 (s, 1H), 10.81 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 494 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 6-Hydroxy-3′-{4-[(3-methoxyphenyl)amino]-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl}biphenyl-3-carboxylic Acid (<b>30</b>)</h4><div class="NLM_p last">Lithium hydroxide (42 mg, 1.00 mmol) was added to a solution of <b>31</b> (50 mg, 0.10 mmol) dissolved in a mixture of tetrahydrofuran/water, and the mixture was stirred at 40 °C for 3 days. The solvent was evaporated, water was added, and the pH was adjusted to 5. The resulting suspension was filtered, and the solid was washed with diethyl ether and dried to give <b>30</b> as a tan solid (25 mg, 0.051 mmol, 51% yield), HPLC purity 97%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.15 (t, <i>J</i> = 6.4 Hz, 2H), 3.61 (td, <i>J</i> = 6.6, 2.5 Hz, 2H), 3.78 (s, 3H), 6.87 (br. s., 1H), 6.94–7.06 (m, 2H), 7.20 (d, <i>J</i> = 8.6 Hz, 1H), 7.25–7.35 (m, 1H), 7.40 (t, <i>J</i> = 7.6 Hz, 1H), 7.58 (br. s., 1H), 7.67–7.76 (m, 1H), 7.76–7.83 (m, 2H), 7.89 (br. s., 1H), 8.00 (br. s., 1H), 8.53 (br. s., 1H), 10.87 (br. s., 1H), 11.77 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 482 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Methyl 6-Hydroxy-3′-{4-[(3-methoxyphenyl)amino]-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl}biphenyl-3-carboxylate (<b>31</b>)</h4><div class="NLM_p last">Methyl 3-bromo-4-hydroxybenzoate (1.51 g, 6.53 mmol) was dissolved in 40 mL of previously degassed dioxane. Bis(pinacolate)diboron (3.32 g, 13.1 mmol), (diphenylphosphino)ferrocene (0.18 g, 0.32 mmol), and potassium acetate (1.92 g, 19. Six mmol) were added, and the mixture was subjected to three cycles of evacuation–backfilling with argon. 1,1′-Bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (0.27 g, 0.33 mmol) was added, and the mixture was subjected again to three cycles of evacuation–backfilling with argon and heated at 80 °C for 18 h. The mixture was cooled to room temperature, water and ethyl acetate were added, and the organic layer was separated and washed with brine. The aqueous layer was extracted twice with ethyl acetate, and the combined organic layers were dried with magnesium sulfate, filtered, and evaporated. After purification by column chromatography using the SP1 Purification system (ethyl acetate–hexane gradient), methyl 4-hydroxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate was obtained as a white solid (1.07 g, 3.75 mmol, 57% yield): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.39 (s, 12H), 3.88 (s, 3H), 6.91 (d, <i>J</i> = 8.6 Hz, 1H), 8.06 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 8.23 (s, 1H), 8.33 (d, <i>J</i> = 2.3 Hz, 1H); MS(ESI) <i>m</i>/<i>z</i> 279 [M + H]<sup>+</sup>. Compound <b>31</b>: Method 2a. Tan solid, HPLC purity 98%. Yield of 39% from <b>22</b> and methyl 4-hydroxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.01 (t, <i>J</i> = 6.4 Hz, 2H), 3.47 (td, <i>J</i> = 6.6, 2.5 Hz, 2H), 3.77 (s, 3H), 3.81 (s, 3H), 6.76 (d, <i>J</i> = 8.6 Hz, 1H), 6.86–7.00 (m, 2H), 7.06 (d, <i>J</i> = 8.2 Hz, 1H), 7.34 (t, <i>J</i> = 8.0 Hz, 1H), 7.45 (s, 1H), 7.51 (t, <i>J</i> = 7.8 Hz, 1H), 7.57–7.66 (m, 1H), 7.78–7.93 (m, 3H), 8.08 (s, 1H), 8.19 (br. s., 1H), 10.58 (br. s., 1H), 11.11 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 496 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 3′-{4-[(3-Methoxyphenyl)amino]-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl}biphenyl-3-carboxamide (<b>32</b>)</h4><div class="NLM_p last">Method 2a. White solid. Yield of 65% from <b>22</b> and 3-carbamoylphenylboronic acid: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.19 (t, <i>J</i> = 6.8 Hz, 2H), 3.64 (t, <i>J</i> = 6.8 Hz, 2H), 3.82 (s, 3H), 6.77 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 6.86 (t, <i>J</i> = 2.0 Hz, 1H), 6.92 (d, <i>J</i> = 7.8 Hz, 1H), 7.35 (d, <i>J</i> = 8.5 Hz, 1H), 7.38 (s, 1H), 7.51 (t, <i>J</i> = 7.4 Hz, 1H), 7.54 (t, <i>J</i> = 7.4 Hz, 1H), 7.61–7.72 (m, 2H), 7.79 (t, <i>J</i> = 8.0 Hz, 1H), 7.87 (d, <i>J</i> = 7.8 Hz, 1H), 8.16 (s, 2H), 10.80 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 465 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-Cyclopropyl-3′-{4-[(3-methoxyphenyl)amino]-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl}biphenyl-3-carboxamide (<b>33</b>)</h4><div class="NLM_p last">Method 2a. Pale yellow solid, HPLC purity 99%. Yield of 48% from <b>22</b> and 3-(cyclopropylcarbamoyl)phenylboronic acid: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 0.58–0.70 (m, 2H), 0.89 (td, <i>J</i> = 7.0, 6.0 Hz, 2H), 2.86–3.01 (m, 1H), 3.19 (t, <i>J</i> = 6.6 Hz, 2H), 3.65 (td, <i>J</i> = 6.6, 2.3 Hz, 2H), 3.81 (s, 3H), 5.78 (br. s., 1H), 6.31 (br. s., 1H), 6.75 (dd, <i>J</i> = 8.0, 2.5 Hz, 1H), 6.85 (t, <i>J</i> = 2.0 Hz, 1H), 6.92 (d, <i>J</i> = 8.2 Hz, 1H), 7.29–7.37 (m, 1H), 7.41 (s, 1H), 7.49 (t, <i>J</i> = 7.6 Hz, 2H), 7.57–7.67 (m, 1H), 7.67–7.85 (m, 3H), 7.98 (s, 1H), 8.15 (s, 1H), 10.81 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 505 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-[2-(Dimethylamino)ethyl]-3′-{4-[(3-methoxyphenyl)amino]-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl}biphenyl-3-carboxamide (<b>34</b>)</h4><div class="NLM_p last"><i>N</i>,<i>N</i>-Dimethylethane-1,2-diamine (0.71 g, 8.06 mmol) was added to a solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1.00 g, 4.03 mmol), 1-hydroxybenzotriazole hydrate (0.82 g, 6.05 mmol), and <i>N</i>-ethyl-<i>N</i>′-(3-(dimethylamino)propyl)carbodiimide hydrochloride (1.16 g, 6.05 mmol) in 8 mL dimethylformamide. The mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure, and the residue taken up in 4% sodium bicarbonate solution. The aqueous phase was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give <i>N</i>-[2-(dimethylamino)ethyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide as a white solid (0.81 g, 2.55 mmol, 63%): MS(ESI) <i>m</i>/<i>z</i> 319 [M + H]<sup>+</sup>. Compound <b>34</b>: Method 2a. Brown solid, HPLC purity 95%. Yield of 80% from <b>22</b> and <i>N</i>-[2-(dimethylamino)ethyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 2.50 (s, 6H), 2.88 (t, <i>J</i> = 5.3 Hz, 2H), 3.09 (t, <i>J</i> = 6.4 Hz, 2H), 3.47–3.62 (m, 2H), 3.64–3.77 (m, 2H), 3.80 (s, 3H), 6.44 (br. s., 1H), 6.73 (d, <i>J</i> = 8.2 Hz, 1H), 6.83 (br. s., 1H), 6.89 (d, <i>J</i> = 8.2 Hz, 1H), 7.27–7.38 (m, 2H), 7.44 (t, <i>J</i> = 8.0 Hz, 1H), 7.48 (t, <i>J</i> = 8.2 Hz, 1H), 7.57–7.80 (m, 4H), 7.86 (d, <i>J</i> = 7.8 Hz, 1H), 8.13 (br. s., 1H), 8.16 (br. s., 1H), 10.71 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 536 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-(3′-Hydroxybiphenyl-3-yl)-4-[(3-methoxyphenyl)amino]-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>35</b>)</h4><div class="NLM_p last">Method 2a. White solid, HPLC purity 99%. Yield of 65% from <b>22</b> and 3-hydroxyphenylboronic acid: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.17 (t, <i>J</i> = 6.8 Hz, 2H), 3.63 (t, <i>J</i> = 6.8 Hz, 2H), 3.83 (s, 3H), 6.78 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 6.81–6.88 (m, 2H), 6.91 (d, <i>J</i> = 7.8 Hz, 1H), 7.07–7.19 (m, 2H), 7.21–7.39 (m, 4H), 7.47 (t, <i>J</i> = 7.8 Hz, 1H), 7.58–7.71 (m, 2H), 8.06 (s, 1H), 10.79 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 438 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-[(3-Methoxyphenyl)amino]-2-{3-[(3-methoxyphenyl)thio]phenyl}-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>36</b>)</h4><div class="NLM_p last">Compound <b>22</b> (120 mg, 0.28 mmol) was dissolved in 2 mL of xylene in a sealed tube. 3-Methoxybenzenethiol (0.071 mL, 0.56 mmol) and tributyltin methoxide (167 mg, 0.56 mmol) were added, and the mixture was heated at 140 °C for 10 min. Tetrakis(triphenylphosphine)palladium (65 mg, 0.06 mmol) was added, and the mixture was stirred at 140 °C overnight. The mixture was cooled to room temperature, and the solvent was evaporated. Ethyl acetate was added, and the organic phase was washed with water (×3) and brine (×3). The combined aqueous layers were extracted twice with ethyl acetate, and the combined organic layers were dried with magnesium sulfate, filtered, and evaporated. The crude was purified by chromatography using the SP1 purification system to give <b>36</b> as a pale yellow solid (89 mg, 0.18 mmol, 64% yield), HPLC purity 98%: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.15 (t, <i>J</i> = 6.8 Hz, 2H), 3.63 (td, <i>J</i> = 6.7, 2.5 Hz, 2H), 3.74 (s, 3H), 3.81 (s, 3H), 5.82 (br. s., 1H), 6.69–6.84 (m, 3H), 6.84–6.96 (m, 3H), 7.19 (t, <i>J</i> = 8.0 Hz, 1H), 7.24–7.40 (m, 4H), 7.69–7.80 (m, 1H), 7.93 (s, 1H), 10.77 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 484 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-Amino-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>37</b>)</h4><div class="NLM_p">Typical procedure for Boc-deprotection and sulfide displacement with ammonia (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, conditions i and j). Method 1ij. Step 1. Trifluoroacetic acid (1 mL, 13 mmol) was added dropwise to a solution of <b>12</b> (R<sup>1</sup> = Ph, 212 mg, 0.53 mmol) dissolved in 5 mL of dichloromethane, and the mixture was allowed to stand at room temperature for 1 h. The mixture was diluted with 50 mL of chloroform and was evaporated to give a residue. Water (5 mL) was added and a solid precipitated. The acidic solution was basified to pH 10 with 4% w/v sodium carbonate solution, and the mixture was sonicated to finely divide the solid, which was collected by filtration, washed twice with water, and dried in a stream of air for 1 h to give 4-(methylsulfonyl)-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one as a tan solid (160 mg, 0.53 mmol, 100% yield): <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.21 (t, <i>J</i> = 5.1 Hz, 2H), 3.38–3.56 (m, 2H), 3.69 (s, 3H), 7.50–7.68 (m, 3H), 8.09–8.20 (m, 2H), 8.32 (s, 1H), 8.52 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 303 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2. The sulfone (125 mg, 0.30 mmol) was suspended in 7 N ammonia in methanol (2.00 mL, 14.00 mmol), and the mixture was heated in the microwave at 70 °C for 2 h and at 100 °C for 5 h. The solvent was evaporated, and the crude was purified by reverse phase in the SP1 purification system to give <b>37</b> as a white solid (38 mg, 0.15 mmol, 52% yield), HPLC purity 98%: partial <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.89 (t, <i>J</i> = 6.8 Hz, 2H), 3.37 (td, <i>J</i> = 6.6, 2.5 Hz, 2H), 7.03 (s, 1H), 7.36–7.54 (m, 3H), 7.79 (br. s., 1H), 7.94 (d, <i>J</i> = 5.9 Hz, 2H); MS(ESI) <i>m</i>/<i>z</i> 240 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 3-[(5-Oxo-2-phenyl-5,6,7,8-tetrahydro-1,6-naphthyridin-4-yl)amino]benzonitrile (<b>38</b>)</h4><div class="NLM_p last">Method 1f. Pale yellow solid, HPLC purity 99%. Yield of 26% from <b>12</b> (R<sup>1</sup> = Ph) and 3-cyanoaniline: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.20 (t, <i>J</i> = 6.8 Hz, 2H), 3.66 (td, <i>J</i> = 6.8, 2.5 Hz, 2H), 5.94 (br. s., 1H), 7.29 (s, 1H), 7.36–7.63 (m, 7H), 7.81–7.93 (m, 2H), 11.00 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 341 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-[(3,5-Dimethoxyphenyl)amino]-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>39</b>)</h4><div class="NLM_p last">Typical procedure for direct sulfide displacement with amines and anilines under conventional heating and subsequent Boc-deprotection under thermal conditions (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, conditions g). Method 1g. A mixture of <b>12</b> (R<sup>1</sup> = Ph, 80 mg, 0.19 mmol) and 3,5-dimethoxyaniline (145 mg, 0.95 mmol) suspended in 2 mL of ethanol was heated at 70 °C overnight in a capped vial. The contents of the vial were transferred to a microwave vessel and heated at 160 °C under microwave irradiation for 30 min. The solvent was concentrated under reduced pressure, and the crude residue was purified by flash chromatography (gradient ethyl acetate-methanol) to give <b>39</b> as a pale yellow solid (14 mg, 0.035 mmol, 19% yield), HPLC purity 99%: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.17 (t, <i>J</i> = 6.6 Hz, 2H), 3.63 (td, <i>J</i> = 6.5, 2.0 Hz, 2H), 3.80 (s, 6H), 6.00 (br. s., 1H), 6.32 (s, 1H), 6.47 (d, <i>J</i> = 2.0 Hz, 2H), 7.33–7.51 (m, 4H), 7.80–7.94 (m, 2H), 10.75 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 376 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 4-{[3-(Hydroxymethyl)phenyl]amino}-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>40</b>)</h4><div class="NLM_p last">Method 1g. Pale yellow solid, HPLC purity 96%. Yield of 40% from <b>12</b> (R<sup>1</sup> = Ph) and 3-aminobenzylalcohol: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.15 (t, <i>J</i> = 6.8 Hz, 2H), 3.61 (t, <i>J</i> = 6.8 Hz, 2H), 4.69 (s, 2H), 7.28 (app d, <i>J</i> = 7.0 Hz, 4H), 7.33–7.47 (m, 4H), 7.71–7.86 (m, 2H), 10.75 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 346 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-{[4-(2-Hydroxyethyl)phenyl]amino}-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>41</b>)</h4><div class="NLM_p last">Method 1g, HPLC purity 90%. Pale yellow solid. Yield of 51% from <b>12</b> (R<sup>1</sup> = Ph) and 2-(4-aminophenyl)ethanol: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 2.91 (t, <i>J</i> = 6.4 Hz, 2H), 3.21 (t, <i>J</i> = 6.6 Hz, 2H), 3.65 (td, <i>J</i> = 6.0, 2.0 Hz, 2H), 3.91 (t, <i>J</i> = 6.4 Hz, 2H), 5.87 (br. s., 1H), 7.23–7.30 (m, 4H), 7.34–7.51 (m, 4H), 7.80–7.93 (m, 2H), 10.79 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 360 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 4-({4-[(2<i>R</i>)-2,3-dihydroxypropyl]phenyl}amino)-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>42</b>)</h4><div class="NLM_p last">2,2-Dimethyl-4-(4-nitrobenzyl)-1,3-dioxolane (1.15 g, 4.85 mmol) was dissolved in 50 mL of ethanol, and 10% Pd/C (0.26 g, 0.24 mmol) was added. The mixture was stirred under nitrogen atmosphere at 20 psi for 2 h. The catalyst was filtered, and the solvent was evaporated to give {4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]phenyl}amine as an orange solid (965 mg, 4.51 mmol, 96% yield): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.36 (s, 3H), 1.44 (s, 3H), 2.50–2.78 (m, 1H), 2.86–3.06 (m, 1H), 3.54–3.73 (m, 1H), 3.95 (dd, <i>J</i> = 8.2, 5.9 Hz, 1H), 4.14–4.40 (m, 1H), 6.68 (d, <i>J</i> = 8.4 Hz, 2H), 7.02 (d, <i>J</i> = 8.4 Hz, 2H); MS(ESI) <i>m</i>/<i>z</i> 208 [M + H]<sup>+</sup>. Compound <b>42</b>: Method 1h. Pale yellow solid, HPLC purity 98%. Yield of 19% from <b>12</b> (R<sup>1</sup> = Ph) and {4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]phenyl}amine: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.54 (dd, <i>J</i> = 13.5, 8.5 Hz, 1H), 2.80 (dd, <i>J</i> = 13.5, 4.5 Hz, 1H), 3.00 (t, <i>J</i> = 6.7 Hz, 2H), 3.46 (td, <i>J</i> = 6.5, 2.5 Hz, 2H), 3.60–3.70 (m, 1H), 4.58–4.64 (m, 2H), 7.22–7.27 (m, 2H), 7.27–7.32 (m, 3H), 7.39–7.51 (m, 3H), 7.89 (d, <i>J</i> = 6.3 Hz, 2H), 8.16 (br. s., 1H), 11.03 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 390 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2-Methoxy-4-[(5-oxo-2-phenyl-5,6,7,8-tetrahydro-1,6-naphthyridin-4-yl)amino]benzoic Acid (<b>43</b>)</h4><div class="NLM_p last">Method 1h, HPLC purity 87%. Pale brown solid. Yield of 16% from <b>12</b> (R<sup>1</sup> = Ph) and 4-amino-2-methoxybenzoic acid: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.17 (t, <i>J</i> = 6.6 Hz, 2H), 3.63 (td, <i>J</i> = 6.8, 2.7 Hz, 2H), 3.82 (s, 3H), 5.90 (br. s., 1H), 6.76 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 6.84 (s, 1H), 6.91 (d, <i>J</i> = 7.8 Hz, 1H), 7.30–7.49 (m, 4H), 7.80–7.92 (m, 2H), 10.76 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 390 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-[(5-Oxo-2-phenyl-5,6,7,8-tetrahydro-1,6-naphthyridin-4-yl)amino]benzamide (<b>44</b>)</h4><div class="NLM_p last">Method 1h. Yellow solid, HPLC purity 97%. Yield of 75% from <b>12</b> (R<sup>1</sup> = Ph) and 4-aminobenzamide: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.13 (t, <i>J</i> = 6.8 Hz, 2H), 3.60 (t, <i>J</i> = 6.8 Hz, 2H), 6.66 (d, <i>J</i> = 8.6 Hz, 2H), 7.37–7.42 (m, 2H), 7.43–7.49 (m, 2H), 7.63 (d, <i>J</i> = 8.6 Hz, 2H), 7.78 (s, 1H), 7.78–7.82 (m, 1H), 7.95 (d, <i>J</i> = 8.6 Hz, 2H); MS(ESI) <i>m</i>/<i>z</i> 359 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 3-[(5-Oxo-2-phenyl-5,6,7,8-tetrahydro-1,6-naphthyridin-4-yl)amino]benzamide (<b>45</b>)</h4><div class="NLM_p last">Method 1h. Pale yellow solid, HPLC purity 98%. Yield of 46% from <b>12</b> (R<sup>1</sup> = Ph) and 3-aminobenzamide: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.03 (t, <i>J</i> = 6.8 Hz, 2H), 3.48 (t, <i>J</i> = 6.8 Hz, 2H), 7.36 (s, 1H), 7.41–7.50 (m, 4H), 7.50–7.57 (m, 2H), 7.67–7.75 (m, 1H), 7.83 (s, 1H), 7.88–7.98 (m, 2H), 8.06 (br. s., 1H), 8.23 (s, 1H), 11.21 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 359 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-[(4-Methylpyridin-3-yl)amino]-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>46</b>)</h4><div class="NLM_p last">Typical procedure for palladium-catalyzed aminations (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, conditions k, and <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, conditions c). Method 1k. Compound <b>37</b> (45 mg, 0.19 mmol) was dissolved in 10 mL of dioxane in a sealed tube. The mixture was subjected to three cycles of evacuation–backfilling with argon, and 3-bromo-4-methylpyridine (26 mg, 0.23 mmol), cesium carbonate (85 mg, 0.26 mmol), bis(diphenylphosphino)-9,9-dimethylxanthene (22 mg, 0.04 mmol), and tris(dibenzylidene acetone)dipalladium(0) (17 mg, 0.02 mmol) were added. The mixture was subjected again to three cycles of evacuation–backfilling, and the mixture was stirred at 120 °C under argon atmosphere overnight. The solvent was evaporated, and dichloromethane and water were added. The organic layer was washed with water (×2), dried with magnesium sulfate, filtered, and evaporated The residue was purified by reverse-phase chromatography using the SP1 purification system to give <b>46</b> as a white solid (26 mg, 0.078 mmol, 42% yield), HPLC purity 100%: partial <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 2.33 (s, 3H), 3.21 (t, <i>J</i> = 6.8 Hz, 2H), 3.67 (td, <i>J</i> = 6.7, 2.5 Hz, 2H), 5.83 (br. s., 1H), 6.89 (s, 1H), 7.34–7.45 (m, 3H), 7.77–7.88 (m, 2H), 8.40 (br. s., 1H), 8.62 (br. s., 1H), 10.66 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 331 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-Phenyl-4-[(pyridin-4-ylmethyl)amino]-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>47</b>)</h4><div class="NLM_p last">Method 1g. White solid, HPLC purity 93%. Yield of 23% from <b>12</b> (R<sup>1</sup> = Ph) and 4-aminomethylpyridine: partial <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.95 (t, <i>J</i> = 6.8 Hz, 2H), 4.70 (d, <i>J</i> = 6.3 Hz, 2H), 6.94 (s, 1H), 7.36 (d, <i>J</i> = 5.1 Hz, 2H), 7.38–7.47 (m, 3H), 7.95 (app d, <i>J</i> = 7.5 Hz, 3H), 8.53 (d, <i>J</i> = 4.7 Hz, 2H), 9.59 (t, <i>J</i> = 6.1 Hz, 1H); MS(ESI) <i>m</i>/<i>z</i> 331 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-Phenyl-4-[(2-pyridin-4-ylethyl)amino]-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>48</b>)</h4><div class="NLM_p last">Method 1h. White solid, HPLC purity 98%. Yield of 19% from <b>12</b> (R<sup>1</sup> = Ph) and 2-(pyridin-4-yl)ethylamine: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.01 (t, <i>J</i> = 7.2 Hz, 2H), 3.11 (t, <i>J</i> = 7.0 Hz, 2H), 3.45–3.69 (m, 4H), 5.85 (br. s., 1H), 6.81 (s, 1H), 7.21 (d, <i>J</i> = 5.5 Hz, 2H), 7.37–7.58 (m, 3H), 7.93 (d, <i>J</i> = 7.8 Hz, 2H), 8.56 (d, <i>J</i> = 5.5 Hz, 2H), 9.09 (t, <i>J</i> = 4.7 Hz, 1H); MS(ESI) <i>m</i>/<i>z</i> 345 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-(1-Naphthylamino)-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>49</b>)</h4><div class="NLM_p last">Method 1h. Pale yellow solid, HPLC purity 98%. Yield of 37% from <b>12</b> (R<sup>1</sup> = Ph) and 1-aminonaphthalene: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.22 (t, <i>J</i> = 6.6 Hz, 2H), 3.68 (td, <i>J</i> = 6.8, 2.5 Hz, 2H), 6.10 (br. s., 1H), 7.00 (s, 1H), 7.27–7.40 (m, 3H), 7.43–7.61 (m, 4H), 7.64–7.85 (m, 3H), 7.84–7.98 (m, 1H), 8.04–8.16 (m, 1H), 11.09 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 366 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-Phenyl-4-(quinolin-5-ylamino)-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>50</b>)</h4><div class="NLM_p last">Method 1h. Pale yellow solid, HPLC purity 98%. Yield of 22% from <b>12</b> (R<sup>1</sup> = Ph) and 5-aminoquinoline: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.23 (t, <i>J</i> = 6.6 Hz, 2H), 3.69 (t, <i>J</i> = 6.4 Hz, 2H), 6.07 (br. s., 1H), 6.99 (s, 1H), 7.30–7.52 (m, 5H), 7.57–7.68 (m, 1H), 7.68–7.85 (m, 2H), 8.07 (d, <i>J</i> = 8.6 Hz, 1H), 8.44 (d, <i>J</i> = 8.2 Hz, 1H), 8.98 (d, <i>J</i> = 2.7 Hz, 1H), 11.15 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 367 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 4-(Isoquinolin-5-ylamino)-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>51</b>)</h4><div class="NLM_p last">Method 1h. Pale yellow solid, HPLC purity 100%. Yield of 7% from <b>12</b> (R<sup>1</sup> = Ph) and 5-aminoisoquinoline: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.23 (t, <i>J</i> = 6.6 Hz, 2H), 3.70 (td, <i>J</i> = 6.6, 2.3 Hz, 2H), 5.93 (br. s., 1H), 7.02 (s, 1H), 7.32–7.42 (m, 3H), 7.66 (t, <i>J</i> = 8.0 Hz, 1H), 7.72–7.82 (m, 3H), 7.84–7.96 (m, 2H), 8.57 (d, <i>J</i> = 5.9 Hz, 1H), 9.33 (s, 1H), 11.21 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 367 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-Phenyl-4-(quinolin-6-ylamino)-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>52</b>)</h4><div class="NLM_p last">Method 1h. Pale yellow solid, HPLC purity 100%. Yield of 11% from <b>12</b> (R<sup>1</sup> = Ph) and 6-aminoquinoline: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.21 (t, <i>J</i> = 6.6 Hz, 2H), 3.67 (td, <i>J</i> = 6.6, 2.5 Hz, 2H), 6.02 (br. s., 1H), 7.37–7.48 (m, 5H), 7.63–7.77 (m, 2H), 7.87 (app dd, <i>J</i> = 6.0, 2.5 Hz, 2H), 8.13 (t, <i>J</i> = 8.6 Hz, 2H), 8.88 (d, <i>J</i> = 2.7 Hz, 1H), 11.06 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 367 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 2-Phenyl-4-(1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-ylamino)-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>53</b>)</h4><div class="NLM_p last">2-Chloronicotinonitrile (0.75 g, 5.30 mmol), copper(I) iodide (50 mg, 0.05 mmol), cesium carbonate (2.59 g, 7.96 mmol), and 1,10-phenanthroline (96 mg, 0.53 mmol) were suspended in 20 mL of dimethylformamide. Hydrazine hydrate (1.6 mL, 31.83 mmol) was added, and the mixture was stirred at 60 °C overnight. The mixture was cooled to room temperature, water was added, and the aqueous phase was extracted with dichloromethane (×3). The combined organic layers were dried with magnesium sulfate, filtered, and evaporated. The crude was purified by column chromatography using the SP1 Purification system (methanol–dichloromethane gradient) to give 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-amine as a yellow solid (0.34 g, 2.51 mmol, 47% yield): <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.55 (s, 2H), 6.94 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 8.10 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 8.33 (dd, <i>J</i> = 4.3, 1.6 Hz, 1H), 11.91 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 135 [M + H]<sup>+</sup>. Compound <b>53</b>: Method 1h. Pale yellow solid, HPLC purity 99%. Yield of 53% from <b>12</b> (R<sup>1</sup> = Ph) and 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-amine: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.08 (t, <i>J</i> = 6.4 Hz, 2H), 3.51 (t, <i>J</i> = 6.6 Hz, 2H), 7.23 (dd, <i>J</i> = 8.0, 4.5 Hz, 1H), 7.39–7.62 (m, 3H), 8.02 (d, <i>J</i> = 5.9 Hz, 2H), 8.10 (d, <i>J</i> = 8.2 Hz, 1H), 8.34 (br. s., 1H), 8.58 (d, <i>J</i> = 4.3 Hz, 1H), 8.67 (s, 1H), 12.37 (s, 1H), 13.19 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 356 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 4-[(1-Methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)amino]-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>54</b>)</h4><div class="NLM_p last">Method 1h. Pale yellow solid, HPLC purity 100%. Yield of 53% from <b>12</b> (R<sup>1</sup> = Ph) and 1-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-amine (prepared as above from 2-chloronicotinonitrile and methylhydrazine): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.25 (t, <i>J</i> = 6.8 Hz, 2H), 3.68 (td, <i>J</i> = 6.8, 2.5 Hz, 2H), 4.14 (s, 3H), 5.81 (br. s., 1H), 7.10 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 7.37–7.57 (m, 3H), 8.07 (app t, <i>J</i> = 8.4 Hz, 3H), 8.57 (d, <i>J</i> = 4.3 Hz, 1H), 8.63 (s, 1H), 11.94 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 371 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 2-Phenyl-4-[(1-phenyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)amino]-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>55</b>)</h4><div class="NLM_p last">Method 1h. Pale yellow solid, HPLC purity 100%. Yield of 40% from <b>12</b> (R<sup>1</sup> = Ph) and 1-phenyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-amine (prepared as above from 2-chloronicotinonitrile and phenylhydrazine): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.27 (t, <i>J</i> = 6.8 Hz, 2H), 3.69 (td, <i>J</i> = 6.8, 2.3 Hz, 2H), 5.90 (br. s., 1H), 7.10–7.33 (m, 2H), 7.41–7.63 (m, 5H), 8.17 (app t, <i>J</i> = 7.0 Hz, 3H), 8.41 (d, <i>J</i> = 8.2 Hz, 2H), 8.66 (d, <i>J</i> = 4.3 Hz, 1H), 9.08 (s, 1H), 12.27 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 433 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-[(1-Oxidoquinolin-5-yl)amino]-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>56</b>)</h4><div class="NLM_p last">5-Bromoquinoline (0.50 g, 2.40 mmol) was dissolved in 20 mL of dichloromethane and cooled to 5 °C in an ice bath. <i>meta</i>-Chloroperbenzoic acid (max purity 77%, 0.88 g, 3.60 mmol) was added, and the mixture was stirred for 30 min at 5 °C. The mixture was then stirred at room temperature for 2 h. The organics were washed three times with 4% w/v sodium carbonate solution, once with brine, and dried over sodium sulfate. The organics were filtered and evaporated to give 5-bromoquinoline 1-oxide as a brown solid (0.48 g, 0.21 mmol, 86% yield): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 7.40 (dd, <i>J</i> = 8.8, 6.1 Hz, 1H), 7.60 (t, <i>J</i> = 8.2 Hz, 1H), 7.93 (d, <i>J</i> = 7.4 Hz, 1H), 8.11 (d, <i>J</i> = 9.0 Hz, 1H), 8.58 (d, <i>J</i> = 6.2 Hz, 1H), 8.76 (d, <i>J</i> = 8.6 Hz, 1H); MS(ESI) <i>m</i>/<i>z</i> 226 [M + H]<sup>+</sup>. Compound <b>56</b>: Method 1k. Yellow solid, HPLC purity 99%. Yield of 35% from <b>37</b> and 5-bromoquinoline 1-oxide: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.06 (t, <i>J</i> = 6.6 Hz, 2H), 3.52 (td, <i>J</i> = 6.5, 2.0 Hz, 2H), 7.21 (s, 1H), 7.35–7.47 (m, 3H), 7.53 (dd, <i>J</i> = 8.8, 6.1 Hz, 1H), 7.81–7.97 (m, 5H), 8.33 (br. s., 1H), 8.43 (t, <i>J</i> = 4.9 Hz, 1H), 8.66 (d, <i>J</i> = 5.9 Hz, 1H), 11.68 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 383 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4-[(3-Methoxyphenyl)amino]-2-phenyl-7,8-dihydropyrido[4,3-<i>d</i>]pyrimidin-5(6<i>H</i>)-one (<b>57</b>)</h4><div class="NLM_p">Step 1. Phenylamidine hydrochloride (0.25 g, 1.58 mmol) was suspended in 5 mL of toluene and 1 mL of dimethylformamide. Sodium hydride (60% dispersion in oil, 0.125 g, 3.15 mmol) was added, and the mixture was stirred for 5 min. A solution of <b>9</b> (0.50 g, 1.58 mmol) dissolved in 4 mL of dimethylformamide was added, and the mixture was stirred at 100 °C for 2 d. The mixture was evaporated, and the crude residue was purified by reverse-phase chromatography using the SP1 Purification system to give <i>tert</i>-butyl 4-(methylthio)-5-oxo-2-phenyl-7,8-dihydropyrido[4,3-<i>d</i>]pyrimidine-6(5<i>H</i>)-carboxylate as a colorless oil (60 mg, 0.15 mmol, 9%): MS(ESI) <i>m</i>/<i>z</i> 373 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2. The sulfide (60 mg, 0.15 mmol) was dissolved in 2 mL of dichloromethane and cooled to 5 °C in an ice-bath. <i>meta</i>-Chloroperbenzoic acid (max purity 77%, 0.10 g, 0.45 mmol) was added, and the mixture was stirred for 30 min at 5 °C. The mixture was then stirred at room temperature for 2 h. The organics were washed three times with 4% w/v sodium carbonate solution, once with brine, and dried over sodium sulfate. The organics were filtered and evaporated to give a crude sample of 4-(methylsulfonyl)-2-phenyl-7,8-dihydropyrido[4,3-<i>d</i>]pyrimidin-5(6<i>H</i>)-one as a colorless oil (84 mg, purity 70% by HPLC). Used as such without further purification: MS(ESI) <i>m</i>/<i>z</i> 305 [M + H]<sup>+</sup>. <b>57</b>: Method 1h. Pale yellow solid, HPLC purity 99%. Yield of 83% from the crude 4-(methylsulfonyl)-2-phenyl-7,8-dihydropyrido[4,3-<i>d</i>]pyrimidin-5(6<i>H</i>)-one and 3-methoxyaniline: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.01 (t, <i>J</i> = 6.8 Hz, 2H), 3.50 (td, <i>J</i> = 6.5, 2.0 Hz, 2H), 3.83 (s, 3H), 6.71 (d, <i>J</i> = 7.8 Hz, 1H), 7.21 (d, <i>J</i> = 8.0 Hz, 1H), 7.33 (t, <i>J</i> = 7.8 Hz, 1H), 7.47–7.71 (m, 4H), 8.26–8.53 (m, 3H), 11.61 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 347 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 4-[(3-Methoxyphenyl)amino]-7-methyl-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>58</b>)</h4><div class="NLM_p last">Method 1h. White solid, HPLC purity 94%. Yield of 56% from <i>tert</i>-butyl 7-methyl-4-(methylsulfonyl)-5-oxo-2-phenyl-7,8-dihydro-1,6-naphthyridine-6(5<i>H</i>)-carboxylate and 3-methoxyaniline: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.39 (d, <i>J</i> = 6.6 Hz, 3H), 2.93 (dd, <i>J</i> = 16.0, 11.0 Hz, 1H), 3.17 (dd, <i>J</i> = 16.0, 5.0 Hz, 1H), 3.82 (s, 3H), 3.95 (ddt, <i>J</i> = 11.0, 5.0, 6.5 Hz, 1H), 5.60 (br. s., 1H), 6.76 (d, <i>J</i> = 8.6 Hz, 1H), 6.84 (s, 1H), 6.92 (d, <i>J</i> = 8.6 Hz, 1H), 7.30–7.49 (m, 5H), 7.83–7.93 (m, 2H), 10.78 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 360 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 4-[(3-Methoxyphenyl)amino]-8-methyl-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>59</b>)</h4><div class="NLM_p last">Method 1h. Brown solid, HPLC purity 96%. Yield of 75% from <i>tert</i>-butyl 8-methyl-4-(methylsulfonyl)-5-oxo-2-phenyl-7,8-dihydro-1,6-naphthyridine-6(5<i>H</i>)-carboxylate and 3-methoxyaniline: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.47 (d, <i>J</i> = 6.6 Hz, 3H), 3.14–3.26 (m, 1H), 3.26–3.40 (m, 1H), 3.74 (ddd, <i>J</i> = 12.0, 5.0, 2.3 Hz, 1H), 3.82 (s, 3H), 5.77 (br. s., 1H), 6.75 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 6.84 (s, 1H), 6.91 (d, <i>J</i> = 7.8 Hz, 1H), 7.31 (t, <i>J</i> = 7.8 Hz, 1H), 7.35–7.47 (m, 4H), 7.86–7.97 (m, 2H), 10.80 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 360 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 4-((3-Methoxyphenyl)amino)-6-phenylnicotinamide (<b>60</b>)</h4><div class="NLM_p">Step 1. 2-Bromo-5-methyl-4-nitropyridine (3.50 g, 16.1 mmol), phenylboronic acid (2.36 g, 19.4 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (0.66 g, 0.81 mmol) were dissolved in 250 mL of dioxane. Twenty-five milliliters of 2 M aqueous sodium carbonate solution was added, and the reaction vessel was subject to two cycles of evacuation–backfilling with argon. The mixture was stirred under argon and heated at 90 °C for 4 h. The mixture was allowed to cool and diluted with ethyl acetate, and the organics were washed twice with water and once with brine. The organics were dried over magnesium sulfate, filtered, and evaporated. The residue was partially purified by flash chromatography (dichloromethane) to give a crude sample of 5-methyl-4-nitro-2-phenylpyridine (3 g, 70% purity by HPLC).</div><div class="NLM_p">Step 2. The crude sample of 5-methyl-4-nitro-2-phenylpyridine (3 g) was dissolved in 20 mL of pyridine and 10 mL of water. Potassium permanganate (7.9 g, 50 mmol) was added portion-wise and with stirring. The mixture was stirred at reflux overnight. The mixture was allowed to cool, further potassium permanganate (7.9 g, 50 mmol) was added portion-wise, and the mixture was stirred at reflux for 6 h. The mixture was cooled and filtered through a plug of Celite, washing the Celite first with water and then ethyl acetate. The biphasic filtrate was separated, and the aqueous was adjusted to pH 4–5 with 2 M hydrochloric acid. The aqueous was extracted three times with ethyl acetate, and the combined organics were washed with brine and dried over magnesium sulfate. Evaporation gave 4-nitro-6-phenylnicotinic acid (1.3 g, 5.4 mmol, 34% yield over two steps): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 7.48–7.66 (m, 3H), 7.95 (s, 1H), 8.11 (t, <i>J</i> = 7.6 Hz, 2H), 9.33 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 243 [M - H]<sup>+</sup>.</div><div class="NLM_p">Step 3. 4-Nitro-6-phenylnicotinic acid (1.3 g, 5.4 mmol) was dissolved in 30 mL of dimethylformamide. Potassium carbonate (1.49 g, 10.8 mmol) and ethyl bromide (0.40 mL, 5.4 mmol) were added, and the mixture was stirred at 50 °C for 2 h. The mixture was diluted with water and extracted three times with ethyl acetate, and the combined organics were washed with brine, dried over magnesium sulfate, and evaporated. The residue was purified by flash chromatography (dichloromethane-hexane, gradient) to give ethyl 4-nitro-6-phenylnicotinate (0.8 g, 2.9 mmol, 54% yield): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.39 (t, <i>J</i> = 7.0 Hz, 3H), 4.44 (q, <i>J</i> = 7.0 Hz, 2H), 7.47–7.63 (m, 3H), 7.99 (s, 1H), 8.02–8.14 (m, 2H), 9.19 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 273 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 4. Ethyl 4-nitro-6-phenylnicotinate (0.8 g, 2.9 mmol) was dissolved in 40 mL of ethanol. Palladium on carbon (10%, 160 mg) was added, and the mixture was agitated under hydrogen atmosphere at 30 psi for 3 h. The mixture was filtered through a plug of Celite, and the filtrate was evaporated to give ethyl 4-amino-6-phenylnicotinate (0.55 g, 2.3 mmol, 74% yield): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.41 (t, <i>J</i> = 7.2 Hz, 3H), 4.38 (q, <i>J</i> = 7.0 Hz, 2H), 6.23 (br. s., 2H), 6.93 (s, 1H), 7.39–7.54 (m, 3H), 7.90–8.00 (m, 2H), 9.01 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 243 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 5. A mixture of ethyl 4-amino-6-phenylnicotinate (100 mg, 0.41 mmol), 3-bromoanisole (0.078 mL, 0.62 mmol), potassium carbonate (120 mg, 0.87 mmol), copper(I) iodide (8 mg, 0.04 mmol), and <i>N</i>,<i>N</i>′-dimethylethane-1,2-diamine (0.009 mL, 0.08 mmol) were suspended in 2 mL of anhydrous dioxane in a pressure tube. The mixture was subject to two cycles of evacuation–backfilling with argon, the tube was sealed, and the mixture was stirred at 140 °C overnight. The mixture was diluted with ethyl acetate and washed with ammonium hydroxide solution and with brine. The organics were dried over magnesium sulfate and evaporated, and the residue purified by reverse-phase chromatography to give ethyl 4-(3-methoxyphenylamino)-6-phenylnicotinate (119 mg, 0.34 mmol, 83% yield): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.44 (t, <i>J</i> = 7.2 Hz, 3H), 3.83 (s, 3H), 4.43 (q, <i>J</i> = 7.0 Hz, 2H), 6.76–6.86 (m, 2H), 6.92 (d, <i>J</i> = 8.6 Hz, 1H), 7.29–7.39 (m, 1H), 7.38–7.49 (m, 4H), 7.84–7.96 (m, 2H), 9.12 (s, 1H), 9.96 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 349 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 6. Ethyl 4-(3-methoxyphenylamino)-6-phenylnicotinate (119 mg, 0.34 mmol) was dissolved in 5 mL of tetrahydrofuran and 5 mL of water. Lithium hydroxide hydrate (72 mg, 1.7 mmol) was added, and the mixture was stirred overnight. The THF was evaporated, and the aqueous solution was purified directly by reverse-phase chromatography to give 4-(3-methoxyphenylamino)-6-phenylnicotinic acid (61 mg, 0.19 mmol, 56% yield) as a white solid: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.79 (s, 3H), 6.82 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 6.93–7.07 (m, 2H), 7.38 (t, <i>J</i> = 8.0 Hz, 1H), 7.43–7.53 (m, 4H), 7.83–7.96 (m, 2H), 8.93 (s, 1H), 10.38 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 319 [M – H]<sup>+</sup>.</div><div class="NLM_p last">Step 7. 4-(3-Methoxyphenylamino)-6-phenylnicotinic acid (50 mg, 0.16 mmol) was dissolved in 2 mL of dimethylformamide. <i>N</i>-Hydroxybenzotriazole (HOBt, 32 mg, 0.24 mmol), 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC, 45 mg, 0.23 mmol), and concentrated ammonia solution (0.013 mL, 0.33 mmol) were added, and the mixture was stirred overnight at room temperature. The mixture was purified directly by reverse-phase chromatography to give <b>60</b> as a white solid (8 mg, 0.025 mmol, 16% yield), HPLC purity 97%: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.72 (s, 3H), 6.75 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 6.80 (s, 1H), 6.89 (d, <i>J</i> = 7.8 Hz, 1H), 7.33 (t, <i>J</i> = 8.0 Hz, 1H), 7.39 (s, 1H), 7.39–7.47 (m, 4H), 7.78 (d, <i>J</i> = 8.2 Hz, 2H), 8.28 (br. s., 1H), 8.73 (s, 1H), 10.32 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 320 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 6-Phenyl-4-(quinolin-5-ylamino)nicotinamide (<b>61</b>)</h4><div class="NLM_p">Step 1. A mixture of ethyl 4-amino-6-phenylnicotinate (see <b>60</b>, step 4, 100 mg, 0.41 mmol), 5-bromoquinoline (129 mg, 0.62 mmol), potassium carbonate (120 mg, 0.87 mmol), copper(I) iodide (8 mg, 0.04 mmol), and <i>N</i>,<i>N</i>′-dimethylethane-1,2-diamine (0.009 mL, 0.08 mmol) were suspended in 2 mL of anhydrous dioxane in a pressure tube. The mixture was subject to two cycles of evacuation–backfilling with argon, the tube was sealed, and the mixture was stirred at 140 °C overnight. The mixture was diluted with ethyl acetate and washed with ammonium hydroxide solution and with brine. The organics were dried over magnesium sulfate and evaporated, and the residue was purified by reverse-phase chromatography to give ethyl 6-phenyl-4-(quinolin-5-ylamino)nicotinate (106 mg, 0.29 mmol, 70% yield): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.49 (t, <i>J</i> = 7.0 Hz, 3H), 4.48 (q, <i>J</i> = 7.0 Hz, 2H), 7.01 (s, 1H), 7.32–7.40 (m, 3H), 7.46 (dd, <i>J</i> = 8.4, 4.1 Hz, 1H), 7.58–7.67 (m, 1H), 7.69–7.78 (m, 2H), 7.80 (t, <i>J</i> = 7.3 Hz, 1H), 8.11 (d, <i>J</i> = 8.6 Hz, 1H), 8.38 (d, <i>J</i> = 8.2 Hz, 1H), 9.00 (d, <i>J</i> = 2.3 Hz, 1H), 9.17 (s, 1H), 10.15 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 370 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 2. Ethyl 6-phenyl-4-(quinolin-5-ylamino)nicotinate (106 mg, 0.29 mmol) was dissolved in 5 mL of tetrahydrofuran and 5 mL of water. Lithium hydroxide hydrate (60 mg, 1.4 mmol) was added, and the mixture was stirred overnight. The THF was evaporated, and the aqueous solution was purified directly by reverse-phase chromatography to give 6-phenyl-4-(quinolin-5-ylamino)nicotinic acid (86 mg, 0.25 mmol, 88% yield) as a yellow solid: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.12 (s, 1H), 7.33–7.48 (m, 3H), 7.60 (dd, <i>J</i> = 8.6, 3.9 Hz, 1H), 7.71–7.93 (m, 4H), 7.94–8.05 (m, 1H), 8.40 (d, <i>J</i> = 8.2 Hz, 1H), 8.98 (s, 2H); MS(ESI) <i>m</i>/<i>z</i> 340 [M – H]<sup>+</sup>.</div><div class="NLM_p last">Step 3. 6-Phenyl-4-(quinolin-5-ylamino)nicotinic acid (60 mg, 0.18 mmol) was suspended in 6 mL of dimethylformamide. HOBt (35 mg, 0.26 mmol), EDC (50 mg, 0.26 mmol), and concentrated ammonia solution (0.014 mL, 0.33 mmol) were added, and the mixture was stirred overnight at room temperature. The mixture was purified directly by reverse-phase chromatography to give <b>61</b> as a white solid (50 mg, 0.15 mmol, 84% yield), HPLC purity 93%: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.21 (s, 1H), 7.34–7.47 (m, 3H), 7.61 (dd, <i>J</i> = 8.4, 4.1 Hz, 1H), 7.72–7.87 (m, 5H), 7.94 (t, <i>J</i> = 8.8 Hz, 1H), 8.32–8.45 (m, 2H), 8.91–9.04 (m, 2H), 11.19 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 341 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>N</i>-Methyl-6-phenyl-4-(quinolin-5-ylamino)nicotinamide (<b>62</b>)</h4><div class="NLM_p last">6-Phenyl-4-(quinolin-5-ylamino)nicotinic acid (see <b>61</b>, step 2, 70 mg, 0.21 mmol) was suspended in 2 mL of dimethylformamide. HOBt (42 mg, 0.31 mmol), EDC (59 mg, 0.31 mmol), and methylamine hydrochloride (29 mg, 0.43 mmol) were added, and the mixture was stirred overnight at room temperature. The mixture was purified directly by reverse-phase chromatography to give <b>62</b> as a white solid (63 mg, 0.18 mmol, 87% yield), HPLC purity 100%; <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.88 (d, <i>J</i> = 4.3 Hz, 3H), 7.25 (s, 1H), 7.36–7.49 (m, 3H), 7.62 (dd, <i>J</i> = 8.4, 4.1 Hz, 1H), 7.76 (d, <i>J</i> = 7.5 Hz, 1H), 7.79–7.90 (m, 3H), 7.95 (d, <i>J</i> = 7.5 Hz, 1H), 8.39 (d, <i>J</i> = 8.2 Hz, 1H), 8.82–8.94 (m, 2H), 8.98 (dd, <i>J</i> = 4.2, 1.6 Hz, 1H), 10.98 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 355 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (5<i>Z</i>)-2-(3-Methoxyphenyl)-4-[(3-methoxyphenyl)amino]-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one Oxime (<b>63</b>)</h4><div class="NLM_p">Step 1. Diisopropylethylamine (0.20 mL, 1.15 mmol) and diphosphorous pentasulfide (110 mg, 0.34 mmol) were added to a solution of <b>24</b> (55 mg, 0.15 mmol) dissolved in 2 mL of warm dioxane. The mixture was stirred at 100 °C overnight, then cooled to room temperature. The suspension was dissolved in dichloromethane and loaded onto a plug of silica. The plug was flushed through with ethyl acetate, giving a yellow filtrate. The filtrate was evaporated and purified by flash chromatography (ethyl acetate/hexanes 50:50) to give 2-(3-methoxyphenyl)-4-[(3-methoxyphenyl)amino]-7,8-dihydro-1,6-naphthyridine-5(6<i>H</i>)-thione (<b>18</b>, R<sup>1</sup> = R<sup>2</sup> = 3-MeO-Ph) as a yellow solid (34 mg, 0.08 mmol, 57% yield): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.18 (t, <i>J</i> = 6.8 Hz, 2H), 3.61 (td, <i>J</i> = 6.8, 3.5 Hz, 2H), 3.82 (s, 3H), 3.85 (s, 3H), 6.78 (dd, <i>J</i> = 7.9, 2.3 Hz, 1H), 6.85 (t, <i>J</i> = 2.1 Hz, 1H), 6.88–7.00 (m, 2H), 7.30 (dd, <i>J</i> = 8.0, 2.8 Hz, 1H), 7.34–7.44 (m, 3H), 7.48 (dd, <i>J</i> = 2.4, 1.4 Hz, 1H), 7.99 (br. s., 1H), 12.09 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 392 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 2. Sodium hydride (60% dispersion in oil, 3.5 mg, 0.09 mmol) was suspended in 0.5 mL of dry tetrahydrofuran. A solution of <b>18</b> (R<sup>1</sup> = R<sup>2</sup> = 3-MeO-Ph, 27 mg, 0.069 mmol) in 0.5 mL of tetrahydrofuran was added dropwise while stirring. The mixture was stirred at 70 °C for 30 min and was then cooled to room temperature. A solution of methyl iodide (13.5 mg, 0.095 mmol) dissolved in 0.2 mL of dry tetrahydrofuran was added, and the mixture was stirred at 70 °C for 2 h. The mixture was evaporated, and the residue was partitioned between dichloromethane and water. The organic layer was separated, washed with brine, and dried over sodium sulfate. Evaporation gave <i>N</i>-2-bis(3-methoxyphenyl)-5-(methylthio)-7,8-dihydro-1,6-naphthyridin-4-amine (<b>19</b>, R<sup>1</sup> = R<sup>2</sup> = 3-MeO-Ph) as a pale yellow solid (24 mg, 0.056 mmol, 82% yield): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 2.43 (s, 3H), 2.79 (t, <i>J</i> = 6.8 Hz, 2H), 3.62–3.74 (m, 2H), 3.72 (s, 3H), 3.75 (s, 3H), 6.57–6.91 (m, 4H), 7.08–7.44 (m, 5H), 7.60 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 406 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 3. Compound <b>19</b> (R<sup>1</sup> = R<sup>2</sup> = 3-MeO-Ph, 12 mg, 0.03 mmol), potassium carbonate (9 mg, 0.06 mmol), and hydroxylamine hydrochloride (4 mg, 0.06 mmol) were suspended in 0.8 mL of ethanol. The mixture was stirred at 70 °C for 30 min, diisopropylethylamine (0.05 mL, 0.29 mmol) was added, and the mixture was stirred at 70 °C overnight. The solvent was evaporated, and the crude was purified by flash chromatography (gradient hexane/ethyl acetate from 50:50 to ethyl acetate) to give <b>63</b> as a white solid (3 mg, 0.007 mmol, 23% yield), HPLC purity 91%. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.16 (br. s., 2H), 3.38–3.61 (m, 2H), 3.68–3.97 (m, 6H), 5.77 (br. s., 1H), 6.80–7.02 (m, 4H), 7.12–7.60 (m, 5H), 10.21 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 391 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> [(5<i>Z</i>)-2-(3-Methoxyphenyl)-4-[(3-methoxyphenyl)amino]-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-ylidene]cyanamide (<b>64</b>)</h4><div class="NLM_p last">Compound <b>19</b> (R<sup>1</sup> = R<sup>2</sup> = 3-MeO-Ph, 12 mg, 0.03 mmol) was treated with cyanamide (5 mg, 0.12 mmol) in 0.8 mL of ethanol. The mixture was stirred at 70 °C for 45 min, then cooled to room temperature and filtered to give <b>64</b> as yellow solid (6 mg, 0.015 mmol, 51% yield), HPLC purity 99%: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.21 (t, <i>J</i> = 6.4 Hz, 2H), 3.73 (td, <i>J</i> = 6.5, 2.5 Hz, 2H), 3.84 (s, 3H), 3.85 (s, 3H), 6.70–7.02 (m, 4H), 7.27–7.42 (m, 5H), 7.43–7.50 (m, 1H), 10.57 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 400 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 2-(3,4-Difluorophenyl)-4-(quinolin-5-ylamino)-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>65</b>)</h4><div class="NLM_p last">Method 1k. White solid, HPLC purity 100%. Yield of 39% from <b>13</b> (R<sup>1</sup> = 3,4-diF-Ph) and 5-bromoquinoline: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.06 (t, <i>J</i> = 6.6 Hz, 2H), 3.45–3.61 (m, 2H), 7.21 (s, 1H), 7.35–7.54 (m, 1H), 7.55–7.83 (m, 3H), 7.87 (d, <i>J</i> = 7.4 Hz, 1H), 7.91–8.03 (m, 2H), 8.33 (br. s., 1H), 8.38 (d, <i>J</i> = 8.6 Hz, 1H), 8.98 (d, <i>J</i> = 3.9 Hz, 1H), 11.65 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 403 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> [(5<i>Z</i>)-2-(3,4-Difluorophenyl)-4-(quinolin-5-ylamino)-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-ylidene]cyanamide (<b>66</b>)</h4><div class="NLM_p last">Yellow solid, HPLC purity 99%. Yield of 26% from <b>19</b> (R<sup>1</sup> = 3,4-diF-Ph, R<sup>2</sup> = 5-quinolyl, derived from <b>65</b> using methods described above): <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 3.25 (t, <i>J</i> = 6.8 Hz, 2H), 3.80 (td, <i>J</i> = 6.8, 2.7 Hz, 2H), 6.84 (s, 1H), 7.01 (br. s., 1H), 7.11 (dd, <i>J</i> = 18.0, 8.6 Hz, 1H), 7.40 (ddd, <i>J</i> = 8.8, 4.0, 2.1 Hz, 1H), 7.48 (dd, <i>J</i> = 8.6, 4.3 Hz, 1H), 7.58 (d, <i>J</i> = 7.4 Hz, 1H), 7.68 (ddd, <i>J</i> = 11.5, 8.0, 2.0 Hz, 1H), 7.82 (t, <i>J</i> = 7.8 Hz, 1H), 8.15 (d, <i>J</i> = 8.6 Hz, 1H), 8.33 (d, <i>J</i> = 8.6 Hz, 1H), 9.01 (dd, <i>J</i> = 4.0, 1.5 Hz, 1H), 10.92 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 427 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 2-(3′-Hydroxybiphenyl-3-yl)-4-(quinolin-5-ylamino)-7,8-dihydro-1,6-naphthyridin-5(6<i>H</i>)-one (<b>67</b>)</h4><div class="NLM_p last">Method 1k. Yellow solid, HPLC purity 99%. Yield of 52% from <b>16</b> (R<sup>3</sup> = 3-HO-Ph) and 5-bromoquinoline: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.08 (t, <i>J</i> = 6.4 Hz, 2H), 3.46–3.62 (m, 2H), 6.78 (d, <i>J</i> = 8.6 Hz, 1H), 6.94–7.11 (m, 2H), 7.17–7.34 (m, 2H), 7.48 (d, <i>J</i> = 7.4 Hz, 1H), 7.56–7.68 (m, 1H), 7.67–7.91 (m, 3H), 7.91–8.01 (m, 1H), 8.07 (s, 1H), 8.31 (br. s., 1H), 8.40 (d, <i>J</i> = 8.6 Hz, 1H), 8.99 (d, <i>J</i> = 3.9 Hz, 1H), 9.57 (br. s., 1H), 11.63 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 459 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 3′-[5-Oxo-4-(quinolin-5-ylamino)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]biphenyl-4-carboxylic Acid (<b>68</b>)</h4><div class="NLM_p last">Method 1k. Pale yellow solid, HPLC purity 97%. Yield of 9% from <b>16</b> (R<sup>3</sup> = 4-HO<sub>2</sub>C-Ph) and 5-bromoquinoline: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.10 (t, <i>J</i> = 6.4 Hz, 2H), 3.54 (br. s., 2H), 7.25 (s, 1H), 7.53 (t, <i>J</i> = 7.6 Hz, 1H), 7.63 (dd, <i>J</i> = 8.6, 4.3 Hz, 1H), 7.70–7.87 (m, 5H), 7.93 (t, <i>J</i> = 8.2 Hz, 1H), 8.03 (d, <i>J</i> = 8.2 Hz, 2H), 8.17 (s, 1H), 8.35 (br. s., 1H), 8.41 (d, <i>J</i> = 8.6 Hz, 1H), 8.99 (d, <i>J</i> = 2.7 Hz, 1H), 11.68 (s, 1H), 12.98 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 487 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Ethyl 3′-[5-Oxo-4-(quinolin-5-ylamino)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]biphenyl-4-carboxylate (<b>69</b>)</h4><div class="NLM_p last">Method 1k. Brown solid, HPLC purity 91%. Yield of 64% from <b>16</b> (R<sup>3</sup> = 4-EtO<sub>2</sub>C-Ph) and 5-bromoquinoline: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.41 (t, <i>J</i> = 7.0 Hz, 3H), 3.25 (t, <i>J</i> = 6.2 Hz, 2H), 3.71 (t, <i>J</i> = 6.5 Hz, 2H), 4.40 (q, <i>J</i> = 7.0 Hz, 2H), 5.92 (br. s., 1H), 7.03 (s, 1H), 7.37–7.54 (m, 2H), 7.55–7.73 (m, 3H), 7.63 (d, <i>J</i> = 7.8 Hz, 2H), 7.77 (t, <i>J</i> = 8.0 Hz, 1H), 7.98–8.20 (m, 4H), 8.45 (d, <i>J</i> = 8.2 Hz, 1H), 8.98 (d, <i>J</i> = 3.1 Hz, 1H), 11.19 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 515 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> <i>N</i>-Cyclopropyl-3′-[5-oxo-4-(quinolin-4-ylamino)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]biphenyl-3-carboxamide (<b>70</b>)</h4><div class="NLM_p last">Method 1k. White solid, HPLC purity 96%. Yield of 34% from <b>16</b> (R<sup>3</sup> = 3-cPrHNOC-Ph) and 4-bromoquinoline: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.52–0.65 (m, 2H), 0.72 (app d, <i>J</i> = 6.6 Hz, 2H), 2.75–2.98 (m, 1H), 3.14 (t, <i>J</i> = 6.2 Hz, 2H), 3.55 (br. s., 2H), 7.47–7.93 (m, 8H), 7.98 (s, 1H), 8.01–8.22 (m, 4H), 8.34 (br. s., 1H), 8.43–8.64 (m, 2H), 8.83 (d, <i>J</i> = 5.1 Hz, 1H), 12.44 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 526 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> <i>N</i>-Cyclopropyl-3′-[4-(isoquinolin-4-ylamino)-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]biphenyl-3-carboxamide (<b>71</b>)</h4><div class="NLM_p last">Method 1k. White solid, HPLC purity 97%. Yield of 42% from <b>16</b> (R<sup>3</sup> = 3-cPrNHOC-Ph and 4-bromoisoquinoline: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 0.64 (br. s., 2H), 0.90 (app d, <i>J</i> = 5.1 Hz, 2H), 2.95 (br. s., 1H), 3.26 (t, <i>J</i> = 6.0 Hz, 2H), 3.73 (t, <i>J</i> = 6.2 Hz, 2H), 5.90 (br. s., 1H), 6.33 (br. s., 1H), 7.06 (br. s., 1H), 7.37–7.58 (m, 3H), 7.60–7.90 (m, 5H), 7.93 (br. s., 1H), 8.00–8.14 (m, 3H), 8.69 (s, 1H), 9.19 (s, 1H), 11.17 (br. s., 1H); MS(ESI) <i>m</i>/<i>z</i> 526 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> <i>N</i>-Cyclopropyl-3′-[5-oxo-4-(quinolin-5-ylamino)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]biphenyl-3-carboxamide (<b>72</b>)</h4><div class="NLM_p last">Method 1k. White solid, HPLC purity 96%. Yield of 20% from <b>16</b> (R<sup>3</sup> = 3-cPrHNOC-Ph) and 5-bromoquinoline: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.49–0.65 (m, 2H), 0.66–0.80 (m, 2H), 2.88 (tt, <i>J</i> = 7.0, 3.5 Hz, 1H), 3.09 (t, <i>J</i> = 6.6 Hz, 2H), 3.54 (t, <i>J</i> = 6.5 Hz, 2H), 7.25 (s, 1H), 7.46–7.69 (m, 3H), 7.79 (app d, <i>J</i> = 9.4 Hz, 6H), 7.91–8.00 (m, 1H), 8.07 (s, 1H), 8.15 (s, 1H), 8.32 (br. s., 1H), 8.41 (d, <i>J</i> = 8.2 Hz, 1H), 8.54 (d, <i>J</i> = 3.9 Hz, 1H), 8.98 (d, <i>J</i> = 2.7 Hz, 1H), 11.66 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 526 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>N</i>-Cyclopropyl-3′-{4-[(1-oxidoquinolin-5-yl)amino]-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl}biphenyl-3-carboxamide (<b>73</b>)</h4><div class="NLM_p last">Compound <b>72</b> (172 mg, 0.28 mmol) was dissolved in 5 mL of dichloromethane and cooled to 5 °C in an ice bath. <i>meta</i>-Chloroperbenzoic acid (max purity 77%, 142 mg, 0.64 mmol) was added, and the mixture was stirred for 30 min at 5 °C. The mixture was then stirred at room temperature for 2 h. The organics were washed three times with 4% w/v sodium carbonate solution, once with brine, and dried over sodium sulfate. The organics were filtered and evaporated, and the residue was purified by reverse-phase chromatography using the SP1 purification system to give 87 as a yellow solid (37 mg, 0.065 mmol, 24% yield), HPLC purity 91%: <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.53–0.65 (m, 2H), 0.70 (t, <i>J</i> = 3.5 Hz, 2H), 2.78–2.96 (m, 1H), 3.10 (t, <i>J</i> = 6.6 Hz, 2H), 3.53 (t, <i>J</i> = 6.4 Hz, 2H), 7.36 (s, 1H), 7.48–7.62 (m, 3H), 7.72–7.98 (m, 7H), 8.08 (s, 1H), 8.21 (s, 1H), 8.38 (d, <i>J</i> = 6.6 Hz, 2H), 8.55 (d, <i>J</i> = 3.5 Hz, 1H), 8.66 (d, <i>J</i> = 6.2 Hz, 1H), 11.75 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 542 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> <i>N</i>-[3-(Dimethylamino)propyl]-3′-[5-oxo-4-(quinolin-5-ylamino)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]biphenyl-3-carboxamide (<b>74</b>)</h4><div class="NLM_p last">Compound <b>17</b> (R<sup>3</sup> = 3-HO<sub>2</sub>C-Ph, R<sup>2</sup> = 5-quinolyl, prepared using methods described above, 150 mg, 0.31 mmol) was dissolved in 5 mL of <i>N</i>,<i>N</i>′-dimethylformamide. 1-Hydroxybenzotriazole hydrate (60 mg, 0.45 mmol) and <i>N</i>-(3-(dimethylamino)propyl)-<i>N</i>′-ethylcarbodiimide hydrochloride (86 mg, 0.45 mmol) were added. The mixture was stirred at room temperature for 30 min. <i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>-Dimethylpropane-1,3-diamine (0.077 mL, 0.62 mmol) was added, and the mixture was stirred at 50 °C for 4 h. The solvent was evaporated, and 4% potassium carbonate aqueous solution and ethyl acetate were added. The organic layer was separated, washed twice with water and twice with brine, dried with magnesium sulfate, filtered, and concentrated. The residue was purified by reverse-phase chromatography using the SP1 purification system to give <b>74</b> as a white solid (28 mg, 0.049 mmol, 16% yield), HPLC purity 99%: <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.97 (quin, <i>J</i> = 5.8 Hz, 2H), 2.51 (s, 6H), 2.81 (t, <i>J</i> = 6.2 Hz, 2H), 3.24 (t, <i>J</i> = 6.6 Hz, 2H), 3.44–3.83 (m, 4H), 6.02 (br. s., 1H), 7.05 (s, 1H), 7.35–7.56 (m, 3H), 7.56–7.94 (m, 5H), 8.05 (d, <i>J</i> = 8.2 Hz, 1H), 8.14 (d, <i>J</i> = 5.1 Hz, 2H), 8.45 (app d, <i>J</i> = 8.6 Hz, 3H), 8.97 (d, <i>J</i> = 3.1 Hz, 1H), 11.20 (s, 1H); MS(ESI) <i>m</i>/<i>z</i> 571 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> PDE4 Activity Determination</h3><div class="NLM_p">PDE4 activity from various human recombinant PDE4 subtypes (PDE4B1, PDE4A4, and PDE4D3) was monitored by measuring the hydrolysis of [<sup>3</sup>H]-cAMP to [<sup>3</sup>H]-AMP using a PDE-SPA kit from Amersham International as previously described.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Enzyme extracts (∼4 μg of protein) were incubated in “low binding” plates (Costar 3604) for 60 min at room temperature. The assay mixture (80 μL) contained 15 nM [<sup>3</sup>H]-cAMP (1 μCi/mL) in the assay buffer (50 mM Tris pH 7.5, 8.3 mM MgCl<sub>2</sub>, 1.7 mM EGTA) and 10 μL of test compound. These compounds were resuspended in DMSO (the final DMSO concentration 5% (v/v)) at a stock concentration of 1 mM. The compounds were tested at different concentrations varying from 10 μM to 10 pM to calculate an IC<sub>50</sub>. These dilutions were done in 96-well plates. In some cases, plates containing diluted compounds were frozen before being assayed. In these cases, the plates were thawed at room temperature and agitated for 15 min.</div><div class="NLM_p last">Hydrolysis of [<sup>3</sup>H]-cAMP was initiated by adding 10 μL of a solution containing PDE4 enzyme, and the plate was then incubated under agitation at room temperature. The reaction was stopped after 60 min (with ∼10–20% substrate conversion) by addition of 50 μL of Phosphodiesterase Scintillation Proximity Assay (SPA) Beads. All reactions were carried out in duplicate. [<sup>3</sup>H]-AMP, captured by the SPA beads, was determined by counting the plates in a Wallac-Microbeta Trilux scintillation counter 1 h after addition of the beads, although the signal was quite stable, and samples may be counted from 1 to 48 h after bead addition. All experiments were run in duplicates as long as one was within twice the value of the other (SD pIC<sub>50</sub> < 0.2). Otherwise, further experiments were run until pIC<sub>50</sub> < 0.2. All data reported are to two significant figures.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> LPS Induced TNF-α in Human Whole Blood (HWB-TNF-α)</h3><div class="NLM_p last">Human whole blood of healthy donors was collected in 50 mL Falcon tubes with heparin (5000 units/mL, Heparin Mayne 5%, MAYNEPHARMA). LPS (lipopolysaccharide from <i>Escherichia coli</i>, Sigma, St. Louis, MO) dissolved in PBS (Dulbecco’s phosphate buffered saline, without calcium and magnesium chloride, Sigma, St. Louis, MO) was added to the tubes to give a final concentration in the assay of 1 μg/mL and preincubated at 37 °C for 10 min with rocking. Increasing concentrations of different inhibitors (2 μL), dissolved in 100% DMSO, were added to the 96-well plates, and 200 μL of blood containing LPS (except for controls) was then distributed into wells. Plates were shaken for 1–2 min, sealed with aluminum foil lid (Beckman Coulter), and then incubated for 24 h at 37 °C under agitation in KelvitronT (Heraeus Instruments). After 24 h, plates were placed on ice, 50 μL of PBS was added, and the reaction was stopped by centrifugation of plates at 2000 rpm (800<i>g</i>) at 4 °C for 15 min. Serum obtained was then subjected to ELISA or kept at −80 °C until use.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> TNF-α Determination</h3><div class="NLM_p">The quantification of TNF-α in human serum was performed using a commercial ELISA kit (DuoSet) obtained from R&D Systems, Inc., and following the manufacturer’s instructions.</div><div class="NLM_p">Plate Preparation: First, R&D DuoSet ELISA 96-well microplates were coated with 4.0 μg/mL mouse antihuman TNF-R diluted in PBS overnight at room temperature. After washing, plates were then blocked with PBS containing 1% BSA for a minimum of 1 h at room temperature and then washed.</div><div class="NLM_p last">Assay Procedure: 100 μL of samples or standard was added and incubated for 2 h at room temperature. After washing (ELX406 Select, BIO-TEK), biotinylated anti-hTNF-α antibody was added and incubated at room temperature for 2 h, followed by incubation with streptavidin–peroxidase for 20 min. Detection of bound hTNF-α was carried out with 100 μL of substrate solution (H<sub>2</sub>O<sub>2</sub> and tetramethylbenzidine) followed by measurement at 450 nm in a SPECTRA max Plus (Molecular Devices). These experiments were performed 2–3 times using the same experimental design. Duplicates from each series of experiments were averaged and expressed as hTNF-α levels in pg/mL.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Inhibition of LPS-Induced Neutrophilia in Rats</h3><div id="sec100" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Dry Powder Administration</h4><div class="NLM_p">A solution of LPS (SIGMA, ref. L-2630, 100 mg/vial) was prepared in 10 mL of PBS (CAMBREX BE17–512F). This was further diluted 1:100 with PBS. Solutions were prepared 24 h before use to ensure dissolution and stored at 4 °C. Test compounds were micronized before use and comixed with lactose to the correct dilution.</div><div class="NLM_p last">Male Sprague–Dawley rats (230–280 g, fasted) were anaesthetized with isofluoroane. Five milligrams of test compound–lactose dry powder mix was loaded into a DP-4 dry powder insufflator fitted with a metal cannula. The cannula was carefully inserted into the trachea of the rats using a laringoscope to guide the needle. Test compound was dispensed with 5 mL of air insufflation via a syringe. The cannula was carefully withdrawn, and the animals were allowed to regain consciousness.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Microspray Administration</h4><div class="NLM_p">A solution of LPS (SIGMA, ref. L-2630, 100 mg/vial) was prepared in 10 mL of PBS (CAMBREX BE17–512F). This was further diluted 1:100 with PBS. Solutions were prepared 24 h before use to ensure dissolution and stored at 4 °C. Test compounds were suspended in PBS containing 0.2% Tween 80 and homogenized in a mortar. Compounds were suspended at their maximum test concentration. Other concentrations were made by 1:10 dilutions with PBS containing 0.2% Tween 80.</div><div class="NLM_p last">Male Sprague–Dawley rats (230–280 g, fasted) were anaesthetized with isoflurane. Test compound suspension (0.2 mL) was loaded into a Penn–Century microsprayer. The needle was carefully inserted into the trachea of the rats, to about 1 cm from the tracheal carina using a laryngoscope to guide the needle. Test compound was dispensed rapidly to aerosolize the suspension. The cannula was carefully withdrawn, and the animals were allowed to regain consciousness.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Nebulization of LPS</h3><div class="NLM_p">One or 18 h after test compound administration, animals were introduced into perspex chambers, and 30 mL of LPS solution was aerosolized using the DeVilbiss nebulizer during 40 min. After 4 h, the animals were euthanized with dolethal (2 g/mL, 10 mL/kg i.p). Two milliliters of PBS was introduced into the lungs via a cannula, and 0.8 mL of BAL solution was withdrawn. A further 2 mL of PBS was introduced and a further 1.8 mL of solution withdrawn. Neutrophils were counted directly by flow cytometry using the FACS.</div><div class="NLM_p last">Control groups were formed by i.t. lactose only and i.t. lactose and LPS aerosol with fluticasone (10% in lactose) and LPS aerosol as positive control.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Animal Studies</h3><div class="NLM_p last">All <i>in vivo</i> experiments were carried out in compliance with the European Committee Directive 2010/63/EU and the Spanish and Catalan laws. Experimental procedures were reviewed by The Animal-Welfare Body of Almirall and approved by the competent authority.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i90"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01751" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74862" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74862" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01751" class="ext-link">10.1021/acs.jmedchem.7b01751</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">PDE selectivity panel for compound <b>72</b>; kinase selectivity panel for compound <b>72</b>; single dose inhibition of LPS-induced lung neutrophilia in rats (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01751/suppl_file/jm7b01751_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01751/suppl_file/jm7b01751_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01751/suppl_file/jm7b01751_si_001.pdf">jm7b01751_si_001.pdf (118.43 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01751/suppl_file/jm7b01751_si_002.csv">jm7b01751_si_002.csv (6.33 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PBD ID codes: <b>3</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwt">3gwt</a>; <b>4</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k1i">5k1i</a>; <b>21</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k32">5k32</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01751" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25143" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25143" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard S. Roberts</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2343-6301" title="Orcid link">http://orcid.org/0000-0003-2343-6301</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b3c1dad0d89dc09dc1dcd1d6c1c7c0f3d4ded2dadf9dd0dcde"><span class="__cf_email__" data-cfemail="5d2f343e36732e732f323f382f292e1d3a303c3431733e3230">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sara Sevilla</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manel Ferrer</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joan Taltavull</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5199-5349" title="Orcid link">http://orcid.org/0000-0002-5199-5349</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Begoña Hernández</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor Segarra</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jordi Gràcia</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7470-6933" title="Orcid link">http://orcid.org/0000-0002-7470-6933</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin D. Lehner</span> - <span class="hlFld-Affiliation affiliation">Bionorica SE, Kerschensteinerstraße 11-15, 92318 Neumarkt, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amadeu Gavaldà</span> - <span class="hlFld-Affiliation affiliation">Experimental Dermatology†, , and , Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Miriam Andrés</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judit Cabedo</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dolors Vilella</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Eichhorn</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics & Metabolism†, , and , Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Calama</span> - <span class="hlFld-Affiliation affiliation">Experimental Dermatology†, , and , Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carla Carcasona</span> - <span class="hlFld-Affiliation affiliation">Experimental Dermatology†, , and , Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Montserrat Miralpeix</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry
& Screening, Pharmacokinetics & Metabolism, and Experimental Dermatology, Almirall S.A., Centro de Investigación y Desarrollo, Crta. Laureà Miró
408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d46e5417-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge the significant technical support provided by Silvia Petit, Carmen Cabello, Jordi Serrat, Agustina de la Cal, Dolores Marín, Laura Estrella, Eulàlia Benavent, and Lluís Boix. We also acknowledge Montse Soler, Irena Bonin, and Joan Aymami for the crystal structure determination. We thank Sonia Espinosa and Josep M. Huerta for their support on physicochemical properties analysis and structural characterization of compounds. This work was funded by Almirall, Spain.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AMP</td><td class="NLM_def"><p class="first last">adenosine monophosphate</p></td></tr><tr><td class="NLM_term">Asn</td><td class="NLM_def"><p class="first last">asparagine</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">cPr</td><td class="NLM_def"><p class="first last">cyclopropyl</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DP</td><td class="NLM_def"><p class="first last">dry powder</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide</p></td></tr><tr><td class="NLM_term">EGTA</td><td class="NLM_def"><p class="first last">ethylene glycol-bis(β-aminoethyl ether)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraacetic acid</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">FACS</td><td class="NLM_def"><p class="first last">fluorescence-activated cell sorting</p></td></tr><tr><td class="NLM_term">Gln</td><td class="NLM_def"><p class="first last">glutamine</p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">GlaxoSmithKline</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">HWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">i.t.</td><td class="NLM_def"><p class="first last">intratracheal</p></td></tr><tr><td class="NLM_term">i.v.</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">MS(ESI)</td><td class="NLM_def"><p class="first last">mass spectrometry by electrospray ionization</p></td></tr><tr><td class="NLM_term">NAP</td><td class="NLM_def"><p class="first last">naphthyridinone</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability assay</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononucleated cell</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PDE</td><td class="NLM_def"><p class="first last">phosphodiesterase</p></td></tr><tr><td class="NLM_term">Phe</td><td class="NLM_def"><p class="first last">phenylalanine</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">Pyr</td><td class="NLM_def"><p class="first last">pyridyl</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SPA</td><td class="NLM_def"><p class="first last">scintillation proximity assay</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TNFα</td><td class="NLM_def"><p class="first last">tumor necrosis factor alpha</p></td></tr><tr><td class="NLM_term">Tris</td><td class="NLM_def"><p class="first last">tris(hydroxymethyl)aminomethane</p></td></tr><tr><td class="NLM_term">UCR2</td><td class="NLM_def"><p class="first last">upstream conserved region 2</p></td></tr><tr><td class="NLM_term">Val</td><td class="NLM_def"><p class="first last">valine</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span> <span> </span><span class="NLM_article-title">Keynote review: phosphodiesterase-4 as a therapeutic target</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(05)03622-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2FS1359-6446%2805%2903622-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=16257373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1503-1519&author=M.+D.+Houslayauthor=P.+Schaferauthor=K.+Y.+Zhang&title=Keynote+review%3A+phosphodiesterase-4+as+a+therapeutic+target&doi=10.1016%2FS1359-6446%2805%2903622-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 as a therapeutic target</span></div><div class="casAuthors">Houslay, Miles D.; Schafer, Peter; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1503-1519</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase-4 selective inhibitors have therapeutic potential for treating major diseases such as asthma and COPD, as well as depression, Parkinson's disease and Alzheimer's disease.  CAMP is a key second messenger in all cells.  It is compartmentalized within cells and its levels are controlled, as a result of spatially discrete signaling cassettes controlling its generation, detection and degrdn.  Underpinning compartmentalized cAMP signaling are ∼20 members of the phosphodiesterase-4 (PDE4) family.  The selective inhibition of this family generates profound, functional effects and PDE4 inhibitors are currently under development to provide potential, novel therapeutics for the treatment of inflammatory diseases, such as asthma, chronic obstructive pulmonary disease and psoriasis, as well as treating depression and serving as cognitive enhancers.  Here, we delineate the range of PDE4 isoforms, their role in signaling, their structural biol. and related preclin. and clin. pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotOabrPCOweLVg90H21EOLACvtfcHk0lgare6N8Bfngw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsrzL&md5=7c75a76543b75145a44ae8f4a2f3b2ac</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903622-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903622-6%26sid%3Dliteratum%253Aachs%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DSchafer%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26atitle%3DKeynote%2520review%253A%2520phosphodiesterase-4%2520as%2520a%2520therapeutic%2520target%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D1503%26epage%3D1519%26doi%3D10.1016%2FS1359-6446%2805%2903622-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, K. H.</span></span> <span> </span><span class="NLM_article-title">PDE4 inhibitors - a review of the current field</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/S0079-6468(08)00202-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2FS0079-6468%2808%2900202-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=19328289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsV2jtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2009&pages=37-74&author=N.+J.+Pressauthor=K.+H.+Banner&title=PDE4+inhibitors+-+a+review+of+the+current+field&doi=10.1016%2FS0079-6468%2808%2900202-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4 inhibitors - a review of the current field</span></div><div class="casAuthors">Press, Neil J.; Banner, Katharine H.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37-74</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review on the phosphodiesterase 4 enzyme inhibitors and their potential therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodvxfZgwsOsbVg90H21EOLACvtfcHk0liNihP6m3x5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsV2jtb0%253D&md5=45a006d23fedc76f4f42f2f424bd4395</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0079-6468%2808%2900202-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6468%252808%252900202-6%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DBanner%26aufirst%3DK.%2BH.%26atitle%3DPDE4%2520inhibitors%2520-%2520a%2520review%2520of%2520the%2520current%2520field%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D47%26spage%3D37%26epage%3D74%26doi%3D10.1016%2FS0079-6468%2808%2900202-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cieslinski, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essayan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torphy, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnette, M. S.</span></span> <span> </span><span class="NLM_article-title">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1038%2Fsj.bjp.0702911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10602317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=1393-1398&author=C.+D.+Manningauthor=M.+Burmanauthor=S.+B.+Christensenauthor=L.+B.+Cieslinskiauthor=D.+M.+Essayanauthor=M.+Grousauthor=T.+J.+Torphyauthor=M.+S.+Barnette&title=Suppression+of+human+inflammatory+cell+function+by+subtype-selective+PDE4+inhibitors+correlates+with+inhibition+of+PDE4A+and+PDE4B&doi=10.1038%2Fsj.bjp.0702911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span></div><div class="casAuthors">Manning, Carol D.; Burman, Miriam; Christensen, Siegfried B.; Cieslinski, Lenora B.; Essayan, David M.; Grous, Marilyn; Torphy, Theodore J.; Barnette, Mary S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1393-1398</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Of the four major phosphodiesterase 4 (PDE4) subtypes, PDE4A, PDE4B and PDE4D are widely expressed in human inflammatory cells, including monocytes and T lymphocytes.  We explored the functional role of these subtypes using ten subtype-selective PDE4 inhibitors, each belonging to one of two classes: (i) dual PDE4A/PDE4B inhibitors or (ii) PDE4D inhibitors.  These compds. were evaluated for their ability to inhibit antigen-stimulated T-cell proliferation and bacterial lipopolysaccharide (LPS)-stimulated tumor necrosis factor α (TNFα) release from peripheral blood monocytes.  All compds. inhibited T-cell proliferation in a concn.-dependent manner; with IC50 values distributed over an approx. 50 fold range.  These compds. also inhibited TNFα release concn.-dependently, with a wider (∼ 1000 fold) range of IC50 values.  In both sets of expts., mean IC50 values were significantly correlated with compd. potency against the catalytic activity of recombinant human PDE4A or PDE4B when analyzed by either linear regression of log IC50 values or by Spearman's rank-order correlation.  The correlation between inhibition of inflammatory cell function and inhibition of recombinant PDE4D catalytic activity was not significant in either anal.  These results suggest that PDE4A and/or PDE4B may play the major role in regulating these two inflammatory cell functions but do not rule out PDE4D as an important mediator of other activities in mononuclear leukocytes and other immune and inflammatory cells.  Much more work is needed to establish the functional roles of the PDE4 subtypes across a broader range of cellular functions and cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3g1B9QQKejbVg90H21EOLACvtfcHk0liNihP6m3x5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D&md5=70490a1a73b83ce887e850e4efd2e738</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702911%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DC.%2BD.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DS.%2BB.%26aulast%3DCieslinski%26aufirst%3DL.%2BB.%26aulast%3DEssayan%26aufirst%3DD.%2BM.%26aulast%3DGrous%26aufirst%3DM.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26aulast%3DBarnette%26aufirst%3DM.%2BS.%26atitle%3DSuppression%2520of%2520human%2520inflammatory%2520cell%2520function%2520by%2520subtype-selective%2520PDE4%2520inhibitors%2520correlates%2520with%2520inhibition%2520of%2520PDE4A%2520and%2520PDE4B%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D1393%26epage%3D1398%26doi%3D10.1038%2Fsj.bjp.0702911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span> <span> </span><span class="NLM_article-title">Antidepressant effects of inhibitors of cyclic AMP phosphodiesterase (PDE4)</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2004.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.tips.2004.01.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=158-163&author=J.+M.+O%E2%80%99Donnellauthor=H.+T.+Zhang&title=Antidepressant+effects+of+inhibitors+of+cyclic+AMP+phosphodiesterase+%28PDE4%29&doi=10.1016%2Fj.tips.2004.01.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DAntidepressant%2520effects%2520of%2520inhibitors%2520of%2520cyclic%2520AMP%2520phosphodiesterase%2520%2528PDE4%2529%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2004%26volume%3D25%26spage%3D158%26epage%3D163%26doi%3D10.1016%2Fj.tips.2004.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagès, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span> <span> </span><span class="NLM_article-title">PDE4 inhibitors: a review of current developments (2005 – 2009)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1501</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1517/13543770903313753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F13543770903313753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=19832118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1501-1519&author=L.+Pag%C3%A8sauthor=A.+Gavald%C3%A0author=M.+D.+Lehner&title=PDE4+inhibitors%3A+a+review+of+current+developments+%282005+%E2%80%93+2009%29&doi=10.1517%2F13543770903313753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4 inhibitors: a review of current developments (2005 - 2009)</span></div><div class="casAuthors">Pages, Lluis; Gavalda, Amadeu; Lehner, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1501-1519</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Despite the sound preclin. database and some promising data from clin. trials, development of PDE4 inhibitors for the treatment of inflammatory or neurol. diseases has been hampered by dose-limiting class-related side effects.  Objective: In the past years, companies opted for different approaches to improve the therapeutic window of their compds. including topical administration of PDE4 inhibitors with the goal of minimizing systemic exposure.  This change in strategy is reflected by the disclosure of novel and chem. diverse mols. that demonstrate the continued interest of pharmaceutical industry in developing PDE4 inhibitors.  Conclusion: This review summarizes the clin. development of PDE4 inhibitors since 2005 and the assocd. patent literature with a focus on strategies applied to minimize systemic adverse effects.  In sum, although a significant no. of new drugs designed for improved tolerability entered clin. trials, so far none of them fulfilled expectations and best progress has been achieved recently with the oral, non-isoform selective PDE4 inhibitor roflumilast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6XZlM2_eQxbVg90H21EOLACvtfcHk0ljeDG_JwWH1uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmu7bM&md5=4041bbd045ffa269e1fa406746193c3e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1517%2F13543770903313753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903313753%26sid%3Dliteratum%253Aachs%26aulast%3DPag%25C3%25A8s%26aufirst%3DL.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DPDE4%2520inhibitors%253A%2520a%2520review%2520of%2520current%2520developments%2520%25282005%2520%25E2%2580%2593%25202009%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1501%26epage%3D1519%26doi%3D10.1517%2F13543770903313753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1016</span>, <span class="refDoi"> DOI: 10.1517/13543776.2013.794789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F13543776.2013.794789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=23642007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=997-1016&author=A.+Gavald%C3%A0author=R.+S.+Roberts&title=Phosphodiesterase-4+inhibitors%3A+a+review+of+current+developments+%282010+-+2012%29&doi=10.1517%2F13543776.2013.794789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012)</span></div><div class="casAuthors">Gavalda, Amadeu; Roberts, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">997-1016</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: At last, after many years of research, roflumilast has become the first oral phosphodiesterase-4 inhibitor to be approved by the medical agencies as an add-on therapy for chronic obstructive pulmonary disease.  A second compd., apremilast is targeted for submission of new drug application for the treatment of psoriasis in the second half of 2013.  These compds. represent a breakthrough and a reward in the field after the many failures to date in clin. development.  Areas covered: This review summarizes the clin. development of PDE4 inhibitors from 2010 - 2012 and the assocd. patent literature with a focus on strategies to overcome the common pitfalls of oral PDE4 inhibitors.  Expert opinion: In the last few years, influenced by the body of published clin. data, many companies have lost interest in PDE4 as a target.  Many of those that have persevered have opted to realign their research programs either toward compds. specifically designed for inhaled delivery or in search of an increase in clin. efficacy by combining two mechanisms in a single compd.  This change is reflected by the continued disclosure of novel and chem. diverse mols., indicating for some in the pharmaceutical industry that all is not yet lost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe0yV5hhUby7Vg90H21EOLACvtfcHk0ljeDG_JwWH1uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3L&md5=9a5961a6f439698b11123ac47c5839aa</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.794789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.794789%26sid%3Dliteratum%253Aachs%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26atitle%3DPhosphodiesterase-4%2520inhibitors%253A%2520a%2520review%2520of%2520current%2520developments%2520%25282010%2520-%25202012%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D997%26epage%3D1016%26doi%3D10.1517%2F13543776.2013.794789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span> <span> </span><span class="NLM_article-title">cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1311</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.968127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F13543776.2014.968127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=25284693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1311-1321&author=A.+Martinezauthor=C.+Gil&title=cAMP-specific+phosphodiesterase+inhibitors%3A+promising+drugs+for+inflammatory+and+neurological+diseases&doi=10.1517%2F13543776.2014.968127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases</span></div><div class="casAuthors">Martinez, Ana; Gil, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1311-1321</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: PDEs are key enzymes in the adenosine and guanosine cyclic nucleotides (cAMP and cGMP) signaling cascade.  Their inhibition increases cyclic nucleotide levels inside the cell.  Thus, pharmacol. modulation of PDE activity can have profound effects on the function of cells and organ systems throughout the body.  Areas covered: Among the large PDE families, only PDE4, PDE7 and PDE8 are cAMP-specific hydrolyzing enzymes. cAMP is an important second messenger not only by its involvement in a vast no. of physiol. processes but also by activation of protein kinase A, exchange protein activated by cAMP (Epac) and cAMP response element-binding (CREB) or cyclic nucleotide-gated channels.  Clearly, such enzymes represent ideal drug targets for the pharmacol. treatment of many pathologies.  The discovery and development of small mols. targeting cAMP-specific PDEs reported in the last 5 years is the focus of the present review.  Expert opinion: The first PDE4 inhibitors recently reached the market, having avoided, by different strategies, their dose-limiting side effects (after more than two decades of drug development).  Meanwhile, new cAMP-specific PDE7 and PDE8 inhibitors emerged as effective and safe drugs for severe unmet diseases.  The therapeutic potential of these inhibitors will be tested in the near future, as many of these drug candidates are ready to start clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPWFQGiKhADrVg90H21EOLACvtfcHk0ljeDG_JwWH1uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FN&md5=f9ef95eeccba94736c36de427c1715b0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.968127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.968127%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGil%26aufirst%3DC.%26atitle%3DcAMP-specific%2520phosphodiesterase%2520inhibitors%253A%2520promising%2520drugs%2520for%2520inflammatory%2520and%2520neurological%2520diseases%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D1311%26epage%3D1321%26doi%3D10.1517%2F13543776.2014.968127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborti, A. K.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 (PDE4) inhibitors in the treatment of COPD: promising drug candidates and future directions</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.2174/0929867323666151117121334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.2174%2F0929867323666151117121334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=26572614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Oiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=129-141&author=N.+Parikhauthor=A.+K.+Chakraborti&title=Phosphodiesterase+4+%28PDE4%29+inhibitors+in+the+treatment+of+COPD%3A+promising+drug+candidates+and+future+directions&doi=10.2174%2F0929867323666151117121334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions</span></div><div class="casAuthors">Parikh, Naisargee; Chakraborti, Asit K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The PDE4 enzyme has been proven to be a versatile drug target for therapeutics to treat diverse disease conditions such as asthma, COPD, diabetes, Huntington's disease, and various other inflammatory disorders.  The treatment of COPD is the most studied utility for PDE4 inhibitors due to their ability to inhibit inflammatory cell responses.  Roflumilast is the only approved drug belonging to this class to treat COPD and has shown significant results in the treatment of asthmatic patients.  This perspective highlights the pharmacol. details of roflumilast and cilomilast.  Moreover, efforts have been made to justify the superiority of roflumilast over cilomilast by detailed comparison of their pharmacol., pharmacokinetic, pharmacodynamic properties and structural features.  Several other mols., with promising PDE4 inhibitory activity have also been highlighted.  Commonly assocd. side effects with this class of compds., their management, and future direction towards the development of PDE4 inhibitors with improved therapeutic index are the focus of this perspective.  More emphasis has been given towards the future development strategies to limit the side effects such as emesis and to achieve better benefit to risk ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHRuuoQ7II8rVg90H21EOLACvtfcHk0ljSQ1gQhRWXmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Oiu70%253D&md5=b7901858db904fcd9a714b2b5d9ec9ef</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F0929867323666151117121334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666151117121334%26sid%3Dliteratum%253Aachs%26aulast%3DParikh%26aufirst%3DN.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26atitle%3DPhosphodiesterase%25204%2520%2528PDE4%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520COPD%253A%2520promising%2520drug%2520candidates%2520and%2520future%2520directions%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26spage%3D129%26epage%3D141%26doi%3D10.2174%2F0929867323666151117121334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulhall, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Droege, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panos, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zafar, M. A.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1597</span>– <span class="NLM_lpage">1611</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1094054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F13543784.2015.1094054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=26419847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1597-1611&author=A.+M.+Mulhallauthor=C.+A.+Droegeauthor=N.+E.+Ernstauthor=R.+J.+Panosauthor=M.+A.+Zafar&title=Phosphodiesterase+4+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+review+of+current+and+developing+drugs&doi=10.1517%2F13543784.2015.1094054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span></div><div class="casAuthors">Mulhall, Aaron M.; Droege, Christopher A.; Ernst, Neil E.; Panos, Ralph J.; Zafar, Muhammad A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1597-1611</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) inhibitors modulate lung inflammation and cause bronchodilation by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway smooth muscle and inflammatory cells.  Roflumilast is the only approved PDE-4 inhibitor (PDE4I) for use in chronic obstructive pulmonary disease (COPD).  Its beneficial clin. effects occur preferentially in patients with chronic bronchitis and frequent COPD exacerbations.  Use of roflumilast as adjunctive or alternate therapy to other COPD medications reduces exacerbations and modestly improves lung function.  This article reviews the current role of PDE4I in COPD treatment emphasizing roflumilast's clin. efficacy and adverse effects.  This article also reviews developing PDE4Is in early clin. trials and in preclin. studies.  After decades of research in drug development, PDE4Is are a welcomed addn. to the COPD therapeutic armamentarium.  In its current clin. role, the salubrious clin. effects of PDE4I in reducing exacerbations and stabilizing the frequent exacerbator phenotype have to be cautiously balanced with numerous adverse effects.  Developing drugs may provide similar or better clin. benefits while minimizing adverse effects by changing the mode of drug delivery to inhaled formulations, combining dual PDE isoenzyme inhibitors (PDE1/4I and PDE3/4I) and by forming hybrid mols. with other bronchodilators (muscarinic receptor antagonist/PDE4I and β2-agonist/PDE4I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFNEyjtRW-erVg90H21EOLACvtfcHk0ljSQ1gQhRWXmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ&md5=8d5130af94558b2950f624ae1528c86f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1094054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1094054%26sid%3Dliteratum%253Aachs%26aulast%3DMulhall%26aufirst%3DA.%2BM.%26aulast%3DDroege%26aufirst%3DC.%2BA.%26aulast%3DErnst%26aufirst%3DN.%2BE.%26aulast%3DPanos%26aufirst%3DR.%2BJ.%26aulast%3DZafar%26aufirst%3DM.%2BA.%26atitle%3DPhosphodiesterase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520review%2520of%2520current%2520and%2520developing%2520drugs%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1597%26epage%3D1611%26doi%3D10.1517%2F13543784.2015.1094054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rabe, K. F.</span></span> <span> </span><span class="NLM_article-title">Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1111%2Fj.1476-5381.2011.01218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=21232047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=53-67&author=K.+F.+Rabe&title=Update+on+roflumilast%2C+a+phosphodiesterase+4+inhibitor+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1476-5381.2011.01218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rabe, Klaus F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-67</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main PDE isoenzyme occurring in cells involved in inflammatory airway disease such as chronic obstructive pulmonary disease (COPD).  COPD is a preventable and treatable disease and is characterized by airflow obstruction that is not fully reversible.  Chronic progressive symptoms, particularly dyspnea, chronic bronchitis and impaired overall health are worse in those who have frequent, acute episodes of symptom exacerbation.  Although several exptl. PDE4 inhibitors are in clin. development, roflumilast, a highly selective PDE4 inhibitor, is the first in its class to be licensed, and has recently been approved in several countries for oral, once-daily treatment of severe COPD.  Clin. trials have demonstrated that roflumilast improves lung function and reduces exacerbation frequency in COPD.  Furthermore, its unique mode of action may offer the potential to target the inflammatory processes underlying COPD.  Roflumilast is effective when used concomitantly with all forms of bronchodilator and even in patients treated with inhaled corticosteroids.  Roflumilast thus represents an important addn. to current therapeutic options for COPD patients with chronic bronchitis, including those who remain symptomatic despite treatment.  This article reviews the current status of PDE4 inhibitors, focusing on the pharmacokinetics, efficacy and safety of roflumilast.  In particular, it provides an overview of the effects of roflumilast on lung function and exacerbations, glucose homoeostasis and wt. loss, and the concomitant use of long-acting beta2-adrenergic receptor agonists and short-acting muscarinic receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryBUcu0ToPGrVg90H21EOLACvtfcHk0liuAwkHGU3p1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D&md5=c6ac3310e2d9ff1c7de86aecbd1356bb</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01218.x%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DUpdate%2520on%2520roflumilast%252C%2520a%2520phosphodiesterase%25204%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D53%26epage%3D67%26doi%3D10.1111%2Fj.1476-5381.2011.01218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loveland, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, D. I.</span></span> <span> </span><span class="NLM_article-title">Apremilast, a cAMP phosphodiesterase-4 inhibitor,demonstrates anti-inflammatory activity in vitro and in a model of psoriasis</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">855</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00559.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1111%2Fj.1476-5381.2009.00559.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=20050849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtF2hs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2010&pages=842-855&author=P.+H.+Schaferauthor=A.+Partonauthor=A.+K.+Gandhiauthor=L.+Caponeauthor=M.+Adamsauthor=L.+Wuauthor=J.+B.+Bartlettauthor=M.+A.+Lovelandauthor=A.+Gilharauthor=Y.-F.+Cheungauthor=G.+S.+Baillieauthor=M.+D.+Houslayauthor=H.-W.+Manauthor=G.+W.+Mullerauthor=D.+I.+Stirling&title=Apremilast%2C+a+cAMP+phosphodiesterase-4+inhibitor%2Cdemonstrates+anti-inflammatory+activity+in+vitro+and+in+a+model+of+psoriasis&doi=10.1111%2Fj.1476-5381.2009.00559.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis</span></div><div class="casAuthors">Schafer, P. H.; Parton, A.; Gandhi, A. K.; Capone, L.; Adams, M.; Wu, L.; Bartlett, J. B.; Loveland, M. A.; Gilhar, A.; Cheung, Y.-F.; Baillie, G. S.; Houslay, M. D.; Man, H.-W.; Muller, G. W.; Stirling, D. I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-855</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and purpose: Apremilast is an orally administered phosphodiesterase-4 inhibitor, currently in phase 2 clin. studies of psoriasis and other chronic inflammatory diseases.  The inhibitory effects of apremilast on pro-inflammatory responses of human primary peripheral blood mononuclear cells (PBMC), polymorphonuclear cells, natural killer (NK) cells and epidermal keratinocytes were explored in vitro, and in a preclin. model of psoriasis.  Exptl. approach: Apremilast was tested in vitro against endotoxin- and superantigen-stimulated PBMC, bacterial peptide and zymosan-stimulated polymorphonuclear cells, immunonoglobulin and cytokine-stimulated NK cells, and UV B light-activated keratinocytes.  Apremilast was orally administered to beige-severe combined immunodeficient mice, xenotransplanted with normal human skin and triggered with human psoriatic NK cells.  Epidermal skin thickness, proliferation index and inflammation markers were analyzed.  Key results: Apremilast inhibited PBMC prodn. of the chemokines CXCL9 and CXCL10, cytokines interferon-γ and tumor necrosis factor (TNF)-α, and interleukins (IL)-2, IL-12 and IL-23.  Prodn. of TNF-α by NK cells and keratinocytes was also inhibited.  In vivo, apremilast significantly reduced epidermal thickness and proliferation, decreased the general histopathol. appearance of psoriasiform features and reduced expression of TNF-α, human leukocyte antigen-DR and intercellular adhesion mol.-1 in the lesioned skin.  Conclusions and implications: Apremilast displayed a broad pattern of anti-inflammatory activity in a variety of cell types and decreased the incidence and severity of a psoriasiform response in vivo.  Inhibition of TNF-α, IL-12 and IL-23 prodn., as well as NK and keratinocyte responses by this phosphodiesterase-4 inhibitor suggests a novel approach to the treatment of psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOuSV-gwfyvbVg90H21EOLACvtfcHk0liuAwkHGU3p1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtF2hs7Y%253D&md5=3d75cda30fed65749902cb790aafdd98</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00559.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00559.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DParton%26aufirst%3DA.%26aulast%3DGandhi%26aufirst%3DA.%2BK.%26aulast%3DCapone%26aufirst%3DL.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DBartlett%26aufirst%3DJ.%2BB.%26aulast%3DLoveland%26aufirst%3DM.%2BA.%26aulast%3DGilhar%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DY.-F.%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DMan%26aufirst%3DH.-W.%26aulast%3DMuller%26aufirst%3DG.%2BW.%26aulast%3DStirling%26aufirst%3DD.%2BI.%26atitle%3DApremilast%252C%2520a%2520cAMP%2520phosphodiesterase-4%2520inhibitor%252Cdemonstrates%2520anti-inflammatory%2520activity%2520in%2520vitro%2520and%2520in%2520a%2520model%2520of%2520psoriasis%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D159%26spage%3D842%26epage%3D855%26doi%3D10.1111%2Fj.1476-5381.2009.00559.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span> <span> </span><span class="NLM_article-title">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNFα responses</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">7628</span>– <span class="NLM_lpage">7633</span>, <span class="refDoi"> DOI: 10.1073/pnas.122041599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1073%2Fpnas.122041599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=12032334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=7628-7633&author=S.+L.+Jinauthor=M.+Conti&title=Induction+of+the+cyclic+nucleotide+phosphodiesterase+PDE4B+is+essential+for+LPS-activated+TNF%CE%B1+responses&doi=10.1073%2Fpnas.122041599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses</span></div><div class="casAuthors">Jin, S.-L. Catherine; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7628-7633</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lipopolysaccharide (LPS) stimulation of the innate immune response requires the activation of signaling cascades that culminate in the synthesis and secretion of proinflammatory cytokines.  Given the inhibitory effects of phosphodiesterase (PDE) inhibitors on LPS-induced cytokine prodn., the authors have investigated LPS responses in mice deficient in PDE4 (type 4 cAMP-specific PDE)-B and PDE4D.  LPS stimulation of mouse peripheral leukocytes induced PDE4B mRNA accumulation and increased PDE4 activity.  This response was completely absent in mice deficient in PDE4B but not PDE4D.  LPS induction of tumor necrosis factor-α secretion by circulating leukocytes was decreased by approx. 90% in mice deficient in PDE4B but not in mice lacking PDE4D.  The impaired LPS response was evident regardless of the LPS dose used for stimulation and was assocd. with a more than 90% decrease in tumor necrosis factor-α mRNA accumulation.  A decreased responsiveness to LPS was also present in other inflammatory cells, including peritoneal and lung macrophages.  These findings demonstrate that PDE4B gene activation by LPS constitutes a feedback regulation essential for an efficient immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczHCRpXjcOrVg90H21EOLACvtfcHk0lhDPU1lsbdpfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D&md5=69e2c4452ce3aa7729376db46cba6a07</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.122041599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.122041599%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DInduction%2520of%2520the%2520cyclic%2520nucleotide%2520phosphodiesterase%2520PDE4B%2520is%2520essential%2520for%2520LPS-activated%2520TNF%25CE%25B1%2520responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D7628%26epage%3D7633%26doi%3D10.1073%2Fpnas.122041599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cieslinski, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essayan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torphy, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnette, M. S.</span></span> <span> </span><span class="NLM_article-title">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1038%2Fsj.bjp.0702911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10602317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=1393-1398&author=C.+D.+Manningauthor=M.+Burmanauthor=S.+B.+Christensenauthor=L.+B.+Cieslinskiauthor=D.+M.+Essayanauthor=M.+Grousauthor=T.+J.+Torphyauthor=M.+S.+Barnette&title=Suppression+of+human+inflammatory+cell+function+by+subtype-selective+PDE4+inhibitors+correlates+with+inhibition+of+PDE4A+and+PDE4B&doi=10.1038%2Fsj.bjp.0702911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span></div><div class="casAuthors">Manning, Carol D.; Burman, Miriam; Christensen, Siegfried B.; Cieslinski, Lenora B.; Essayan, David M.; Grous, Marilyn; Torphy, Theodore J.; Barnette, Mary S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1393-1398</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Of the four major phosphodiesterase 4 (PDE4) subtypes, PDE4A, PDE4B and PDE4D are widely expressed in human inflammatory cells, including monocytes and T lymphocytes.  We explored the functional role of these subtypes using ten subtype-selective PDE4 inhibitors, each belonging to one of two classes: (i) dual PDE4A/PDE4B inhibitors or (ii) PDE4D inhibitors.  These compds. were evaluated for their ability to inhibit antigen-stimulated T-cell proliferation and bacterial lipopolysaccharide (LPS)-stimulated tumor necrosis factor α (TNFα) release from peripheral blood monocytes.  All compds. inhibited T-cell proliferation in a concn.-dependent manner; with IC50 values distributed over an approx. 50 fold range.  These compds. also inhibited TNFα release concn.-dependently, with a wider (∼ 1000 fold) range of IC50 values.  In both sets of expts., mean IC50 values were significantly correlated with compd. potency against the catalytic activity of recombinant human PDE4A or PDE4B when analyzed by either linear regression of log IC50 values or by Spearman's rank-order correlation.  The correlation between inhibition of inflammatory cell function and inhibition of recombinant PDE4D catalytic activity was not significant in either anal.  These results suggest that PDE4A and/or PDE4B may play the major role in regulating these two inflammatory cell functions but do not rule out PDE4D as an important mediator of other activities in mononuclear leukocytes and other immune and inflammatory cells.  Much more work is needed to establish the functional roles of the PDE4 subtypes across a broader range of cellular functions and cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3g1B9QQKejbVg90H21EOLACvtfcHk0lhDPU1lsbdpfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D&md5=70490a1a73b83ce887e850e4efd2e738</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702911%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DC.%2BD.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DS.%2BB.%26aulast%3DCieslinski%26aufirst%3DL.%2BB.%26aulast%3DEssayan%26aufirst%3DD.%2BM.%26aulast%3DGrous%26aufirst%3DM.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26aulast%3DBarnette%26aufirst%3DM.%2BS.%26atitle%3DSuppression%2520of%2520human%2520inflammatory%2520cell%2520function%2520by%2520subtype-selective%2520PDE4%2520inhibitors%2520correlates%2520with%2520inhibition%2520of%2520PDE4A%2520and%2520PDE4B%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D1393%26epage%3D1398%26doi%3D10.1038%2Fsj.bjp.0702911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehnart, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrens, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belevych, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, A. R.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2005.07.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.cell.2005.07.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2005&pages=25-35&author=S.+E.+Lehnartauthor=X.+H.+Wehrensauthor=S.+Reikenauthor=S.+Warrierauthor=A.+E.+Belevychauthor=R.+D.+Harveyauthor=W.+Richterauthor=S.+L.+Jinauthor=M.+Contiauthor=A.+R.+Marks&title=Phosphodiesterase+4D+deficiency+in+the+ryanodine-receptor+complex+promotes+heart+failure+and+arrhythmias&doi=10.1016%2Fj.cell.2005.07.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.07.030%26sid%3Dliteratum%253Aachs%26aulast%3DLehnart%26aufirst%3DS.%2BE.%26aulast%3DWehrens%26aufirst%3DX.%2BH.%26aulast%3DReiken%26aufirst%3DS.%26aulast%3DWarrier%26aufirst%3DS.%26aulast%3DBelevych%26aufirst%3DA.%2BE.%26aulast%3DHarvey%26aufirst%3DR.%2BD.%26aulast%3DRichter%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DMarks%26aufirst%3DA.%2BR.%26atitle%3DPhosphodiesterase%25204D%2520deficiency%2520in%2520the%2520ryanodine-receptor%2520complex%2520promotes%2520heart%2520failure%2520and%2520arrhythmias%26jtitle%3DCell%26date%3D2005%26volume%3D123%26spage%3D25%26epage%3D35%26doi%3D10.1016%2Fj.cell.2005.07.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamatiou, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.-L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachance, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laliberté, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.-C.</span></span> <span> </span><span class="NLM_article-title">Deletion of phosphodiesterase 4D in mice shortens a2-adrenoceptor-mediated anaesthesia, a behavioural correlate of emesis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1052</span>, <span class="refDoi"> DOI: 10.1172/JCI0215506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1172%2FJCI0215506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=1045-1052&author=A.+Robichaudauthor=P.+B.+Stamatiouauthor=S.-L.+C.+Jinauthor=N.+Lachanceauthor=D.+MacDonaldauthor=F.+Lalibert%C3%A9author=S.+Liuauthor=Z.+Huangauthor=M.+Contiauthor=C.-C.+Chan&title=Deletion+of+phosphodiesterase+4D+in+mice+shortens+a2-adrenoceptor-mediated+anaesthesia%2C+a+behavioural+correlate+of+emesis&doi=10.1172%2FJCI0215506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1172%2FJCI0215506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0215506%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DA.%26aulast%3DStamatiou%26aufirst%3DP.%2BB.%26aulast%3DJin%26aufirst%3DS.-L.%2BC.%26aulast%3DLachance%26aufirst%3DN.%26aulast%3DMacDonald%26aufirst%3DD.%26aulast%3DLalibert%25C3%25A9%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DC.-C.%26atitle%3DDeletion%2520of%2520phosphodiesterase%25204D%2520in%2520mice%2520shortens%2520a2-adrenoceptor-mediated%2520anaesthesia%252C%2520a%2520behavioural%2520correlate%2520of%2520emesis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D110%26spage%3D1045%26epage%3D1052%26doi%3D10.1172%2FJCI0215506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocque, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, R. T.</span></span> <span> </span><span class="NLM_article-title">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1825</span>, <span class="refDoi"> DOI: 10.1126/science.288.5472.1822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1126%2Fscience.288.5472.1822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10846163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2000&pages=1822-1825&author=R.+X.+Xuauthor=A.+M.+Hassellauthor=D.+Vanderwallauthor=M.+H.+Lambertauthor=W.+D.+Holmesauthor=M.+A.+Lutherauthor=W.+J.+Rocqueauthor=M.+V.+Milburnauthor=Y.+Zhaoauthor=H.+Keauthor=R.+T.+Nolte&title=Atomic+structure+of+PDE4%3A+insights+into+phosphodiesterase+mechanism+and+specificity&doi=10.1126%2Fscience.288.5472.1822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span></div><div class="casAuthors">Xu, Robert X.; Hassell, Anne M.; Vanderwall, Dana; Lambert, Millard H.; Holmes, William D.; Luther, Michael A.; Rocque, Warren J.; Milburn, Michael V.; Zhao, Yingdong; Ke, Hengming; Nolte, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">5472</span>),
    <span class="NLM_cas:pages">1822-1825</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cyclic nucleotides are second messengers that are essential in vision, muscle contraction, neurotransmission, exocytosis, cell growth, and differentiation.  These mols. are degraded by a family of enzymes known as phosphodiesterases, which serve a crit. function by regulating the intracellular concn. of cyclic nucleotides.  We have detd. the three-dimensional structure of the catalytic domain of phosphodiesterase 4B2B to 1.77 angstrom resoln.  The active site has been identified and contains a cluster of two metal atoms.  The structure suggests the mechanism of action and basis for specificity and will provide a framework for structure-assisted drug design for members of the phosphodiesterase family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjHOVmP5GzU7Vg90H21EOLACvtfcHk0liy1xHDJ12PmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D&md5=4f7e42a9f7a6a0763a9dcc064ad903c2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.288.5472.1822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.288.5472.1822%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%2BX.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DVanderwall%26aufirst%3DD.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DHolmes%26aufirst%3DW.%2BD.%26aulast%3DLuther%26aufirst%3DM.%2BA.%26aulast%3DRocque%26aufirst%3DW.%2BJ.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26atitle%3DAtomic%2520structure%2520of%2520PDE4%253A%2520insights%2520into%2520phosphodiesterase%2520mechanism%2520and%2520specificity%26jtitle%3DScience%26date%3D2000%26volume%3D288%26spage%3D1822%26epage%3D1825%26doi%3D10.1126%2Fscience.288.5472.1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colicelli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">13220</span>– <span class="NLM_lpage">13226</span>, <span class="refDoi"> DOI: 10.1021/bi034653e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi034653e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=13220-13226&author=Q.+Huaiauthor=J.+Colicelliauthor=H.+Ke&title=The+crystal+structure+of+AMP-bound+PDE4+suggests+a+mechanism+for+phosphodiesterase+catalysis&doi=10.1021%2Fbi034653e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fbi034653e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi034653e%26sid%3Dliteratum%253Aachs%26aulast%3DHuai%26aufirst%3DQ.%26aulast%3DColicelli%26aufirst%3DJ.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DThe%2520crystal%2520structure%2520of%2520AMP-bound%2520PDE4%2520suggests%2520a%2520mechanism%2520for%2520phosphodiesterase%2520catalysis%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26spage%3D13220%26epage%3D13226%26doi%3D10.1021%2Fbi034653e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2007.05.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.jmb.2007.05.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=17582435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2007&pages=302-307&author=H.+Wangauthor=H.+Robinsonauthor=H.+Ke&title=The+molecular+basis+for+different+recognition+of+substrates+by+phosphodiesterase+families+4+and+10&doi=10.1016%2Fj.jmb.2007.05.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10</span></div><div class="casAuthors">Wang, Huanchen; Robinson, Howard; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-307</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are key enzymes that control the cellular concns. of the second messengers cAMP and cGMP.  The mechanism for selective recognition of substrates cAMP and cGMP by individual PDE families remains a puzzle.  To understand the mechanism for substrate recognition by PDE enzymes, the crystal structure of the catalytic domain of an inactive D201N mutant of PDE4D2 in complex with substrate cAMP has been detd. at 1.56 Å resoln.  The structure shows that Gln369 forms only one hydrogen bond with the adenine of cAMP.  This finding provides exptl. evidence against the hypothesis of two hydrogen bonds between the invariant glutamine and the substrate cAMP in PDE4, and thus suggests that the widely circulated "glutamine switch" model is unlikely to be the mechanism for substrate recognition by PDEs.  A structure comparison between PDE4D2-cAMP and PDE10A2-cAMP reveals an anti configuration of cAMP in PDE4D2 but syn in PDE10A2, in addn. to different contact patterns of cAMP in these two structures.  These observations imply that individual PDE families have their characteristic mechanisms for substrate recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr8WN9h4LiP7Vg90H21EOLACvtfcHk0li-HqlQDengaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D&md5=2f7f20be9aba1cae9a4d90e349581583</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2007.05.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2007.05.060%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DThe%2520molecular%2520basis%2520for%2520different%2520recognition%2520of%2520substrates%2520by%2520phosphodiesterase%2520families%25204%2520and%252010%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D371%26spage%3D302%26epage%3D307%26doi%3D10.1016%2Fj.jmb.2007.05.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>408</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1042/BJ20070970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1042%2FBJ20070970" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2007&pages=193-201&author=H.+Wangauthor=M.+S.+Pengauthor=Y.+Chenauthor=J.+Gengauthor=H.+Robinsonauthor=M.+D.+Houslayauthor=I.+Caiauthor=H.+Ke&title=Structures+of+the+four+subfamilies+of+phosphodiesterase-4+provide+insight+into+the+selectivity+of+their+inhibitors&doi=10.1042%2FBJ20070970"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1042%2FBJ20070970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070970%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DM.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DCai%26aufirst%3DI.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DStructures%2520of%2520the%2520four%2520subfamilies%2520of%2520phosphodiesterase-4%2520provide%2520insight%2520into%2520the%2520selectivity%2520of%2520their%2520inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D408%26spage%3D193%26epage%3D201%26doi%3D10.1042%2FBJ20070970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the design of selective phosphodiesterase</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2013.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.cellsig.2013.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=24361374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=657-663&author=D.+Foxauthor=A.+B.+Burginauthor=M.+E.+Gurney&title=Structural+basis+for+the+design+of+selective+phosphodiesterase&doi=10.1016%2Fj.cellsig.2013.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the design of selective phosphodiesterase 4B inhibitors</span></div><div class="casAuthors">Fox, David, III; Burgin, Alex B.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">657-663</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Phosphodiesterase-4B (PDE4B) regulates the pro-inflammatory Toll Receptor -Tumor Necrosis Factor α (TNFα) pathway in monocytes, macrophages and microglial cells.  As such, it is an important, although under-exploited mol. target for anti-inflammatory drugs.  This is due in part to the difficulty of developing selective PDE4B inhibitors as the amino acid sequence of the PDE4 active site is identical in all PDE4 subtypes (PDE4A-D).  We show that highly selective PDE4B inhibitors can be designed by exploiting sequence differences outside the active site.  Specifically, PDE4B selectivity can be achieved by capture of a C-terminal regulatory helix, now termed CR3 (Control Region 3), across the active site in a conformation that closes access by cAMP.  PDE4B selectivity is driven by a single amino acid polymorphism in CR3 (Leu674 in PDE4B1 vs. Gln594 in PDE4D).  The reciprocal mutations in PDE4B and PDE4D cause a 70-80 fold shift in selectivity.  Our structural studies show that CR3 is flexible and can adopt multiple orientations and multiple registries in the closed conformation.  The new co-crystal structure with bound ligand provides a guide map for the design of PDE4B selective anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKu3hgg1Kl7Vg90H21EOLACvtfcHk0ljUDtPzhtobhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D&md5=ab8e72afbfeadffeae27950206402bd9</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2013.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2013.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DD.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DStructural%2520basis%2520for%2520the%2520design%2520of%2520selective%2520phosphodiesterase%26jtitle%3DCell.%2520Signalling%26date%3D2014%26volume%3D26%26spage%3D657%26epage%3D663%26doi%3D10.1016%2Fj.cellsig.2013.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naganuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maekawara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagumo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsuka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawanishi, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective PDE4B inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3174</span>– <span class="NLM_lpage">3176</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.bmcl.2009.04.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=19447034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1eks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3174-3176&author=K.+Naganumaauthor=A.+Omuraauthor=N.+Maekawaraauthor=M.+Saitohauthor=N.+Ohkawaauthor=T.+Kubotaauthor=H.+Nagumoauthor=T.+Kodamaauthor=M.+Takemuraauthor=Y.+Ohtsukaauthor=J.+Nakamuraauthor=R.+Tsujitaauthor=K.+Kawasakiauthor=H.+Yokoiauthor=M.+Kawanishi&title=Discovery+of+selective+PDE4B+inhibitors&doi=10.1016%2Fj.bmcl.2009.04.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective PDE4B inhibitors</span></div><div class="casAuthors">Naganuma, Kenji; Omura, Akifumi; Maekawara, Naomi; Saitoh, Masahiro; Ohkawa, Naoto; Kubota, Takashi; Nagumo, Hiromitsu; Kodama, Toshiyuki; Takemura, Masayoshi; Ohtsuka, Yuji; Nakamura, Junji; Tsujita, Ryuichi; Kawasaki, Koh; Yokoi, Hirotsugu; Kawanishi, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3174-3176</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study the first PDE4B selective inhibitor is described.  Optimization of lead 2-arylpyrimidine derivs. afforded a series of potent PDE4B inhibitors I (R1 = Me, Et, H2C:CHCH2, CN, CHO, etc.; R2 = Me, Et, n-Pr; R3 = Ph, 4-MeC6H4, 2-thienyl, 2-pyridyl, etc.; R4 = H, F; R5 = CO2H, CH2CO2H) with >100-fold selectivity over the PDE4D isoenzyme.  With a good pharmacokinetic profile, a selected compd. I (R1 = Et; R2 = Me; R3 = 5-chloro-2-thienyl; R4 = H; R5 = CH2CO2H) exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOGQ4ols6Z1rVg90H21EOLACvtfcHk0ljUDtPzhtobhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1eks7w%253D&md5=aca08592557e5d34da5b02835b0e49d8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.121%26sid%3Dliteratum%253Aachs%26aulast%3DNaganuma%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DA.%26aulast%3DMaekawara%26aufirst%3DN.%26aulast%3DSaitoh%26aufirst%3DM.%26aulast%3DOhkawa%26aufirst%3DN.%26aulast%3DKubota%26aufirst%3DT.%26aulast%3DNagumo%26aufirst%3DH.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DTakemura%26aufirst%3DM.%26aulast%3DOhtsuka%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DTsujita%26aufirst%3DR.%26aulast%3DKawasaki%26aufirst%3DK.%26aulast%3DYokoi%26aufirst%3DH.%26aulast%3DKawanishi%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520selective%2520PDE4B%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3174%26epage%3D3176%26doi%3D10.1016%2Fj.bmcl.2009.04.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="note"><p class="first last">For recent examples of inhaled PDE4 inhibitors, see:</p></div><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonough, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmour, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearman, M. S.</span></span> <span> </span><span class="NLM_article-title">Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4661</span>– <span class="NLM_lpage">4676</span>, <span class="refDoi"> DOI: 10.1021/jm5001216</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5001216" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4661-4676&author=C.+De+Saviauthor=R.+J.+Coxauthor=D.+J.+Warnerauthor=A.+R.+Cookauthor=M.+R.+Dickinsonauthor=A.+McDonoughauthor=L.+C.+Morrillauthor=B.+Parkerauthor=G.+Andrewsauthor=S.+S.+Youngauthor=P.+S.+Gilmourauthor=R.+Rileyauthor=M.+S.+Dearman&title=Efficacious+inhaled+PDE4+inhibitors+with+low+emetic+potential+and+long+duration+of+action+for+the+treatment+of+COPD&doi=10.1021%2Fjm5001216"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Fjm5001216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5001216%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26aulast%3DCook%26aufirst%3DA.%2BR.%26aulast%3DDickinson%26aufirst%3DM.%2BR.%26aulast%3DMcDonough%26aufirst%3DA.%26aulast%3DMorrill%26aufirst%3DL.%2BC.%26aulast%3DParker%26aufirst%3DB.%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DS.%2BS.%26aulast%3DGilmour%26aufirst%3DP.%2BS.%26aulast%3DRiley%26aufirst%3DR.%26aulast%3DDearman%26aufirst%3DM.%2BS.%26atitle%3DEfficacious%2520inhaled%2520PDE4%2520inhibitors%2520with%2520low%2520emetic%2520potential%2520and%2520long%2520duration%2520of%2520action%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4661%26epage%3D4676%26doi%3D10.1021%2Fjm5001216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashimoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokomizo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span> <span> </span><span class="NLM_article-title">An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>768</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.ejphar.2015.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=26455478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslaktb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=768&publication_year=2015&pages=41-48&author=S.+Kubotaauthor=M.+Watanabeauthor=M.+Shiratoauthor=T.+Okunoauthor=I.+Higashimotoauthor=K.+Machidaauthor=T.+Yokomizoauthor=H.+Inoue&title=An+inhaled+phosphodiesterase+4+inhibitor+E6005+suppresses+pulmonary+inflammation+in+mice&doi=10.1016%2Fj.ejphar.2015.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice</span></div><div class="casAuthors">Kubota, Shingo; Watanabe, Masaki; Shirato, Manabu; Okuno, Toshiaki; Higashimoto, Ikkou; Machida, Kentaro; Yokomizo, Takehiko; Inoue, Hiromasa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">768</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is a progressive lung disease assocd. with significant morbidity and mortality.  Although several oral phosphodiesterase 4 (PDE4) inhibitors have been developed for the treatment of COPD, their use has been restricted because of side effects including nausea and emesis.  We hypothesized that delivery of a dry powd. PDE4 inhibitor by inhalation would minimize systemic absorption and enable local PDE4 inhibition to suppress inflammation within the lung.  Neutrophilic pulmonary inflammation was induced in mice by intratracheal administration of lipopolysaccharide.  Mice were treated intratracheally with a new dry powder PDE4 inhibitor, E6005 (Me 4-[({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}amino) carbonyl] benzoate).  The pharmacokinetics, cell profiles and levels of cytokines, chemokines, and lipid mediators in bronchoalveolar lavage fluid (BALF), and lung histol. were assessed.  Intratracheal administration of E6005 to mice resulted in high concns. of the compd. in the lungs.  Histol. anal. of E6005-treated mice demonstrated reduced inflammation of lung tissue that correlated with a decrease in BALF levels of neutrophils, proinflammatory cytokines, chemokines, and cysteinyl leukotrienes.  Thus, intratracheal administration of E6005 effectively suppresses neutrophilic pulmonary inflammation, suggesting that the new inhaled dry powder PDE4 inhibitor represents an alternative to the conventional oral formulation for treating COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCroPjN3zdrVg90H21EOLACvtfcHk0lhZuUbiuQywuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslaktb7M&md5=c9b32400cdd79ee002234c8542122163</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DKubota%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DShirato%26aufirst%3DM.%26aulast%3DOkuno%26aufirst%3DT.%26aulast%3DHigashimoto%26aufirst%3DI.%26aulast%3DMachida%26aufirst%3DK.%26aulast%3DYokomizo%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DH.%26atitle%3DAn%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520E6005%2520suppresses%2520pulmonary%2520inflammation%2520in%2520mice%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D768%26spage%3D41%26epage%3D48%26doi%3D10.1016%2Fj.ejphar.2015.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carzaniga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccellati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patacchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span> <span> </span><span class="NLM_article-title">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1124%2Fjpet.114.220541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=25576075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=559-567&author=N.+Morettoauthor=P.+Carusoauthor=R.+Boscoauthor=G.+Marchiniauthor=F.+Pastoreauthor=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=E.+Ghidiniauthor=R.+De+Fantiauthor=C.+Capaldiauthor=L.+Carzanigaauthor=E.+Hirschauthor=C.+Buccellatiauthor=A.+Salaauthor=C.+Carniniauthor=R.+Patacchiniauthor=M.+Delcanaleauthor=M.+Civelliauthor=G.+Villettiauthor=F.+Facchinetti&title=CHF6001+I%3A+a+novel+highly+potent+and+selective+phosphodiesterase+4+inhibitor+with+robust+anti-inflammatory+activity+and+suitable+for+topical+pulmonary+administration&doi=10.1124%2Fjpet.114.220541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span></div><div class="casAuthors">Moretto, Nadia; Caruso, Paola; Bosco, Raffaella; Marchini, Gessica; Pastore, Fiorella; Armani, Elisabetta; Amari, Gabriele; Rizzi, Andrea; Ghidini, Eleonora; De Fanti, Renato; Capaldi, Carmelida; Carzaniga, Laura; Hirsch, Emilio; Buccellati, Carola; Sala, Angelo; Carnini, Chiara; Patacchini, Riccardo; Delcanale, Maurizio; Civelli, Maurizio; Villetti, Gino; Facchinetti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">559-567, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study examd. the pharmacol. characterization of CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide], a novel phosphodiesterase (PDE)4 inhibitor designed for treating pulmonary inflammatory diseases via inhaled administration.  CHF6001 was 7- and 923-fold more potent than roflumilast and cilomilast, resp., in inhibiting PDE4 enzymic activity (IC50 = 0.026 ± 0.006 nM).  CHF6001 inhibited PDE4 isoforms A-D with equal potency, showed an elevated ratio of high-affinity rolipram binding site vs. low-affinity rolipram binding site (i.e., >40) and displayed >20,000-fold selectivity vs. PDE4 compared with a panel of PDEs.  CHF6001 effectively inhibited (subnanomolar IC50 values) the release of tumor necrosis factor-α from human peripheral blood mononuclear cells, human acute monocytic leukemia cell line macrophages (THP-1), and rodent macrophages (RAW264.7 and NR8383).  Moreover, CHF6001 potently inhibited the activation of oxidative burst in neutrophils and eosinophils, neutrophil chemotaxis, and the release of interferon-γ from CD4+ T cells.  In all these functional assays, CHF6001 was more potent than previously described PDE4 inhibitors, including roflumilast, UK-500,001 [2-(3,4-difluorophenoxy)-5-fluoro-N-((1S,4S)-4-(2-hydroxy-5-methylbenzamido)cyclohexyl)nicotinamide], and cilomilast, and it was comparable to GSK256066 [6-((3-(dimethylcarbamoyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide].  When administered intratracheally to rats as a micronized dry powder, CHF6001 inhibited liposaccharide-induced pulmonary neutrophilia (ED50 = 0.205 μmol/kg) and leukocyte infiltration (ED50 = 0.188 μmol/kg) with an efficacy comparable to a high dose of budesonide (1 μmol/kg i.p.).  In sum, CHF6001 has the potential to be an effective topical treatment of conditions assocd. with pulmonary inflammation, including asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYb2WLQC5SbVg90H21EOLACvtfcHk0lgdKVfb1z1qvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D&md5=2be98d624fe49f7aba8673fa8aea8688</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220541%26sid%3Dliteratum%253Aachs%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DBosco%26aufirst%3DR.%26aulast%3DMarchini%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DBuccellati%26aufirst%3DC.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DFacchinetti%26aufirst%3DF.%26atitle%3DCHF6001%2520I%253A%2520a%2520novel%2520highly%2520potent%2520and%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520with%2520robust%2520anti-inflammatory%2520activity%2520and%2520suitable%2520for%2520topical%2520pulmonary%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D559%26epage%3D567%26doi%3D10.1124%2Fjpet.114.220541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leaker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandeuil, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collarini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariotti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2016.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.pupt.2016.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=27373438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eisLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=1-6&author=D.+Singhauthor=B.+Leakerauthor=M.+Boyceauthor=M.+A.+Nandeuilauthor=S.+Collariniauthor=F.+Mariottiauthor=D.+Santoroauthor=P.+J.+Barnes&title=A+novel+inhaled+phosphodiesterase+4+inhibitor+%28CHF6001%29+reduces+the+allergen+challenge+response+in+asthmatic+patients&doi=10.1016%2Fj.pupt.2016.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19dR"><div class="casContent"><span class="casTitleNuber">19d</span><div class="casTitle"><span class="NLM_cas:atitle">A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients</span></div><div class="casAuthors">Singh, D.; Leaker, B.; Boyce, M.; Nandeuil, M. A.; Collarini, S.; Mariotti, F.; Santoro, D.; Barnes, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of obstructive lung diseases.  The efficacy and safety of CHF6001 were investigated in a double blind, placebo controlled, 3-way cross-over study using the allergen challenge model.  Thirty-six atopic asthmatics who were not taking inhaled corticosteroids and who demonstrated a late asthmatic response (LAR) to inhaled allergen at screening were randomized to receive CHF6001 400 μg or 1200 μg or placebo administered once a day using a dry powder inhaler.  The three treatment periods were 9 days; allergen challenges were performed on day 9 and induced sputum was obtained after 10 h from challenge.  Washout periods between treatments were up to 5 wk.  Both CHF6001 doses significantly attenuated the LAR; the primary endpoint anal. showed that CHF6001 400 μg and 1200 μg caused redns. of 19.7% (p = 0.015) and 28.2% (p < 0.001) resp. of the weighted FEV1 AUC4-10h compared with placebo.  The difference between the CHF6001 doses was not statistically significant (p = 0.223).  Compared with placebo, CHF6001 caused greater redn. in sputum eosinophil counts, although these changes were not statistically significant.  CHF6001 was well tolerated, with similar nos. of adverse events in each treatment period.  This inhaled PDE4 inhibitor has the potential to provide clin. benefits in patients with atopic asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFxltgVfb-QrVg90H21EOLACvtfcHk0lgdKVfb1z1qvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eisLzI&md5=cb8064827c2d80be4ae9b9d5f591c514</span></div><a href="/servlet/linkout?suffix=cit19d&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2016.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2016.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DLeaker%26aufirst%3DB.%26aulast%3DBoyce%26aufirst%3DM.%26aulast%3DNandeuil%26aufirst%3DM.%2BA.%26aulast%3DCollarini%26aufirst%3DS.%26aulast%3DMariotti%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DD.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DA%2520novel%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520%2528CHF6001%2529%2520reduces%2520the%2520allergen%2520challenge%2520response%2520in%2520asthmatic%2520patients%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D40%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.pupt.2016.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, D.</span></span> <span> </span><span class="NLM_article-title">Optimisation of DMPK by the inhaled route: challenges and approaches</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.2174/138920012800166571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.2174%2F138920012800166571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=22299825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=457-473&author=A.+E.+Cooperauthor=D.+Fergusonauthor=D.+Grime&title=Optimisation+of+DMPK+by+the+inhaled+route%3A+challenges+and+approaches&doi=10.2174%2F138920012800166571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimisation of DMPK by the inhaled route: challenges and approaches</span></div><div class="casAuthors">Cooper, Anne E.; Ferguson, Douglas; Grime, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-473</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics.  Historically optimization of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung.  Recent efforts have led to an increased understanding of lung concns. and how to maximize exposure to achieve the desired pharmacol. response at a dose consistent with development of an inhaled product.  Although there is a prerequisite for excellent potency in inhalation delivery, it is essential that this be combined with pharmacokinetic properties that allow sufficient free concn. at the effect site in lung to exert the pharmacol. response for an appropriate dosing interval.  Increases in basicity, polarity and/or decreases in aq. soly. can extend pharmacokinetic duration and assist in finding the right balance between lung and systemic exposure.  Current evidence suggests there are similarities in lung retention in rat and dog and that animal lung concn. data can enable pharmacokinetic-pharmacodynamic relationships to be derived thus providing more confidence in the requirements for man.  Although inhaled delivery is challenging from a pharmacokinetic point of view, direct evaluation of exposure in the target organ has enabled further understanding of the drivers for drug disposition and highlighted the need for further development of predictive lung pharmacokinetic tools in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxztkVtHyCeLVg90H21EOLACvtfcHk0lj0T3lhiaZ8Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D&md5=1dec4f52aeda55fe6ea888c289216d94</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.2174%2F138920012800166571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012800166571%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGrime%26aufirst%3DD.%26atitle%3DOptimisation%2520of%2520DMPK%2520by%2520the%2520inhaled%2520route%253A%2520challenges%2520and%2520approaches%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D457%26epage%3D473%26doi%3D10.2174%2F138920012800166571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A. D.</span></span> <span> </span><span class="NLM_article-title">Inhalation by design</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1563</span>– <span class="NLM_lpage">1565</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.4155%2Ffmc.11.132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=21942245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1563-1565&author=L.+J.+Jonesauthor=A.+D.+Hughes&title=Inhalation+by+design&doi=10.4155%2Ffmc.11.132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhalation by design</span></div><div class="casAuthors">Jones, Lyn H.; Hughes, Adam D.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1563-1565</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcRzo0BxXXfLVg90H21EOLACvtfcHk0lj0T3lhiaZ8Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvF&md5=fe2e7db8a6fa8ea5575f7d0e6b331eb9</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.132%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BJ.%26aulast%3DHughes%26aufirst%3DA.%2BD.%26atitle%3DInhalation%2520by%2520design%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1563%26epage%3D1565%26doi%3D10.4155%2Ffmc.11.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tayab, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic/pharmacodynamics evaluation of inhalation drugs: application to targeted pulmonary delivery systems</span>. <i>Expert Opin. Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1517/17425247.2.3.519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F17425247.2.3.519" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=519-532&author=Z.+R.+Tayabauthor=G.+Hochhaus&title=Pharmacokinetic%2Fpharmacodynamics+evaluation+of+inhalation+drugs%3A+application+to+targeted+pulmonary+delivery+systems&doi=10.1517%2F17425247.2.3.519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1517%2F17425247.2.3.519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425247.2.3.519%26sid%3Dliteratum%253Aachs%26aulast%3DTayab%26aufirst%3DZ.%2BR.%26aulast%3DHochhaus%26aufirst%3DG.%26atitle%3DPharmacokinetic%252Fpharmacodynamics%2520evaluation%2520of%2520inhalation%2520drugs%253A%2520application%2520to%2520targeted%2520pulmonary%2520delivery%2520systems%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2005%26volume%3D2%26spage%3D519%26epage%3D532%26doi%3D10.1517%2F17425247.2.3.519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. O.,  III</span></span> <span> </span><span class="NLM_article-title">Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilisation on pharmacokinetic properties</span>. <i>Drug Dev. Ind. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3109/03639040903092319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.3109%2F03639040903092319" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2010&pages=1-30&author=J.+A.+Tolmanauthor=R.+O.+Williams&title=Advances+in+the+pulmonary+delivery+of+poorly+water-soluble+drugs%3A+influence+of+solubilisation+on+pharmacokinetic+properties&doi=10.3109%2F03639040903092319"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3109%2F03639040903092319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03639040903092319%26sid%3Dliteratum%253Aachs%26aulast%3DTolman%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BO.%26atitle%3DAdvances%2520in%2520the%2520pulmonary%2520delivery%2520of%2520poorly%2520water-soluble%2520drugs%253A%2520influence%2520of%2520solubilisation%2520on%2520pharmacokinetic%2520properties%26jtitle%3DDrug%2520Dev.%2520Ind.%2520Pharm.%26date%3D2010%26volume%3D36%26spage%3D1%26epage%3D30%26doi%3D10.3109%2F03639040903092319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. O.,  III</span></span> <span> </span><span class="NLM_article-title">Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilisation o pharmacokinetic properties</span>. <i>Drug Dev. Ind. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3109/03639040903092319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.3109%2F03639040903092319" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2010&pages=1-30&author=J.+A.+Tolmanauthor=R.+O.+Williams&title=Advances+in+the+pulmonary+delivery+of+poorly+water-soluble+drugs%3A+influence+of+solubilisation+o+pharmacokinetic+properties&doi=10.3109%2F03639040903092319"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3109%2F03639040903092319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03639040903092319%26sid%3Dliteratum%253Aachs%26aulast%3DTolman%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BO.%26atitle%3DAdvances%2520in%2520the%2520pulmonary%2520delivery%2520of%2520poorly%2520water-soluble%2520drugs%253A%2520influence%2520of%2520solubilisation%2520o%2520pharmacokinetic%2520properties%26jtitle%3DDrug%2520Dev.%2520Ind.%2520Pharm.%26date%3D2010%26volume%3D36%26spage%3D1%26epage%3D30%26doi%3D10.3109%2F03639040903092319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span> <span> </span><span class="NLM_article-title">Optimisation of DMPK by the inhaled route: challenges and approaches</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.2174/138920012800166571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.2174%2F138920012800166571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=22299825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=457-473&author=A.+E.+Cooperauthor=D.+Fergusonauthor=K.+Grime&title=Optimisation+of+DMPK+by+the+inhaled+route%3A+challenges+and+approaches&doi=10.2174%2F138920012800166571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Optimisation of DMPK by the inhaled route: challenges and approaches</span></div><div class="casAuthors">Cooper, Anne E.; Ferguson, Douglas; Grime, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-473</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics.  Historically optimization of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung.  Recent efforts have led to an increased understanding of lung concns. and how to maximize exposure to achieve the desired pharmacol. response at a dose consistent with development of an inhaled product.  Although there is a prerequisite for excellent potency in inhalation delivery, it is essential that this be combined with pharmacokinetic properties that allow sufficient free concn. at the effect site in lung to exert the pharmacol. response for an appropriate dosing interval.  Increases in basicity, polarity and/or decreases in aq. soly. can extend pharmacokinetic duration and assist in finding the right balance between lung and systemic exposure.  Current evidence suggests there are similarities in lung retention in rat and dog and that animal lung concn. data can enable pharmacokinetic-pharmacodynamic relationships to be derived thus providing more confidence in the requirements for man.  Although inhaled delivery is challenging from a pharmacokinetic point of view, direct evaluation of exposure in the target organ has enabled further understanding of the drivers for drug disposition and highlighted the need for further development of predictive lung pharmacokinetic tools in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxztkVtHyCeLVg90H21EOLACvtfcHk0lgGyADTBy-w5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D&md5=1dec4f52aeda55fe6ea888c289216d94</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F138920012800166571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012800166571%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGrime%26aufirst%3DK.%26atitle%3DOptimisation%2520of%2520DMPK%2520by%2520the%2520inhaled%2520route%253A%2520challenges%2520and%2520approaches%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D457%26epage%3D473%26doi%3D10.2174%2F138920012800166571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Felding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Refer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladefoged, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thormann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinggaard, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Søhoel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO29102), a soft-drug Inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5893</span>– <span class="NLM_lpage">5903</span>, <span class="refDoi"> DOI: 10.1021/jm500378a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500378a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5893-5903&author=F.+Feldingauthor=M.+D.+S%C3%B8rensenauthor=T.+D.+Poulsenauthor=J.+Larsenauthor=C.+Anderssonauthor=P.+Referauthor=K.+Engellauthor=L.+G.+Ladefogedauthor=T.+Thormannauthor=A.+M.+Vinggaardauthor=P.+Hegardtauthor=A.+S%C3%B8hoelauthor=S.+F.+Nielsen&title=Discovery+and+early+clinical+development+of+2-%7B6-%5B2-%283%2C5-dichloro-4-pyridyl%29acetyl%5D-2%2C3-dimethoxyphenoxy%7D-N-propylacetamide+%28LEO29102%29%2C+a+soft-drug+Inhibitor+of+phosphodiesterase+4+for+topical+treatment+of+atopic+dermatitis&doi=10.1021%2Fjm500378a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1021%2Fjm500378a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500378a%26sid%3Dliteratum%253Aachs%26aulast%3DFelding%26aufirst%3DF.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DM.%2BD.%26aulast%3DPoulsen%26aufirst%3DT.%2BD.%26aulast%3DLarsen%26aufirst%3DJ.%26aulast%3DAndersson%26aufirst%3DC.%26aulast%3DRefer%26aufirst%3DP.%26aulast%3DEngell%26aufirst%3DK.%26aulast%3DLadefoged%26aufirst%3DL.%2BG.%26aulast%3DThormann%26aufirst%3DT.%26aulast%3DVinggaard%26aufirst%3DA.%2BM.%26aulast%3DHegardt%26aufirst%3DP.%26aulast%3DS%25C3%25B8hoel%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520development%2520of%25202-%257B6-%255B2-%25283%252C5-dichloro-4-pyridyl%2529acetyl%255D-2%252C3-dimethoxyphenoxy%257D-N-propylacetamide%2520%2528LEO29102%2529%252C%2520a%2520soft-drug%2520Inhibitor%2520of%2520phosphodiesterase%25204%2520for%2520topical%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5893%26epage%3D5903%26doi%3D10.1021%2Fjm500378a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bodor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, P.</span></span> <span> </span><span class="NLM_article-title">Soft drug design: general principles and recent applications</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10608921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=58-101&author=N.+Bodorauthor=P.+Buchwald&title=Soft+drug+design%3A+general+principles+and+recent+applications&doi=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Soft drug design: general principles and recent applications</span></div><div class="casAuthors">Bodor, Nicholas; Buchwald, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-101</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review with 208 refs.  Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metab. considerations into the drug design process.  Soft drugs are new therapeutic agents that undergo predictable metab. to inactive metabolites after exerting their therapeutic effect.  Hence, they are obtained by building into the mol., in addn. to the activity, the most desired way in which the mol. is to be deactivated and detoxified.  In an attempt to systematize and summarize the related work done in a no. of labs., including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts.  A no. of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles.  Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, β-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others.  Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compds. used in the same field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphV1vhXwTl8LVg90H21EOLACvtfcHk0lhEO-Fixr5Gyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D&md5=e0ca493ba31d001e62a759be0fc4bcc8</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-1128%2528200001%252920%253A1%253C58%253A%253AAID-MED3%253E3.0.CO%253B2-X%26sid%3Dliteratum%253Aachs%26aulast%3DBodor%26aufirst%3DN.%26aulast%3DBuchwald%26aufirst%3DP.%26atitle%3DSoft%2520drug%2520design%253A%2520general%2520principles%2520and%2520recent%2520applications%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2000%26volume%3D20%26spage%3D58%26epage%3D101%26doi%3D10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerud, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and the drug–target residence time concept</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.drudis.2013.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=23500610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=697-707&author=G.+Dahlauthor=T.+Akerud&title=Pharmacokinetics+and+the+drug%E2%80%93target+residence+time+concept&doi=10.1016%2Fj.drudis.2013.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and the drug-target residence time concept</span></div><div class="casAuthors">Dahl, Goeran; Akerud, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">697-707</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The concept of drug-target residence time has been in focus in recent drug discovery literature.  However, few studies consider the combined effect of pharmacokinetics (PK) and binding kinetics (BK) on the duration of effect of a drug.  Using a simple model that takes both PK and BK into account, we found that prolongation of binding owing to a long drug-target residence time can only occur when the binding dissocn. is slower than the PK elimination.  Data for several drugs and/or drug candidates in the literature indicate that the opposite is obsd., i.e., they have a slower elimination compared with dissocn.  These observations greatly reduce the usability of drug-target residence times for estg. the duration of effect of a drug in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon2xZ9fJkTybVg90H21EOLACvtfcHk0lhEO-Fixr5Gyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D&md5=73b190a44d359f55ee19af9099846505</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DAkerud%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520the%2520drug%25E2%2580%2593target%2520residence%2520time%2520concept%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D697%26epage%3D707%26doi%3D10.1016%2Fj.drudis.2013.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Liefde, I.</span></span> <span> </span><span class="NLM_article-title">Slow antagonist dissociation and long-lasting in vivo receptor protection</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2006.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.tips.2006.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsFSmu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=355-359&author=G.+Vauquelinauthor=I.+Van+Liefde&title=Slow+antagonist+dissociation+and+long-lasting+in+vivo+receptor+protection&doi=10.1016%2Fj.tips.2006.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Slow antagonist dissociation and long-lasting in vivo receptor protection</span></div><div class="casAuthors">Vauquelin, Georges; Van Liefde, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">355-359</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The ability of antagonists to form slowly dissocg. complexes with their cognate receptors has repeatedly been proposed to contribute to their long-lasting clin. actions.  Yet specific conditions seem to be necessary for this to take place.  The elimination rate of the free antagonist and the variation of agonist concn. with time have important roles.  Slowly dissocg. antagonists are likely to exert longer efficient receptor protection in vivo than are fast-dissocg. antagonists when the half-life of the antagonist-receptor complex exceeds that of the free antagonist.  However, when the half-life of the free antagonist prevails, longer effective protection by slowly dissocg. antagonists occurs only if the receptor is exposed to rapid fluctuations in free agonist concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCVnyLMr2SRbVg90H21EOLACvtfcHk0lhEO-Fixr5Gyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsFSmu7o%253D&md5=cb7f4428b23136b31523a233d9b11dcf</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2006.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2006.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26aulast%3DVan%2BLiefde%26aufirst%3DI.%26atitle%3DSlow%2520antagonist%2520dissociation%2520and%2520long-lasting%2520in%2520vivo%2520receptor%2520protection%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D355%26epage%3D359%26doi%3D10.1016%2Fj.tips.2006.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">The Role of target binding kinetics in drug discovery</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1796</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1002%2Fcmdc.201500310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=26506404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1793-1796&author=D.+Guoauthor=L.+H.+Heitmanauthor=A.+P.+IJzerman&title=The+Role+of+target+binding+kinetics+in+drug+discovery&doi=10.1002%2Fcmdc.201500310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25cR"><div class="casContent"><span class="casTitleNuber">25c</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Target Binding Kinetics in Drug Discovery</span></div><div class="casAuthors">Guo, Dong; Heitman, Laura H.; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1793-1796</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Traditionally structure-activity/affinity relationships (SAR) have dominated research in medicinal chem.  However, structure-kinetics relationships (SKR) can be very informative too.  In this viewpoint we explore the mol. determinants of binding kinetics and discuss challenges for future binding kinetics studies.  A scheme for future kinetics-directed drug design and discovery is also proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiX7v30ryLZLVg90H21EOLACvtfcHk0ljsUu1hZGH5_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjurfF&md5=8442ba4d4ec014762ed470f7f6131d09</span></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500310%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26atitle%3DThe%2520Role%2520of%2520target%2520binding%2520kinetics%2520in%2520drug%2520discovery%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1793%26epage%3D1796%26doi%3D10.1002%2Fcmdc.201500310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">For some recent reviews on the role of residence time, see:</p></div><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Swinney, D. C.</span></span> <span> </span><span class="NLM_article-title">Applications of binding kinetics to drug discovery</span>. <i>Pharm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1007/BF03256679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1007%2FBF03256679" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=23-34&author=D.+C.+Swinney&title=Applications+of+binding+kinetics+to+drug+discovery&doi=10.1007%2FBF03256679"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1007%2FBF03256679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03256679%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DApplications%2520of%2520binding%2520kinetics%2520to%2520drug%2520discovery%26jtitle%3DPharm.%2520Med.%26date%3D2008%26volume%3D22%26spage%3D23%26epage%3D34%26doi%3D10.1007%2FBF03256679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Swinney, D. C.</span></span> <span> </span><span class="NLM_article-title">The role of binding kinetics in therapeutically useful drug action</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=19152211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt12ltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=31-39&author=D.+C.+Swinney&title=The+role+of+binding+kinetics+in+therapeutically+useful+drug+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">The role of binding kinetics in therapeutically useful drug action</span></div><div class="casAuthors">Swinney, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">2040-3437</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Binding kinetics help define how a medicine will communicate with physiol. to produce a desired therapeutic response.  Clin. efficacy, duration of action, clin. differentiation and safety may all be influenced by binding kinetics.  The optimization of binding kinetics can be used to maximize a drug's therapeutic index and thereby decrease drug attrition.  The gap between basic scientific principles and the potential medical value of a drug is currently bridged by the use of empirical assays.  The value of binding kinetics to drug discovery will be increased through an improved ability to identify optimal kinetic mechanisms and define kinetic structure activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8IoReBfGAabVg90H21EOLACvtfcHk0ljsUu1hZGH5_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt12ltrk%253D&md5=129948a7fb0a60f3b9995e5aedb700a4</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DThe%2520role%2520of%2520binding%2520kinetics%2520in%2520therapeutically%2520useful%2520drug%2520action%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2009%26volume%3D12%26spage%3D31%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <span> </span><span class="NLM_article-title">The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1517/17460441003677725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F17460441003677725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=22823083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFSgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=305-309&author=R.+A.+Copeland&title=The+dynamics+of+drug-target+interactions%3A+drug-target+residence+time+and+its+impact+on+efficacy+and+safety&doi=10.1517%2F17460441003677725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26cR"><div class="casContent"><span class="casTitleNuber">26c</span><div class="casTitle"><span class="NLM_cas:atitle">The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety</span></div><div class="casAuthors">Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-310</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The extent and duration of pharmacol. action is detd. by the lifetime of drug occupancy on a mol. target.  This lifetime is defined by dynamic processes that control the rates of drug assocn. and dissocn. from the target.  Recently, the term residence time has been coined to describe exptl. measurements that can be related to the lifetime of the binary drug-target complex, and this in turn to durable, pharmacodynamic activity.  The residence time concept and its impact on drug optimization are reviewed here.  Examples are provided that demonstrate how a long residence time can improve drug efficacy in vivo.  Addnl., optimization of drug-target residence time can help to mitigate off-target mediated toxicity, hence, improving drug safety and tolerability.  Recent applications of the residence time concept to both drug discovery and development are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyt3KrIYdRjbVg90H21EOLACvtfcHk0liQxsB6pjwZyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFSgsbo%253D&md5=aca925e00abefddf6e92d83b470d96f1</span></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=10.1517%2F17460441003677725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441003677725%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DThe%2520dynamics%2520of%2520drug-target%2520interactions%253A%2520drug-target%2520residence%2520time%2520and%2520its%2520impact%2520on%2520efficacy%2520and%2520safety%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2010%26volume%3D5%26spage%3D305%26epage%3D309%26doi%3D10.1517%2F17460441003677725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monsma, F.</span></span> <span> </span><span class="NLM_article-title">Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1517/17460441.2010.520700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F17460441.2010.520700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=22827742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlaiu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1023-1029&author=R.+Zhangauthor=F.+Monsma&title=Binding+kinetics+and+mechanism+of+action%3A+toward+the+discovery+and+development+of+better+and+best+in+class+drugs&doi=10.1517%2F17460441.2010.520700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26dR"><div class="casContent"><span class="casTitleNuber">26d</span><div class="casTitle"><span class="NLM_cas:atitle">Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs</span></div><div class="casAuthors">Zhang, Rumin; Monsma, Frederick</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1023-1029</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Binding kinetics (BK), an often overlooked key aspect of the broader concept of drug mechanism of action (MOA), is increasingly recognized as a springboard from pharmacokinetics (PK) to pharmacodynamics, and as a crit. differentiator and predictor for drug efficacy and safety.  Just as greater attention to PK issues has helped reduce the attrition of drugs tested in clin. trials, the emerging paradigm shift from primarily affinity/potency-emphasized to a more holistic BK-perceptive and MOA-informed approach is expected to further enhance the success of drug discovery and development.  This perspective attempts to envision what this new approach looks like when proper emphasis is placed on BK and MOA in designing better and best in class drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7O7ymOCyIe7Vg90H21EOLACvtfcHk0liQxsB6pjwZyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlaiu77O&md5=9b3efefdf67fd2c9303537a15dcc8d98</span></div><a href="/servlet/linkout?suffix=cit26d&amp;dbid=16384&amp;doi=10.1517%2F17460441.2010.520700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2010.520700%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DMonsma%26aufirst%3DF.%26atitle%3DBinding%2520kinetics%2520and%2520mechanism%2520of%2520action%253A%2520toward%2520the%2520discovery%2520and%2520development%2520of%2520better%2520and%2520best%2520in%2520class%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2010%26volume%3D5%26spage%3D1023%26epage%3D1029%26doi%3D10.1517%2F17460441.2010.520700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeadon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevethick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agoram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entwistle, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, F. J.</span></span> <span> </span><span class="NLM_article-title">Inhalation by design: novel tertiary amine muscarinic M<sub>3</sub> receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6888</span>– <span class="NLM_lpage">6904</span>, <span class="refDoi"> DOI: 10.1021/jm200884j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200884j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SltbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6888-6904&author=P.%0AA.+Glossopauthor=C.+A.+Watsonauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=D.+S.+Middletonauthor=A.+Woodauthor=K.+Jamesauthor=D.+Robertsauthor=R.+S.+Strangauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=N.+P.+Clarkeauthor=M.+A.+Trevethickauthor=I.+Machinauthor=E.+F.+Stuartauthor=S.+M.+Evansauthor=A.+C.+Harrisonauthor=D.+A.+Fairmanauthor=B.+Agoramauthor=J.+L.+Burrowsauthor=N.+Feederauthor=C.+K.+Fultonauthor=B.+R.+Dillonauthor=D.+A.+Entwistleauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+tertiary+amine+muscarinic+M3+receptor+antagonists+with+slow+off-rate+binding+kinetics+for+inhaled+once-daily+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1021%2Fjm200884j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhalation by Design: Novel Tertiary Amine Muscarinic M3 Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Glossop, Paul A.; Watson, Christine A. L.; Price, David A.; Bunnage, Mark E.; Middleton, Donald S.; Wood, Anthony; James, Kim; Roberts, Dannielle; Strang, Ross S.; Yeadon, Michael; Perros-Huguet, Christelle; Clarke, Nicholas P.; Trevethick, Michael A.; Machin, Ian; Stuart, Emilio F.; Evans, Steven M.; Harrison, Anthony C.; Fairman, David A.; Agoram, Balaji; Burrows, Jane L.; Feeder, Neil; Fulton, Craig K.; Dillon, Barry R.; Entwistle, David A.; Spence, Fiona J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6888-6904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel tertiary amine series of potent muscarinic M3 receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease.  Geminal di-Me functionality present in this series of compds. confers very long dissociative half-life (slow off-rate) from the M3 receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips.  Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation.  Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug-drug interactions, and reduce systemically mediated adverse events.  Compd. 47 (PF-3635659) is identified as a Phase II clin. candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs8Q4T5oR53bVg90H21EOLACvtfcHk0lgHtsON1C2LDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SltbzM&md5=ca9b632b4c7982fb44c0d5dd17a056bf</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1021%2Fjm200884j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200884j%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DWatson%26aufirst%3DC.%2BA.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DMiddleton%26aufirst%3DD.%2BS.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DD.%26aulast%3DStrang%26aufirst%3DR.%2BS.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DMachin%26aufirst%3DI.%26aulast%3DStuart%26aufirst%3DE.%2BF.%26aulast%3DEvans%26aufirst%3DS.%2BM.%26aulast%3DHarrison%26aufirst%3DA.%2BC.%26aulast%3DFairman%26aufirst%3DD.%2BA.%26aulast%3DAgoram%26aufirst%3DB.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DFulton%26aufirst%3DC.%2BK.%26aulast%3DDillon%26aufirst%3DB.%2BR.%26aulast%3DEntwistle%26aufirst%3DD.%2BA.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520tertiary%2520amine%2520muscarinic%2520M3%2520receptor%2520antagonists%2520with%2520slow%2520off-rate%2520binding%2520kinetics%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6888%26epage%3D6904%26doi%3D10.1021%2Fjm200884j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewthwaite, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeadon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevethick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, F. J.</span></span> <span> </span><span class="NLM_article-title">Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6640</span>– <span class="NLM_lpage">6652</span>, <span class="refDoi"> DOI: 10.1021/jm1005989</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&author=P.+A.+Glossopauthor=C.+A.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+ultra-long-acting+%CE%B2%282%29-adrenoreceptor+agonists+for+inhaled+once-daily+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease+that+utilize+a+sulfonamide+agonist+headgroup&doi=10.1021%2Fjm1005989"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520ultra-long-acting%2520%25CE%25B2%25282%2529-adrenoreceptor%2520agonists%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520that%2520utilize%2520a%2520sulfonamide%2520agonist%2520headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6640%26epage%3D6652%26doi%3D10.1021%2Fjm1005989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Claus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiewe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friess, W.</span></span> <span> </span><span class="NLM_article-title">How can we bring high drug doses to the lung?</span>. <i>Eur. J. Pharm. Biopharm.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.ejpb.2013.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.ejpb.2013.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=24300444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVSgsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=1-6&author=S.+Clausauthor=C.+Weilerauthor=J.+Schieweauthor=W.+Friess&title=How+can+we+bring+high+drug+doses+to+the+lung%3F&doi=10.1016%2Fj.ejpb.2013.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">How can we bring high drug doses to the lung?</span></div><div class="casAuthors">Claus, Sarah; Weiler, Claudius; Schiewe, Joerg; Friess, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the last decades, dry powder inhalation has become a very attractive option for pulmonary drug delivery to treat lung diseases like cystic fibroses and lung infections.  In contrast to the traditional pulmonary application of drugs for asthma and chronic obstructive pulmonary disease, these therapies require higher lung doses to be administered.  The developments and improvements toward high dose powder pulmonary drug delivery are summarized and discussed in this chapter.  These include the invention and improvement of novel inhaler devices as well as the further development of formulation principles and new powder engineering methods.  The implementation of these strategies is subsequently described for some prototypes and formulations in research and development stage as well as for already marketed dry powder products.  Finally, possible adverse effects that can occur after inhalation of high powder doses are shortly addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV5Llh5PaWsrVg90H21EOLACvtfcHk0lgHtsON1C2LDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVSgsrzN&md5=a0bd5801e0c672b787282b3c2636a1df</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2013.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2013.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DClaus%26aufirst%3DS.%26aulast%3DWeiler%26aufirst%3DC.%26aulast%3DSchiewe%26aufirst%3DJ.%26aulast%3DFriess%26aufirst%3DW.%26atitle%3DHow%2520can%2520we%2520bring%2520high%2520drug%2520doses%2520to%2520the%2520lung%253F%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2014%26volume%3D86%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.ejpb.2013.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petavy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, A. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-11-26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1186%2F1465-9921-11-26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=20193079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=26-34&author=D.+Singhauthor=F.+Petavyauthor=A.+J.+Macdonald&title=The+inhaled+phosphodiesterase+4+inhibitor+GSK256066+reduces+allergen+challenge+responses+in+asthma&doi=10.1186%2F1465-9921-11-26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span></div><div class="casAuthors">Singh Dave; Petavy Frank; Macdonald Alex J; Lazaar Aili L; O'Connor Brian J</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects.  We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild asthmatics.  METHODS:  In a randomised, double blind, cross-over study, 24 steroid naive atopic asthmatics with both early (EAR) and late (LAR) responses to inhaled allergen received inhaled GSK256066 87.5 mcg once per day and placebo for 7 days, followed by allergen challenge.  Methacholine reactivity was measured 24 h post-allergen.  Plasma pharmacokinetics were measured.  The primary endpoint was the effect on LAR.  RESULTS:  GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo.  GSK256066 significantly reduced the EAR, inhibiting the fall in minimum and weighted mean FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014) respectively compared to placebo.  There was no effect on pre-allergen FEV1 or methacholine reactivity post allergen.  GSK256066 was well tolerated, with low systemic exposure; plasma levels were not measurable after 4 hours in the majority of subjects.  CONCLUSIONS:  GSK256066 demonstrated a protective effect on the EAR and LAR.  This is the first inhaled PDE4 inhibitor to show therapeutic potential in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6sWKb5nMe2ROk4JA3soTqfW6udTcc2eZd4GSMkgn3vbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D&md5=88d976c3aa2d963dc83c5fa8e32e4f62</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-26%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DPetavy%26aufirst%3DF.%26aulast%3DMacdonald%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520GSK256066%2520reduces%2520allergen%2520challenge%2520responses%2520in%2520asthma%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D26%26epage%3D34%26doi%3D10.1186%2F1465-9921-11-26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballantine, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindvaal, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranshaw, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanke, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, J. O.</span></span> <span> </span><span class="NLM_article-title">Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5261</span>– <span class="NLM_lpage">5265</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.bmcl.2009.04.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5261-5265&author=M.+D.+Woodrowauthor=S.+P.+Ballantineauthor=M.+D.+Barkerauthor=B.+J.+Clarkeauthor=J.+Dawsonauthor=T.+W.+Deanauthor=C.+J.+Delvesauthor=B.+Evansauthor=S.+L.+Goughauthor=S.+B.+Guntripauthor=S.+Holmanauthor=D.+S.+Holmesauthor=M.+Kranzauthor=M.+K.+Lindvaalauthor=F.+S.+Lucasauthor=M.+Neuauthor=L.+E.+Ranshawauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=P.+Wardauthor=J.+O.+Wiseman&title=Quinolines+as+a+novel+structural+class+of+potent+and+selective+PDE4+inhibitors.+Optimisation+for+inhaled+administration&doi=10.1016%2Fj.bmcl.2009.04.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DWoodrow%26aufirst%3DM.%2BD.%26aulast%3DBallantine%26aufirst%3DS.%2BP.%26aulast%3DBarker%26aufirst%3DM.%2BD.%26aulast%3DClarke%26aufirst%3DB.%2BJ.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DDean%26aufirst%3DT.%2BW.%26aulast%3DDelves%26aufirst%3DC.%2BJ.%26aulast%3DEvans%26aufirst%3DB.%26aulast%3DGough%26aufirst%3DS.%2BL.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHolman%26aufirst%3DS.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DLindvaal%26aufirst%3DM.%2BK.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DQuinolines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520and%2520selective%2520PDE4%2520inhibitors.%2520Optimisation%2520for%2520inhaled%2520administration%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5261%26epage%3D5265%26doi%3D10.1016%2Fj.bmcl.2009.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gràcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buil, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segarra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagès, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Biphenyl pyridazinone derivatives as inhaled PDE4 inhibitors: structural biology and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10479</span>– <span class="NLM_lpage">10497</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10479-10497&author=J.+Gr%C3%A0ciaauthor=M.+A.+Builauthor=J.+Castroauthor=P.+Eichhornauthor=M.+Ferrerauthor=A.+Gavald%C3%A0author=B.+Hern%C3%A1ndezauthor=V.+Segarraauthor=M.+D.+Lehnerauthor=I.+Morenoauthor=L.+Pag%C3%A8sauthor=R.+S.+Robertsauthor=J.+Serratauthor=S.+Sevillaauthor=J.+Taltavullauthor=M.+Andr%C3%A9sauthor=J.+Cabedoauthor=D.+Vilellaauthor=E.+Calamaauthor=C.+Carcasonaauthor=M.+Miralpeix&title=Biphenyl+pyridazinone+derivatives+as+inhaled+PDE4+inhibitors%3A+structural+biology+and+structure-activity+relationships&doi=10.1021%2Facs.jmedchem.6b00829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships</span></div><div class="casAuthors">Gracia, Jordi; Buil, Maria Antonia; Castro, Jordi; Eichhorn, Peter; Ferrer, Manel; Gavalda, Amadeu; Hernandez, Begona; Segarra, Victor; Lehner, Martin D.; Moreno, Imma; Pages, Lluis; Roberts, Richard S.; Serrat, Jordi; Sevilla, Sara; Taltavull, Joan; Andres, Miriam; Cabedo, Judit; Vilella, Dolors; Calama, Elena; Carcasona, Carla; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10479-10497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclic nucleotide cAMP is an ubiquitous second messenger involved in a plethora of cellular responses to biol. agents involving activation of adenylyl cyclase.  Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs.  In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD.  Here the authors describe efforts to discover novel, highly potent inhaled inhibitors of PDE4.  Through structure based design, with the intervention of a wide variety of functional groups and physichochem. profiles to occupy the solvent-filled pocket of the PDE4 enzyme, the authors modified the structure of the authors' oral PDE4 inhibitors to reach compds. up to picomolar enzymic potencies.  In vitro potencies were demonstrated in a rat lung neutrophilia model by suspension microspray administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCrwH5GRUxx7Vg90H21EOLACvtfcHk0lggpo-DxzuHbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE&md5=13709b5d62c06b553655f88f65ff3bdf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00829%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25A0cia%26aufirst%3DJ.%26aulast%3DBuil%26aufirst%3DM.%2BA.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DEichhorn%26aufirst%3DP.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DMoreno%26aufirst%3DI.%26aulast%3DPag%25C3%25A8s%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26aulast%3DSerrat%26aufirst%3DJ.%26aulast%3DSevilla%26aufirst%3DS.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DBiphenyl%2520pyridazinone%2520derivatives%2520as%2520inhaled%2520PDE4%2520inhibitors%253A%2520structural%2520biology%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10479%26epage%3D10497%26doi%3D10.1021%2Facs.jmedchem.6b00829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2004.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.molcel.2004.07.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=279-286&author=K.+Y.+Zhangauthor=G.+L.+Cardauthor=Y.+Suzukiauthor=D.+R.+Artisauthor=D.+Fongauthor=S.+Gilletteauthor=D.+Hsiehauthor=J.+Neimanauthor=B.+L.+Westauthor=C.+Zhangauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=G.+Bollag&title=A+glutamine+switch+mechanism+for+nucleotide+selectivity+by+phosphodiesterases&doi=10.1016%2Fj.molcel.2004.07.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DNeiman%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DA%2520glutamine%2520switch%2520mechanism%2520for%2520nucleotide%2520selectivity%2520by%2520phosphodiesterases%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D23%26spage%3D279%26epage%3D286%26doi%3D10.1016%2Fj.molcel.2004.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="note"><p class="first last">Erratum in:</p></div><div class="NLM_citation" id="cit32a1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">659</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2004.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.molcel.2004.08.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Zhang%2C+K.+Y.%3B+Card%2C+G.+L.%3B+Suzuki%2C+Y.%3B+Artis%2C+D.+R.%3B+Fong%2C+D.%3B+Gillette%2C+S.%3B+Hsieh%2C+D.%3B+Neiman%2C+J.%3B+West%2C+B.+L.%3B+Zhang%2C+C.%3B+Milburn%2C+M.+V.%3B+Kim%2C+S.+H.%3B+Schlessinger%2C+J.%3B+Bollag%2C+G.+Mol.+Cell+2004%2C+27%2C+659%2C+10.1016%2Fj.molcel.2004.08.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a1&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DNeiman%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DBollag%26aufirst%3DG.%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D27%26spage%3D659%26doi%3D10.1016%2Fj.molcel.2004.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrafnsdottir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1038/nbt.1598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1038%2Fnbt.1598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=20037581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=63-72&author=A.+B.+Burginauthor=O.+T.+Magnussonauthor=J.+Singhauthor=P.+Witteauthor=B.+L.+Stakerauthor=J.+M.+Bjornssonauthor=M.+Thorsteinsdottirauthor=S.+Hrafnsdottirauthor=T.+Hagenauthor=A.+S.+Kiselyovauthor=L.+J.+Stewartauthor=M.+E.+Gurney&title=Design+of+phosphodiesterase+4D+%28PDE4D%29+allosteric+modulators+for+enhancing+cognition+with+improved+safety&doi=10.1038%2Fnbt.1598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span></div><div class="casAuthors">Burgin, Alex B.; Magnusson, Olafur T.; Singh, Jasbir; Witte, Pam; Staker, Bart L.; Bjornsson, Jon M.; Thorsteinsdottir, Margret; Hrafnsdottir, Sigrun; Hagen, Timothy; Kiselyov, Alex S.; Stewart, Lance J.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions.  Here we present seven co-crystal structures of PDE4 and bound inhibitors that show the regulatory domain closed across the active site, thereby revealing the structural basis of PDE4 regulation.  This structural insight, together with supporting mutagenesis and kinetic studies, allowed us to design small-mol. allosteric modulators of PDE4D that do not completely inhibit enzymic activity (Imax ∼ 80-90%).  These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biol. activity in cellular and in vivo models.  Our results may facilitate the design of CNS therapeutics modulating cAMP signaling for the treatment of Alzheimer's disease, Huntington's disease, schizophrenia and depression, where brain distribution is desired for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr18KdQE2oVsbVg90H21EOLACvtfcHk0liIEoDO_3NZMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ&md5=1e8651a7116206eefddb9fa6b79d5112</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1598%26sid%3Dliteratum%253Aachs%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DP.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DBjornsson%26aufirst%3DJ.%2BM.%26aulast%3DThorsteinsdottir%26aufirst%3DM.%26aulast%3DHrafnsdottir%26aufirst%3DS.%26aulast%3DHagen%26aufirst%3DT.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDesign%2520of%2520phosphodiesterase%25204D%2520%2528PDE4D%2529%2520allosteric%2520modulators%2520for%2520enhancing%2520cognition%2520with%2520improved%2520safety%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D63%26epage%3D72%26doi%3D10.1038%2Fnbt.1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevilla, S.</span></span> <span> </span><span class="NLM_article-title">A modular synthesis of novel 4-amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as PDE4 inhibitors</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4821</span>– <span class="NLM_lpage">4825</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2013.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.tetlet.2013.06.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=4821-4825&author=M.+Ferrerauthor=R.+S.+Robertsauthor=S.+Sevilla&title=A+modular+synthesis+of+novel+4-amino-7%2C8-dihydro-1%2C6-naphthyridin-5%286H%29-ones+as+PDE4+inhibitors&doi=10.1016%2Fj.tetlet.2013.06.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2013.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2013.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26aulast%3DSevilla%26aufirst%3DS.%26atitle%3DA%2520modular%2520synthesis%2520of%2520novel%25204-amino-7%252C8-dihydro-1%252C6-naphthyridin-5%25286H%2529-ones%2520as%2520PDE4%2520inhibitors%26jtitle%3DTetrahedron%2520Lett.%26date%3D2013%26volume%3D54%26spage%3D4821%26epage%3D4825%26doi%3D10.1016%2Fj.tetlet.2013.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alex, A.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eZRr3qJdzVIKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkaichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7037</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.bmc.2013.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=24094436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGnsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=7025-7037&author=T.+Gotoauthor=A.+Shiinaauthor=T.+Yoshinoauthor=K.+Mizukamiauthor=K.+Hiraharaauthor=O.+Suzukiauthor=Y.+Sogawaauthor=T.+Takahashiauthor=T.+Mikkaichiauthor=N.+Nakaoauthor=M.+Takahashiauthor=M.+Hasegawaauthor=S.+Sasaki&title=Synthesis+and+biological+evaluation+of+5-carbamoyl-2-phenylpyrimidine+derivatives+as+novel+and+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmc.2013.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors</span></div><div class="casAuthors">Goto, Taiji; Shiina, Akiko; Yoshino, Toshiharu; Mizukami, Kiyoshi; Hirahara, Kazuki; Suzuki, Osamu; Sogawa, Yoshitaka; Takahashi, Tomoko; Mikkaichi, Tsuyoshi; Nakao, Naoki; Takahashi, Mizuki; Hasegawa, Masashi; Sasaki, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7025-7037</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">5-Carbamoyl-2-phenylpyrimidine deriv. has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM).  Modification of the carboxylic acid moiety of the deriv. gave N-neopentylacetamide deriv., which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia in mice (ID50 = 16 mg/kg, i.p.).  Furthermore, based on the x-ray crystallog. of N-neopentylacetamide deriv. bound to the human PDE4B catalytic domain, the authors designed 7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one deriv. I, which has a fused bicyclic lactam scaffold.  Compd. I exhibited excellent inhibitory activity against LPS-induced tumor necrosis factor alpha (TNF-α) prodn. in mouse splenocytes (IC50 = 0.21 nM) and in vivo anti-inflammatory activity against LPS-induced pulmonary neutrophilia in mice (41% inhibition at a dose of 1.0 mg/kg, i.t.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo66taMP2rurVg90H21EOLACvtfcHk0liJD7ERMkQ3iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGnsL%252FN&md5=53de746f90ef183a3c89b36895c3fe2b</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DShiina%26aufirst%3DA.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DMizukami%26aufirst%3DK.%26aulast%3DHirahara%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DO.%26aulast%3DSogawa%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DMikkaichi%26aufirst%3DT.%26aulast%3DNakao%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25205-carbamoyl-2-phenylpyrimidine%2520derivatives%2520as%2520novel%2520and%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D7025%26epage%3D7037%26doi%3D10.1016%2Fj.bmc.2013.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkaichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span> <span> </span><span class="NLM_article-title">Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3325</span>– <span class="NLM_lpage">3328</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.03.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.bmcl.2013.03.104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3325-3328&author=T.+Gotoauthor=A.+Shiinaauthor=T.+Yoshinoauthor=K.+Mizukamiauthor=K.+Hiraharaauthor=O.+Suzukiauthor=Y.+Sogawaauthor=T.+Takahashiauthor=T.+Mikkaichiauthor=N.+Nakaoauthor=M.+Takahashiauthor=M.+Hasegawaauthor=S.+Sasaki&title=Identification+of+the+fused+bicyclic+4-amino-2-phenylpyrimidine+derivatives+as+novel+and+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2013.03.104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.104%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DShiina%26aufirst%3DA.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DMizukami%26aufirst%3DK.%26aulast%3DHirahara%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DO.%26aulast%3DSogawa%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DMikkaichi%26aufirst%3DT.%26aulast%3DNakao%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520the%2520fused%2520bicyclic%25204-amino-2-phenylpyrimidine%2520derivatives%2520as%2520novel%2520and%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3325%26epage%3D3328%26doi%3D10.1016%2Fj.bmcl.2013.03.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leriche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamiot-Clerc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feutrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derimay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grépin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.bmcl.2015.11.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=26681511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=454-459&author=J.+Le+Rouxauthor=C.+Lericheauthor=P.+Chamiot-Clercauthor=J.+Feutrillauthor=F.+Halleyauthor=D.+Papinauthor=N.+Derimayauthor=C.+Muglerauthor=C.+Gr%C3%A9pinauthor=L.+Schio&title=Preparation+and+optimization+of+pyrazolo%5B1%2C5-a%5Dpyrimidines+as+new+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2015.11.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors</span></div><div class="casAuthors">Le Roux, Jacques; Leriche, Caroline; Chamiot-Clerc, Philippe; Feutrill, John; Halley, Frank; Papin, David; Derimay, Nathalie; Mugler, Christelle; Grepin, Claudine; Schio, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">454-459</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of pyrazolo[1,5-a]pyrimidines exemplified by compd. I, has been identified with moderate activity (IC50 = 165 nM), following GSK256066 rescaffolding.  Compd. I optimization at positions 2, 3, 6 and 7 gave compd. II with high in vitro activity (IC50 = 0.7 nM).  Modeling studies based on the PDB structure 3GWT with compd. III showed the expected overlay with the carboxamide, the aryl moiety and the sulfone.  Cyclization of the primary amide to the 5 position of the pyrazolo[1,5-a]pyrimidines scaffold afforded compds. IV [R = 3-MeO, 3,5-Cl] with 200-fold enhancement in activity and cellular potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmgso9aPgRr7Vg90H21EOLACvtfcHk0liJD7ERMkQ3iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ&md5=962985b2b1ff0cb57e104018b75d23fa</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.093%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRoux%26aufirst%3DJ.%26aulast%3DLeriche%26aufirst%3DC.%26aulast%3DChamiot-Clerc%26aufirst%3DP.%26aulast%3DFeutrill%26aufirst%3DJ.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DPapin%26aufirst%3DD.%26aulast%3DDerimay%26aufirst%3DN.%26aulast%3DMugler%26aufirst%3DC.%26aulast%3DGr%25C3%25A9pin%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DPreparation%2520and%2520optimization%2520of%2520pyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520new%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D454%26epage%3D459%26doi%3D10.1016%2Fj.bmcl.2015.11.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amadasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surface, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyrakis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozzarelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellogg, G. E.</span></span> <span> </span><span class="NLM_article-title">Robust classification of “relevant” water molecules in putative protein binding sites</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1063</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1021/jm701023h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701023h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1063-1067&author=A.+Amadasiauthor=J.+A.+Surfaceauthor=F.+Spyrakisauthor=P.+Cozziniauthor=A.+Mozzarelliauthor=G.+E.+Kellogg&title=Robust+classification+of+%E2%80%9Crelevant%E2%80%9D+water+molecules+in+putative+protein+binding+sites&doi=10.1021%2Fjm701023h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm701023h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701023h%26sid%3Dliteratum%253Aachs%26aulast%3DAmadasi%26aufirst%3DA.%26aulast%3DSurface%26aufirst%3DJ.%2BA.%26aulast%3DSpyrakis%26aufirst%3DF.%26aulast%3DCozzini%26aufirst%3DP.%26aulast%3DMozzarelli%26aufirst%3DA.%26aulast%3DKellogg%26aufirst%3DG.%2BE.%26atitle%3DRobust%2520classification%2520of%2520%25E2%2580%259Crelevant%25E2%2580%259D%2520water%2520molecules%2520in%2520putative%2520protein%2520binding%2520sites%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1063%26epage%3D1067%26doi%3D10.1021%2Fjm701023h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span>Roflumilast. <a href="https://www.drugbank.ca/drugs/DB01656" class="extLink">https://www.drugbank.ca/drugs/DB01656</a> (accessed Jan 25, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Roflumilast.+https%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01656+%28accessed+Jan+25%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Percival, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falgueyret, J. P.</span></span> <span> </span><span class="NLM_article-title">Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A)</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>241</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1997.7542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1006%2Fbbrc.1997.7542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=1997&pages=175-180&author=M.+D.+Percivalauthor=B.+Yehauthor=J.+P.+Falgueyret&title=Zinc+dependent+activation+of+cAMP-specific+phosphodiesterase+%28PDE4A%29&doi=10.1006%2Fbbrc.1997.7542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1997.7542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1997.7542%26sid%3Dliteratum%253Aachs%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DYeh%26aufirst%3DB.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26atitle%3DZinc%2520dependent%2520activation%2520of%2520cAMP-specific%2520phosphodiesterase%2520%2528PDE4A%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1997%26volume%3D241%26spage%3D175%26epage%3D180%26doi%3D10.1006%2Fbbrc.1997.7542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19a','cit19b','cit19c','cit19d'],'ref20':['cit20a','cit20b','cit20c'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24a','cit24b'],'ref25':['cit25a','cit25b','cit25c'],'ref26':['cit26a','cit26b','cit26c','cit26d'],'ref27':['cit27a','cit27b'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32a1'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36a','cit36b'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Huihui Ti, Yang Zhou, Xue Liang, Runfeng Li, Ke Ding, <span class="NLM_string-name hlFld-ContribAuthor">Xin Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 5944-5978. <a href="https://doi.org/10.1021/acs.jmedchem.8b01520" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01520%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BTreatments%252Bfor%252BChronic%252BObstructive%252BPulmonary%252BDisease%252B%252528COPD%252529%252BUsing%252BLow-Molecular-Weight%252BDrugs%252B%252528LMWDs%252529%26aulast%3DTi%26aufirst%3DHuihui%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D30092018%26date%3D12022019%26date%3D25012019%26volume%3D62%26issue%3D13%26spage%3D5944%26epage%3D5978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Domenico Alberga, Daniela Trisciuzzi, Michele Montaruli, Francesco Leonetti, Giuseppe Felice Mangiatordi, <span class="NLM_string-name hlFld-ContribAuthor">Orazio Nicolotti</span>. </span><span class="cited-content_cbyCitation_article-title">A New Approach for Drug Target and Bioactivity Prediction: The Multifingerprint Similarity Search Algorithm (MuSSeL). </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (1)
                                     , 586-596. <a href="https://doi.org/10.1021/acs.jcim.8b00698" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00698%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DA%252BNew%252BApproach%252Bfor%252BDrug%252BTarget%252Band%252BBioactivity%252BPrediction%25253A%252BThe%252BMultifingerprint%252BSimilarity%252BSearch%252BAlgorithm%252B%252528MuSSeL%252529%26aulast%3DAlberga%26aufirst%3DDomenico%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D08102018%26date%3D14122018%26date%3D28112018%26volume%3D59%26issue%3D1%26spage%3D586%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rabdan M.  Tikhov</span>, <span class="hlFld-ContribAuthor ">Nikolai Yu.  Kuznetsov</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of piperidine-2,4-dione-type azaheterocycles and their application in modern drug development and natural product synthesis. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (15)
                                     , 2793-2812. <a href="https://doi.org/10.1039/D0OB00287A" title="DOI URL">https://doi.org/10.1039/D0OB00287A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00287A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00287A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConstruction%252Bof%252Bpiperidine-2%25252C4-dione-type%252Bazaheterocycles%252Band%252Btheir%252Bapplication%252Bin%252Bmodern%252Bdrug%252Bdevelopment%252Band%252Bnatural%252Bproduct%252Bsynthesis%26aulast%3DTikhov%26aufirst%3DRabdan%2BM.%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D15%26spage%3D2793%26epage%3D2812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan E.  Phillips</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.00259" title="DOI URL">https://doi.org/10.3389/fphar.2020.00259</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.00259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.00259%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DInhaled%252BPhosphodiesterase%252B4%252B%252528PDE4%252529%252BInhibitors%252Bfor%252BInflammatory%252BRespiratory%252BDiseases%26aulast%3DPhillips%26aufirst%3DJonathan%2BE.%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yixian  Liao</span>, <span class="hlFld-ContribAuthor ">Xiuhua  Jia</span>, <span class="hlFld-ContribAuthor ">Yongmei  Tang</span>, <span class="hlFld-ContribAuthor ">Sumei  Li</span>, <span class="hlFld-ContribAuthor ">Yipeng  Zang</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Zi-Ning  Cui</span>, <span class="hlFld-ContribAuthor ">Gaopeng  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (22)
                                     , 126720. <a href="https://doi.org/10.1016/j.bmcl.2019.126720" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126720</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126720%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Binhibitors%252Bof%252Bphosphodiesterase%252B4%252Bwith%252B1-phenyl-3%25252C4-dihydroisoquinoline%252Bscaffold%25253A%252BStructure-based%252Bdrug%252Bdesign%252Band%252Bfragment%252Bidentification%26aulast%3DLiao%26aufirst%3DYixian%26date%3D2019%26volume%3D29%26issue%3D22%26spage%3D126720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Ping  Gao</span>, <span class="hlFld-ContribAuthor ">Lin  Sun</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient drug discovery by rational lead hybridization based on crystallographic overlay. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (3)
                                     , 805-813. <a href="https://doi.org/10.1016/j.drudis.2018.11.021" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.11.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.11.021%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DEfficient%252Bdrug%252Bdiscovery%252Bby%252Brational%252Blead%252Bhybridization%252Bbased%252Bon%252Bcrystallographic%252Boverlay%26aulast%3DZhang%26aufirst%3DShuo%26date%3D2019%26volume%3D24%26issue%3D3%26spage%3D805%26epage%3D813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentin S.  Dorokhov</span>, <span class="hlFld-ContribAuthor ">Ivan S.  Golovanov</span>, <span class="hlFld-ContribAuthor ">Vladimir A.  Tartakovsky</span>, <span class="hlFld-ContribAuthor ">Alexey Yu.  Sukhorukov</span>, <span class="hlFld-ContribAuthor ">Sema L.  Ioffe</span>. </span><span class="cited-content_cbyCitation_article-title">Diastereoselective synthesis and profiling of bicyclic imidazolidinone derivatives bearing a difluoromethylated catechol unit as potent phosphodiesterase 4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (38)
                                     , 6900-6908. <a href="https://doi.org/10.1039/C8OB01039K" title="DOI URL">https://doi.org/10.1039/C8OB01039K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB01039K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB01039K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDiastereoselective%252Bsynthesis%252Band%252Bprofiling%252Bof%252Bbicyclic%252Bimidazolidinone%252Bderivatives%252Bbearing%252Ba%252Bdifluoromethylated%252Bcatechol%252Bunit%252Bas%252Bpotent%252Bphosphodiesterase%252B4%252Binhibitors%26aulast%3DDorokhov%26aufirst%3DValentin%2BS.%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D38%26spage%3D6900%26epage%3D6908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures and affinities<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> of approved oral drugs roflumilast <b>1</b> and apremilast <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of the X-ray structures of <b>4</b> (colored by element, pdb code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5kli">5kli</a>) and inhaled clinical candidate GSK256066 <b>3</b> (in blue, pdb code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwt">3gwt</a>). Only glutamine-369 and the two metal ions (magnesium in green, zinc in gray) of the PDE4D enzyme are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Conceptual design and interactions of the naphthyridinone (NAP) series. Active site regions are defined as follows with respect to the cartoon view above: [1] The pi-clamp region (between Phe-372 and Phe-340). [2] The “glutamine switch” glutamine-369.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> [3] The small lipophilic pocket. [4] The large lipophilic pocket. [5] The metal binding zone containing the zinc and magnesium ions responsible for the catalytic activity. [6] The solvent exposed pocket; in the full PDE4 isoenzyme, the helices of the upstream conserved region (UCR2), a negative regulator of cAMP hydrolysis, partially fill this area.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In truncated protein sequences, coding only for the PDE4 active site, this zone is exposed to the bulk solvent, hence the name.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route to Naphthyridinones <b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DCC, DMAP, DCM, 5 °C, 94% yield; (b) EtOAc, reflux, 83% yield; (c) CS<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt then MeI, DMF, 70% yield; (d) R<sup>1</sup>COMe, <i>t</i>BuOK, DMSO, THF, rt, 3 h, then NH<sub>4</sub>OAc, AcOH, 90 °C, 6–55% yield; (e) mCPBA, DCM, 5 °C, 77–100% yield; (f) R<sup>2</sup>NH<sub>2</sub>, EtOH, reflux, then TFA, DCM, rt if necessary, 20–62% yield; (g) R<sup>2</sup>NH<sub>2</sub>, EtOH, reflux, then 160 °C (microwave), 0.5 h, 14–51% yield; (h) R<sup>2</sup>NH<sub>2</sub>, EtOH, 160 °C (microwave), 0.5–18 h, 7–83% yield; (i) TFA, DCM, rt; (j) NH<sub>3</sub> (7 N MeOH), 140 °C (microwave), 67–97% yield over two steps; (k) R<sup>2</sup>Hal, Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, dioxane, 90 °C, 28–41% yield.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Route to R<sup>3</sup>-Aryl Substituted Naphthyridinones <b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) R<sup>3</sup>Hal, Cs<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, dioxane, 90 °C, 4–80% yield from <b>14</b>, 41–95% yield from <b>15</b>; (b) thiol, Pd(PPh<sub>3</sub>)<sub>4</sub>, Bu<sub>3</sub>SnOMe, xylene, reflux, 64% yield; (c) R<sup>2</sup>Hal, Cs<sub>1k</sub>O<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, dioxane, 90 °C, 9–64% yield.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthetic Route to Carbonyl-Variant Naphthyridinones <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) P<sub>4</sub>S<sub>10</sub>, iPrNEt<sub>2</sub>, dioxane, 90 °C, 18 h, 58–99% yield; (b) NaH, MeI, DMF, 60 °C, 3 h, 81–82% yield; (c) NH<sub>2</sub>OH·HCl, K<sub>2</sub>CO<sub>3</sub>, EtOH, 70 °C, 18 h, 23% yield; (d) NH<sub>2</sub>CN, EtOH or THF, 70 °C, 1–2 h, 26–51% yield.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray structure of first synthesized NAP <b>21</b> bound to the active site of PDE4D (magnesium, green sphere; zinc, gray; pdb code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k32">5k32</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PK profiles of compound <b>72</b> in rat. (a) i.v. dose = 500 μg/kg. (b) i.t. dose of dry powder = 1000 μg/kg, as a 5% w/w mixture with lactose. Percentages in the i.t. PK graph refer to the percentage of the total dose (250 μg compound/animal) recovered from the lungs by methanol extraction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/medium/jm-2017-01751w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Dose–responses of roflumilast <b>1</b> and compound <b>72</b> in a LPS-induced rat neutrophilia model. Compounds were administered in suspension by intratracheal microspray delivery. (b) Time-course inhibition of LPS-induced rat neutrophilia. Roflumilast <b>1</b> and compound <b>72</b> were given by i.t. administration of dry powder comixed with lactose. n.t.: not tested.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01751/20180315/images/large/jm-2017-01751w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01751&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i94">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76466" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76466" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span> <span> </span><span class="NLM_article-title">Keynote review: phosphodiesterase-4 as a therapeutic target</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(05)03622-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2FS1359-6446%2805%2903622-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=16257373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1503-1519&author=M.+D.+Houslayauthor=P.+Schaferauthor=K.+Y.+Zhang&title=Keynote+review%3A+phosphodiesterase-4+as+a+therapeutic+target&doi=10.1016%2FS1359-6446%2805%2903622-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 as a therapeutic target</span></div><div class="casAuthors">Houslay, Miles D.; Schafer, Peter; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1503-1519</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase-4 selective inhibitors have therapeutic potential for treating major diseases such as asthma and COPD, as well as depression, Parkinson's disease and Alzheimer's disease.  CAMP is a key second messenger in all cells.  It is compartmentalized within cells and its levels are controlled, as a result of spatially discrete signaling cassettes controlling its generation, detection and degrdn.  Underpinning compartmentalized cAMP signaling are ∼20 members of the phosphodiesterase-4 (PDE4) family.  The selective inhibition of this family generates profound, functional effects and PDE4 inhibitors are currently under development to provide potential, novel therapeutics for the treatment of inflammatory diseases, such as asthma, chronic obstructive pulmonary disease and psoriasis, as well as treating depression and serving as cognitive enhancers.  Here, we delineate the range of PDE4 isoforms, their role in signaling, their structural biol. and related preclin. and clin. pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotOabrPCOweLVg90H21EOLACvtfcHk0ljC5elfYcSWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsrzL&md5=7c75a76543b75145a44ae8f4a2f3b2ac</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903622-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903622-6%26sid%3Dliteratum%253Aachs%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DSchafer%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26atitle%3DKeynote%2520review%253A%2520phosphodiesterase-4%2520as%2520a%2520therapeutic%2520target%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D1503%26epage%3D1519%26doi%3D10.1016%2FS1359-6446%2805%2903622-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, K. H.</span></span> <span> </span><span class="NLM_article-title">PDE4 inhibitors - a review of the current field</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/S0079-6468(08)00202-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2FS0079-6468%2808%2900202-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=19328289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsV2jtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2009&pages=37-74&author=N.+J.+Pressauthor=K.+H.+Banner&title=PDE4+inhibitors+-+a+review+of+the+current+field&doi=10.1016%2FS0079-6468%2808%2900202-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4 inhibitors - a review of the current field</span></div><div class="casAuthors">Press, Neil J.; Banner, Katharine H.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37-74</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review on the phosphodiesterase 4 enzyme inhibitors and their potential therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodvxfZgwsOsbVg90H21EOLACvtfcHk0ljWQJATEoh3Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsV2jtb0%253D&md5=45a006d23fedc76f4f42f2f424bd4395</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0079-6468%2808%2900202-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6468%252808%252900202-6%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DBanner%26aufirst%3DK.%2BH.%26atitle%3DPDE4%2520inhibitors%2520-%2520a%2520review%2520of%2520the%2520current%2520field%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D47%26spage%3D37%26epage%3D74%26doi%3D10.1016%2FS0079-6468%2808%2900202-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cieslinski, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essayan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torphy, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnette, M. S.</span></span> <span> </span><span class="NLM_article-title">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1038%2Fsj.bjp.0702911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10602317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=1393-1398&author=C.+D.+Manningauthor=M.+Burmanauthor=S.+B.+Christensenauthor=L.+B.+Cieslinskiauthor=D.+M.+Essayanauthor=M.+Grousauthor=T.+J.+Torphyauthor=M.+S.+Barnette&title=Suppression+of+human+inflammatory+cell+function+by+subtype-selective+PDE4+inhibitors+correlates+with+inhibition+of+PDE4A+and+PDE4B&doi=10.1038%2Fsj.bjp.0702911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span></div><div class="casAuthors">Manning, Carol D.; Burman, Miriam; Christensen, Siegfried B.; Cieslinski, Lenora B.; Essayan, David M.; Grous, Marilyn; Torphy, Theodore J.; Barnette, Mary S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1393-1398</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Of the four major phosphodiesterase 4 (PDE4) subtypes, PDE4A, PDE4B and PDE4D are widely expressed in human inflammatory cells, including monocytes and T lymphocytes.  We explored the functional role of these subtypes using ten subtype-selective PDE4 inhibitors, each belonging to one of two classes: (i) dual PDE4A/PDE4B inhibitors or (ii) PDE4D inhibitors.  These compds. were evaluated for their ability to inhibit antigen-stimulated T-cell proliferation and bacterial lipopolysaccharide (LPS)-stimulated tumor necrosis factor α (TNFα) release from peripheral blood monocytes.  All compds. inhibited T-cell proliferation in a concn.-dependent manner; with IC50 values distributed over an approx. 50 fold range.  These compds. also inhibited TNFα release concn.-dependently, with a wider (∼ 1000 fold) range of IC50 values.  In both sets of expts., mean IC50 values were significantly correlated with compd. potency against the catalytic activity of recombinant human PDE4A or PDE4B when analyzed by either linear regression of log IC50 values or by Spearman's rank-order correlation.  The correlation between inhibition of inflammatory cell function and inhibition of recombinant PDE4D catalytic activity was not significant in either anal.  These results suggest that PDE4A and/or PDE4B may play the major role in regulating these two inflammatory cell functions but do not rule out PDE4D as an important mediator of other activities in mononuclear leukocytes and other immune and inflammatory cells.  Much more work is needed to establish the functional roles of the PDE4 subtypes across a broader range of cellular functions and cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3g1B9QQKejbVg90H21EOLACvtfcHk0ljWQJATEoh3Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D&md5=70490a1a73b83ce887e850e4efd2e738</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702911%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DC.%2BD.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DS.%2BB.%26aulast%3DCieslinski%26aufirst%3DL.%2BB.%26aulast%3DEssayan%26aufirst%3DD.%2BM.%26aulast%3DGrous%26aufirst%3DM.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26aulast%3DBarnette%26aufirst%3DM.%2BS.%26atitle%3DSuppression%2520of%2520human%2520inflammatory%2520cell%2520function%2520by%2520subtype-selective%2520PDE4%2520inhibitors%2520correlates%2520with%2520inhibition%2520of%2520PDE4A%2520and%2520PDE4B%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D1393%26epage%3D1398%26doi%3D10.1038%2Fsj.bjp.0702911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span> <span> </span><span class="NLM_article-title">Antidepressant effects of inhibitors of cyclic AMP phosphodiesterase (PDE4)</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2004.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.tips.2004.01.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=158-163&author=J.+M.+O%E2%80%99Donnellauthor=H.+T.+Zhang&title=Antidepressant+effects+of+inhibitors+of+cyclic+AMP+phosphodiesterase+%28PDE4%29&doi=10.1016%2Fj.tips.2004.01.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DAntidepressant%2520effects%2520of%2520inhibitors%2520of%2520cyclic%2520AMP%2520phosphodiesterase%2520%2528PDE4%2529%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2004%26volume%3D25%26spage%3D158%26epage%3D163%26doi%3D10.1016%2Fj.tips.2004.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagès, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span> <span> </span><span class="NLM_article-title">PDE4 inhibitors: a review of current developments (2005 – 2009)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1501</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1517/13543770903313753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F13543770903313753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=19832118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1501-1519&author=L.+Pag%C3%A8sauthor=A.+Gavald%C3%A0author=M.+D.+Lehner&title=PDE4+inhibitors%3A+a+review+of+current+developments+%282005+%E2%80%93+2009%29&doi=10.1517%2F13543770903313753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4 inhibitors: a review of current developments (2005 - 2009)</span></div><div class="casAuthors">Pages, Lluis; Gavalda, Amadeu; Lehner, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1501-1519</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Despite the sound preclin. database and some promising data from clin. trials, development of PDE4 inhibitors for the treatment of inflammatory or neurol. diseases has been hampered by dose-limiting class-related side effects.  Objective: In the past years, companies opted for different approaches to improve the therapeutic window of their compds. including topical administration of PDE4 inhibitors with the goal of minimizing systemic exposure.  This change in strategy is reflected by the disclosure of novel and chem. diverse mols. that demonstrate the continued interest of pharmaceutical industry in developing PDE4 inhibitors.  Conclusion: This review summarizes the clin. development of PDE4 inhibitors since 2005 and the assocd. patent literature with a focus on strategies applied to minimize systemic adverse effects.  In sum, although a significant no. of new drugs designed for improved tolerability entered clin. trials, so far none of them fulfilled expectations and best progress has been achieved recently with the oral, non-isoform selective PDE4 inhibitor roflumilast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6XZlM2_eQxbVg90H21EOLACvtfcHk0lg1Rp6OzpybTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmu7bM&md5=4041bbd045ffa269e1fa406746193c3e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1517%2F13543770903313753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903313753%26sid%3Dliteratum%253Aachs%26aulast%3DPag%25C3%25A8s%26aufirst%3DL.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DPDE4%2520inhibitors%253A%2520a%2520review%2520of%2520current%2520developments%2520%25282005%2520%25E2%2580%2593%25202009%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1501%26epage%3D1519%26doi%3D10.1517%2F13543770903313753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1016</span>, <span class="refDoi"> DOI: 10.1517/13543776.2013.794789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F13543776.2013.794789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=23642007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=997-1016&author=A.+Gavald%C3%A0author=R.+S.+Roberts&title=Phosphodiesterase-4+inhibitors%3A+a+review+of+current+developments+%282010+-+2012%29&doi=10.1517%2F13543776.2013.794789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012)</span></div><div class="casAuthors">Gavalda, Amadeu; Roberts, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">997-1016</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: At last, after many years of research, roflumilast has become the first oral phosphodiesterase-4 inhibitor to be approved by the medical agencies as an add-on therapy for chronic obstructive pulmonary disease.  A second compd., apremilast is targeted for submission of new drug application for the treatment of psoriasis in the second half of 2013.  These compds. represent a breakthrough and a reward in the field after the many failures to date in clin. development.  Areas covered: This review summarizes the clin. development of PDE4 inhibitors from 2010 - 2012 and the assocd. patent literature with a focus on strategies to overcome the common pitfalls of oral PDE4 inhibitors.  Expert opinion: In the last few years, influenced by the body of published clin. data, many companies have lost interest in PDE4 as a target.  Many of those that have persevered have opted to realign their research programs either toward compds. specifically designed for inhaled delivery or in search of an increase in clin. efficacy by combining two mechanisms in a single compd.  This change is reflected by the continued disclosure of novel and chem. diverse mols., indicating for some in the pharmaceutical industry that all is not yet lost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe0yV5hhUby7Vg90H21EOLACvtfcHk0lg1Rp6OzpybTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3L&md5=9a5961a6f439698b11123ac47c5839aa</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.794789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.794789%26sid%3Dliteratum%253Aachs%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26atitle%3DPhosphodiesterase-4%2520inhibitors%253A%2520a%2520review%2520of%2520current%2520developments%2520%25282010%2520-%25202012%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D997%26epage%3D1016%26doi%3D10.1517%2F13543776.2013.794789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span> <span> </span><span class="NLM_article-title">cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1311</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.968127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F13543776.2014.968127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=25284693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1311-1321&author=A.+Martinezauthor=C.+Gil&title=cAMP-specific+phosphodiesterase+inhibitors%3A+promising+drugs+for+inflammatory+and+neurological+diseases&doi=10.1517%2F13543776.2014.968127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases</span></div><div class="casAuthors">Martinez, Ana; Gil, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1311-1321</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: PDEs are key enzymes in the adenosine and guanosine cyclic nucleotides (cAMP and cGMP) signaling cascade.  Their inhibition increases cyclic nucleotide levels inside the cell.  Thus, pharmacol. modulation of PDE activity can have profound effects on the function of cells and organ systems throughout the body.  Areas covered: Among the large PDE families, only PDE4, PDE7 and PDE8 are cAMP-specific hydrolyzing enzymes. cAMP is an important second messenger not only by its involvement in a vast no. of physiol. processes but also by activation of protein kinase A, exchange protein activated by cAMP (Epac) and cAMP response element-binding (CREB) or cyclic nucleotide-gated channels.  Clearly, such enzymes represent ideal drug targets for the pharmacol. treatment of many pathologies.  The discovery and development of small mols. targeting cAMP-specific PDEs reported in the last 5 years is the focus of the present review.  Expert opinion: The first PDE4 inhibitors recently reached the market, having avoided, by different strategies, their dose-limiting side effects (after more than two decades of drug development).  Meanwhile, new cAMP-specific PDE7 and PDE8 inhibitors emerged as effective and safe drugs for severe unmet diseases.  The therapeutic potential of these inhibitors will be tested in the near future, as many of these drug candidates are ready to start clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPWFQGiKhADrVg90H21EOLACvtfcHk0lg1Rp6OzpybTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FN&md5=f9ef95eeccba94736c36de427c1715b0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.968127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.968127%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGil%26aufirst%3DC.%26atitle%3DcAMP-specific%2520phosphodiesterase%2520inhibitors%253A%2520promising%2520drugs%2520for%2520inflammatory%2520and%2520neurological%2520diseases%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D1311%26epage%3D1321%26doi%3D10.1517%2F13543776.2014.968127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborti, A. K.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 (PDE4) inhibitors in the treatment of COPD: promising drug candidates and future directions</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.2174/0929867323666151117121334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.2174%2F0929867323666151117121334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=26572614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Oiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=129-141&author=N.+Parikhauthor=A.+K.+Chakraborti&title=Phosphodiesterase+4+%28PDE4%29+inhibitors+in+the+treatment+of+COPD%3A+promising+drug+candidates+and+future+directions&doi=10.2174%2F0929867323666151117121334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions</span></div><div class="casAuthors">Parikh, Naisargee; Chakraborti, Asit K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The PDE4 enzyme has been proven to be a versatile drug target for therapeutics to treat diverse disease conditions such as asthma, COPD, diabetes, Huntington's disease, and various other inflammatory disorders.  The treatment of COPD is the most studied utility for PDE4 inhibitors due to their ability to inhibit inflammatory cell responses.  Roflumilast is the only approved drug belonging to this class to treat COPD and has shown significant results in the treatment of asthmatic patients.  This perspective highlights the pharmacol. details of roflumilast and cilomilast.  Moreover, efforts have been made to justify the superiority of roflumilast over cilomilast by detailed comparison of their pharmacol., pharmacokinetic, pharmacodynamic properties and structural features.  Several other mols., with promising PDE4 inhibitory activity have also been highlighted.  Commonly assocd. side effects with this class of compds., their management, and future direction towards the development of PDE4 inhibitors with improved therapeutic index are the focus of this perspective.  More emphasis has been given towards the future development strategies to limit the side effects such as emesis and to achieve better benefit to risk ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHRuuoQ7II8rVg90H21EOLACvtfcHk0lhun6qK_Xpcbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Oiu70%253D&md5=b7901858db904fcd9a714b2b5d9ec9ef</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F0929867323666151117121334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666151117121334%26sid%3Dliteratum%253Aachs%26aulast%3DParikh%26aufirst%3DN.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26atitle%3DPhosphodiesterase%25204%2520%2528PDE4%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520COPD%253A%2520promising%2520drug%2520candidates%2520and%2520future%2520directions%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26spage%3D129%26epage%3D141%26doi%3D10.2174%2F0929867323666151117121334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulhall, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Droege, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panos, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zafar, M. A.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1597</span>– <span class="NLM_lpage">1611</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1094054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F13543784.2015.1094054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=26419847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1597-1611&author=A.+M.+Mulhallauthor=C.+A.+Droegeauthor=N.+E.+Ernstauthor=R.+J.+Panosauthor=M.+A.+Zafar&title=Phosphodiesterase+4+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+review+of+current+and+developing+drugs&doi=10.1517%2F13543784.2015.1094054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span></div><div class="casAuthors">Mulhall, Aaron M.; Droege, Christopher A.; Ernst, Neil E.; Panos, Ralph J.; Zafar, Muhammad A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1597-1611</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) inhibitors modulate lung inflammation and cause bronchodilation by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway smooth muscle and inflammatory cells.  Roflumilast is the only approved PDE-4 inhibitor (PDE4I) for use in chronic obstructive pulmonary disease (COPD).  Its beneficial clin. effects occur preferentially in patients with chronic bronchitis and frequent COPD exacerbations.  Use of roflumilast as adjunctive or alternate therapy to other COPD medications reduces exacerbations and modestly improves lung function.  This article reviews the current role of PDE4I in COPD treatment emphasizing roflumilast's clin. efficacy and adverse effects.  This article also reviews developing PDE4Is in early clin. trials and in preclin. studies.  After decades of research in drug development, PDE4Is are a welcomed addn. to the COPD therapeutic armamentarium.  In its current clin. role, the salubrious clin. effects of PDE4I in reducing exacerbations and stabilizing the frequent exacerbator phenotype have to be cautiously balanced with numerous adverse effects.  Developing drugs may provide similar or better clin. benefits while minimizing adverse effects by changing the mode of drug delivery to inhaled formulations, combining dual PDE isoenzyme inhibitors (PDE1/4I and PDE3/4I) and by forming hybrid mols. with other bronchodilators (muscarinic receptor antagonist/PDE4I and β2-agonist/PDE4I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFNEyjtRW-erVg90H21EOLACvtfcHk0lhun6qK_Xpcbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ&md5=8d5130af94558b2950f624ae1528c86f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1094054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1094054%26sid%3Dliteratum%253Aachs%26aulast%3DMulhall%26aufirst%3DA.%2BM.%26aulast%3DDroege%26aufirst%3DC.%2BA.%26aulast%3DErnst%26aufirst%3DN.%2BE.%26aulast%3DPanos%26aufirst%3DR.%2BJ.%26aulast%3DZafar%26aufirst%3DM.%2BA.%26atitle%3DPhosphodiesterase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520review%2520of%2520current%2520and%2520developing%2520drugs%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1597%26epage%3D1611%26doi%3D10.1517%2F13543784.2015.1094054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rabe, K. F.</span></span> <span> </span><span class="NLM_article-title">Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1111%2Fj.1476-5381.2011.01218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=21232047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=53-67&author=K.+F.+Rabe&title=Update+on+roflumilast%2C+a+phosphodiesterase+4+inhibitor+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1476-5381.2011.01218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rabe, Klaus F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-67</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main PDE isoenzyme occurring in cells involved in inflammatory airway disease such as chronic obstructive pulmonary disease (COPD).  COPD is a preventable and treatable disease and is characterized by airflow obstruction that is not fully reversible.  Chronic progressive symptoms, particularly dyspnea, chronic bronchitis and impaired overall health are worse in those who have frequent, acute episodes of symptom exacerbation.  Although several exptl. PDE4 inhibitors are in clin. development, roflumilast, a highly selective PDE4 inhibitor, is the first in its class to be licensed, and has recently been approved in several countries for oral, once-daily treatment of severe COPD.  Clin. trials have demonstrated that roflumilast improves lung function and reduces exacerbation frequency in COPD.  Furthermore, its unique mode of action may offer the potential to target the inflammatory processes underlying COPD.  Roflumilast is effective when used concomitantly with all forms of bronchodilator and even in patients treated with inhaled corticosteroids.  Roflumilast thus represents an important addn. to current therapeutic options for COPD patients with chronic bronchitis, including those who remain symptomatic despite treatment.  This article reviews the current status of PDE4 inhibitors, focusing on the pharmacokinetics, efficacy and safety of roflumilast.  In particular, it provides an overview of the effects of roflumilast on lung function and exacerbations, glucose homoeostasis and wt. loss, and the concomitant use of long-acting beta2-adrenergic receptor agonists and short-acting muscarinic receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryBUcu0ToPGrVg90H21EOLACvtfcHk0liIei5lfv-BQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D&md5=c6ac3310e2d9ff1c7de86aecbd1356bb</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01218.x%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DUpdate%2520on%2520roflumilast%252C%2520a%2520phosphodiesterase%25204%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D53%26epage%3D67%26doi%3D10.1111%2Fj.1476-5381.2011.01218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loveland, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, D. I.</span></span> <span> </span><span class="NLM_article-title">Apremilast, a cAMP phosphodiesterase-4 inhibitor,demonstrates anti-inflammatory activity in vitro and in a model of psoriasis</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">855</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00559.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1111%2Fj.1476-5381.2009.00559.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=20050849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtF2hs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2010&pages=842-855&author=P.+H.+Schaferauthor=A.+Partonauthor=A.+K.+Gandhiauthor=L.+Caponeauthor=M.+Adamsauthor=L.+Wuauthor=J.+B.+Bartlettauthor=M.+A.+Lovelandauthor=A.+Gilharauthor=Y.-F.+Cheungauthor=G.+S.+Baillieauthor=M.+D.+Houslayauthor=H.-W.+Manauthor=G.+W.+Mullerauthor=D.+I.+Stirling&title=Apremilast%2C+a+cAMP+phosphodiesterase-4+inhibitor%2Cdemonstrates+anti-inflammatory+activity+in+vitro+and+in+a+model+of+psoriasis&doi=10.1111%2Fj.1476-5381.2009.00559.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis</span></div><div class="casAuthors">Schafer, P. H.; Parton, A.; Gandhi, A. K.; Capone, L.; Adams, M.; Wu, L.; Bartlett, J. B.; Loveland, M. A.; Gilhar, A.; Cheung, Y.-F.; Baillie, G. S.; Houslay, M. D.; Man, H.-W.; Muller, G. W.; Stirling, D. I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-855</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and purpose: Apremilast is an orally administered phosphodiesterase-4 inhibitor, currently in phase 2 clin. studies of psoriasis and other chronic inflammatory diseases.  The inhibitory effects of apremilast on pro-inflammatory responses of human primary peripheral blood mononuclear cells (PBMC), polymorphonuclear cells, natural killer (NK) cells and epidermal keratinocytes were explored in vitro, and in a preclin. model of psoriasis.  Exptl. approach: Apremilast was tested in vitro against endotoxin- and superantigen-stimulated PBMC, bacterial peptide and zymosan-stimulated polymorphonuclear cells, immunonoglobulin and cytokine-stimulated NK cells, and UV B light-activated keratinocytes.  Apremilast was orally administered to beige-severe combined immunodeficient mice, xenotransplanted with normal human skin and triggered with human psoriatic NK cells.  Epidermal skin thickness, proliferation index and inflammation markers were analyzed.  Key results: Apremilast inhibited PBMC prodn. of the chemokines CXCL9 and CXCL10, cytokines interferon-γ and tumor necrosis factor (TNF)-α, and interleukins (IL)-2, IL-12 and IL-23.  Prodn. of TNF-α by NK cells and keratinocytes was also inhibited.  In vivo, apremilast significantly reduced epidermal thickness and proliferation, decreased the general histopathol. appearance of psoriasiform features and reduced expression of TNF-α, human leukocyte antigen-DR and intercellular adhesion mol.-1 in the lesioned skin.  Conclusions and implications: Apremilast displayed a broad pattern of anti-inflammatory activity in a variety of cell types and decreased the incidence and severity of a psoriasiform response in vivo.  Inhibition of TNF-α, IL-12 and IL-23 prodn., as well as NK and keratinocyte responses by this phosphodiesterase-4 inhibitor suggests a novel approach to the treatment of psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOuSV-gwfyvbVg90H21EOLACvtfcHk0liIei5lfv-BQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtF2hs7Y%253D&md5=3d75cda30fed65749902cb790aafdd98</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00559.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00559.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DParton%26aufirst%3DA.%26aulast%3DGandhi%26aufirst%3DA.%2BK.%26aulast%3DCapone%26aufirst%3DL.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DBartlett%26aufirst%3DJ.%2BB.%26aulast%3DLoveland%26aufirst%3DM.%2BA.%26aulast%3DGilhar%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DY.-F.%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DMan%26aufirst%3DH.-W.%26aulast%3DMuller%26aufirst%3DG.%2BW.%26aulast%3DStirling%26aufirst%3DD.%2BI.%26atitle%3DApremilast%252C%2520a%2520cAMP%2520phosphodiesterase-4%2520inhibitor%252Cdemonstrates%2520anti-inflammatory%2520activity%2520in%2520vitro%2520and%2520in%2520a%2520model%2520of%2520psoriasis%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D159%26spage%3D842%26epage%3D855%26doi%3D10.1111%2Fj.1476-5381.2009.00559.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span> <span> </span><span class="NLM_article-title">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNFα responses</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">7628</span>– <span class="NLM_lpage">7633</span>, <span class="refDoi"> DOI: 10.1073/pnas.122041599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1073%2Fpnas.122041599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=12032334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=7628-7633&author=S.+L.+Jinauthor=M.+Conti&title=Induction+of+the+cyclic+nucleotide+phosphodiesterase+PDE4B+is+essential+for+LPS-activated+TNF%CE%B1+responses&doi=10.1073%2Fpnas.122041599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses</span></div><div class="casAuthors">Jin, S.-L. Catherine; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7628-7633</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lipopolysaccharide (LPS) stimulation of the innate immune response requires the activation of signaling cascades that culminate in the synthesis and secretion of proinflammatory cytokines.  Given the inhibitory effects of phosphodiesterase (PDE) inhibitors on LPS-induced cytokine prodn., the authors have investigated LPS responses in mice deficient in PDE4 (type 4 cAMP-specific PDE)-B and PDE4D.  LPS stimulation of mouse peripheral leukocytes induced PDE4B mRNA accumulation and increased PDE4 activity.  This response was completely absent in mice deficient in PDE4B but not PDE4D.  LPS induction of tumor necrosis factor-α secretion by circulating leukocytes was decreased by approx. 90% in mice deficient in PDE4B but not in mice lacking PDE4D.  The impaired LPS response was evident regardless of the LPS dose used for stimulation and was assocd. with a more than 90% decrease in tumor necrosis factor-α mRNA accumulation.  A decreased responsiveness to LPS was also present in other inflammatory cells, including peritoneal and lung macrophages.  These findings demonstrate that PDE4B gene activation by LPS constitutes a feedback regulation essential for an efficient immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczHCRpXjcOrVg90H21EOLACvtfcHk0ljmnHuMk3UnYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D&md5=69e2c4452ce3aa7729376db46cba6a07</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.122041599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.122041599%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DInduction%2520of%2520the%2520cyclic%2520nucleotide%2520phosphodiesterase%2520PDE4B%2520is%2520essential%2520for%2520LPS-activated%2520TNF%25CE%25B1%2520responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D7628%26epage%3D7633%26doi%3D10.1073%2Fpnas.122041599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cieslinski, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essayan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torphy, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnette, M. S.</span></span> <span> </span><span class="NLM_article-title">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1038%2Fsj.bjp.0702911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10602317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=1393-1398&author=C.+D.+Manningauthor=M.+Burmanauthor=S.+B.+Christensenauthor=L.+B.+Cieslinskiauthor=D.+M.+Essayanauthor=M.+Grousauthor=T.+J.+Torphyauthor=M.+S.+Barnette&title=Suppression+of+human+inflammatory+cell+function+by+subtype-selective+PDE4+inhibitors+correlates+with+inhibition+of+PDE4A+and+PDE4B&doi=10.1038%2Fsj.bjp.0702911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span></div><div class="casAuthors">Manning, Carol D.; Burman, Miriam; Christensen, Siegfried B.; Cieslinski, Lenora B.; Essayan, David M.; Grous, Marilyn; Torphy, Theodore J.; Barnette, Mary S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1393-1398</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Of the four major phosphodiesterase 4 (PDE4) subtypes, PDE4A, PDE4B and PDE4D are widely expressed in human inflammatory cells, including monocytes and T lymphocytes.  We explored the functional role of these subtypes using ten subtype-selective PDE4 inhibitors, each belonging to one of two classes: (i) dual PDE4A/PDE4B inhibitors or (ii) PDE4D inhibitors.  These compds. were evaluated for their ability to inhibit antigen-stimulated T-cell proliferation and bacterial lipopolysaccharide (LPS)-stimulated tumor necrosis factor α (TNFα) release from peripheral blood monocytes.  All compds. inhibited T-cell proliferation in a concn.-dependent manner; with IC50 values distributed over an approx. 50 fold range.  These compds. also inhibited TNFα release concn.-dependently, with a wider (∼ 1000 fold) range of IC50 values.  In both sets of expts., mean IC50 values were significantly correlated with compd. potency against the catalytic activity of recombinant human PDE4A or PDE4B when analyzed by either linear regression of log IC50 values or by Spearman's rank-order correlation.  The correlation between inhibition of inflammatory cell function and inhibition of recombinant PDE4D catalytic activity was not significant in either anal.  These results suggest that PDE4A and/or PDE4B may play the major role in regulating these two inflammatory cell functions but do not rule out PDE4D as an important mediator of other activities in mononuclear leukocytes and other immune and inflammatory cells.  Much more work is needed to establish the functional roles of the PDE4 subtypes across a broader range of cellular functions and cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3g1B9QQKejbVg90H21EOLACvtfcHk0lh0L3lqc4SqZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D&md5=70490a1a73b83ce887e850e4efd2e738</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702911%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DC.%2BD.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DS.%2BB.%26aulast%3DCieslinski%26aufirst%3DL.%2BB.%26aulast%3DEssayan%26aufirst%3DD.%2BM.%26aulast%3DGrous%26aufirst%3DM.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26aulast%3DBarnette%26aufirst%3DM.%2BS.%26atitle%3DSuppression%2520of%2520human%2520inflammatory%2520cell%2520function%2520by%2520subtype-selective%2520PDE4%2520inhibitors%2520correlates%2520with%2520inhibition%2520of%2520PDE4A%2520and%2520PDE4B%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D1393%26epage%3D1398%26doi%3D10.1038%2Fsj.bjp.0702911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehnart, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrens, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belevych, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, A. R.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2005.07.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.cell.2005.07.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2005&pages=25-35&author=S.+E.+Lehnartauthor=X.+H.+Wehrensauthor=S.+Reikenauthor=S.+Warrierauthor=A.+E.+Belevychauthor=R.+D.+Harveyauthor=W.+Richterauthor=S.+L.+Jinauthor=M.+Contiauthor=A.+R.+Marks&title=Phosphodiesterase+4D+deficiency+in+the+ryanodine-receptor+complex+promotes+heart+failure+and+arrhythmias&doi=10.1016%2Fj.cell.2005.07.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.07.030%26sid%3Dliteratum%253Aachs%26aulast%3DLehnart%26aufirst%3DS.%2BE.%26aulast%3DWehrens%26aufirst%3DX.%2BH.%26aulast%3DReiken%26aufirst%3DS.%26aulast%3DWarrier%26aufirst%3DS.%26aulast%3DBelevych%26aufirst%3DA.%2BE.%26aulast%3DHarvey%26aufirst%3DR.%2BD.%26aulast%3DRichter%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DMarks%26aufirst%3DA.%2BR.%26atitle%3DPhosphodiesterase%25204D%2520deficiency%2520in%2520the%2520ryanodine-receptor%2520complex%2520promotes%2520heart%2520failure%2520and%2520arrhythmias%26jtitle%3DCell%26date%3D2005%26volume%3D123%26spage%3D25%26epage%3D35%26doi%3D10.1016%2Fj.cell.2005.07.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamatiou, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.-L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachance, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laliberté, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.-C.</span></span> <span> </span><span class="NLM_article-title">Deletion of phosphodiesterase 4D in mice shortens a2-adrenoceptor-mediated anaesthesia, a behavioural correlate of emesis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1052</span>, <span class="refDoi"> DOI: 10.1172/JCI0215506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1172%2FJCI0215506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=1045-1052&author=A.+Robichaudauthor=P.+B.+Stamatiouauthor=S.-L.+C.+Jinauthor=N.+Lachanceauthor=D.+MacDonaldauthor=F.+Lalibert%C3%A9author=S.+Liuauthor=Z.+Huangauthor=M.+Contiauthor=C.-C.+Chan&title=Deletion+of+phosphodiesterase+4D+in+mice+shortens+a2-adrenoceptor-mediated+anaesthesia%2C+a+behavioural+correlate+of+emesis&doi=10.1172%2FJCI0215506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1172%2FJCI0215506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0215506%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DA.%26aulast%3DStamatiou%26aufirst%3DP.%2BB.%26aulast%3DJin%26aufirst%3DS.-L.%2BC.%26aulast%3DLachance%26aufirst%3DN.%26aulast%3DMacDonald%26aufirst%3DD.%26aulast%3DLalibert%25C3%25A9%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DC.-C.%26atitle%3DDeletion%2520of%2520phosphodiesterase%25204D%2520in%2520mice%2520shortens%2520a2-adrenoceptor-mediated%2520anaesthesia%252C%2520a%2520behavioural%2520correlate%2520of%2520emesis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D110%26spage%3D1045%26epage%3D1052%26doi%3D10.1172%2FJCI0215506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocque, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, R. T.</span></span> <span> </span><span class="NLM_article-title">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1825</span>, <span class="refDoi"> DOI: 10.1126/science.288.5472.1822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1126%2Fscience.288.5472.1822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10846163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2000&pages=1822-1825&author=R.+X.+Xuauthor=A.+M.+Hassellauthor=D.+Vanderwallauthor=M.+H.+Lambertauthor=W.+D.+Holmesauthor=M.+A.+Lutherauthor=W.+J.+Rocqueauthor=M.+V.+Milburnauthor=Y.+Zhaoauthor=H.+Keauthor=R.+T.+Nolte&title=Atomic+structure+of+PDE4%3A+insights+into+phosphodiesterase+mechanism+and+specificity&doi=10.1126%2Fscience.288.5472.1822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span></div><div class="casAuthors">Xu, Robert X.; Hassell, Anne M.; Vanderwall, Dana; Lambert, Millard H.; Holmes, William D.; Luther, Michael A.; Rocque, Warren J.; Milburn, Michael V.; Zhao, Yingdong; Ke, Hengming; Nolte, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">5472</span>),
    <span class="NLM_cas:pages">1822-1825</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cyclic nucleotides are second messengers that are essential in vision, muscle contraction, neurotransmission, exocytosis, cell growth, and differentiation.  These mols. are degraded by a family of enzymes known as phosphodiesterases, which serve a crit. function by regulating the intracellular concn. of cyclic nucleotides.  We have detd. the three-dimensional structure of the catalytic domain of phosphodiesterase 4B2B to 1.77 angstrom resoln.  The active site has been identified and contains a cluster of two metal atoms.  The structure suggests the mechanism of action and basis for specificity and will provide a framework for structure-assisted drug design for members of the phosphodiesterase family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjHOVmP5GzU7Vg90H21EOLACvtfcHk0liKLS0AjRkycA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D&md5=4f7e42a9f7a6a0763a9dcc064ad903c2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.288.5472.1822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.288.5472.1822%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%2BX.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DVanderwall%26aufirst%3DD.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DHolmes%26aufirst%3DW.%2BD.%26aulast%3DLuther%26aufirst%3DM.%2BA.%26aulast%3DRocque%26aufirst%3DW.%2BJ.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26atitle%3DAtomic%2520structure%2520of%2520PDE4%253A%2520insights%2520into%2520phosphodiesterase%2520mechanism%2520and%2520specificity%26jtitle%3DScience%26date%3D2000%26volume%3D288%26spage%3D1822%26epage%3D1825%26doi%3D10.1126%2Fscience.288.5472.1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colicelli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">13220</span>– <span class="NLM_lpage">13226</span>, <span class="refDoi"> DOI: 10.1021/bi034653e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi034653e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=13220-13226&author=Q.+Huaiauthor=J.+Colicelliauthor=H.+Ke&title=The+crystal+structure+of+AMP-bound+PDE4+suggests+a+mechanism+for+phosphodiesterase+catalysis&doi=10.1021%2Fbi034653e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fbi034653e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi034653e%26sid%3Dliteratum%253Aachs%26aulast%3DHuai%26aufirst%3DQ.%26aulast%3DColicelli%26aufirst%3DJ.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DThe%2520crystal%2520structure%2520of%2520AMP-bound%2520PDE4%2520suggests%2520a%2520mechanism%2520for%2520phosphodiesterase%2520catalysis%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26spage%3D13220%26epage%3D13226%26doi%3D10.1021%2Fbi034653e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2007.05.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.jmb.2007.05.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=17582435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2007&pages=302-307&author=H.+Wangauthor=H.+Robinsonauthor=H.+Ke&title=The+molecular+basis+for+different+recognition+of+substrates+by+phosphodiesterase+families+4+and+10&doi=10.1016%2Fj.jmb.2007.05.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10</span></div><div class="casAuthors">Wang, Huanchen; Robinson, Howard; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-307</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are key enzymes that control the cellular concns. of the second messengers cAMP and cGMP.  The mechanism for selective recognition of substrates cAMP and cGMP by individual PDE families remains a puzzle.  To understand the mechanism for substrate recognition by PDE enzymes, the crystal structure of the catalytic domain of an inactive D201N mutant of PDE4D2 in complex with substrate cAMP has been detd. at 1.56 Å resoln.  The structure shows that Gln369 forms only one hydrogen bond with the adenine of cAMP.  This finding provides exptl. evidence against the hypothesis of two hydrogen bonds between the invariant glutamine and the substrate cAMP in PDE4, and thus suggests that the widely circulated "glutamine switch" model is unlikely to be the mechanism for substrate recognition by PDEs.  A structure comparison between PDE4D2-cAMP and PDE10A2-cAMP reveals an anti configuration of cAMP in PDE4D2 but syn in PDE10A2, in addn. to different contact patterns of cAMP in these two structures.  These observations imply that individual PDE families have their characteristic mechanisms for substrate recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr8WN9h4LiP7Vg90H21EOLACvtfcHk0liKLS0AjRkycA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D&md5=2f7f20be9aba1cae9a4d90e349581583</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2007.05.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2007.05.060%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DThe%2520molecular%2520basis%2520for%2520different%2520recognition%2520of%2520substrates%2520by%2520phosphodiesterase%2520families%25204%2520and%252010%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D371%26spage%3D302%26epage%3D307%26doi%3D10.1016%2Fj.jmb.2007.05.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>408</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1042/BJ20070970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1042%2FBJ20070970" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2007&pages=193-201&author=H.+Wangauthor=M.+S.+Pengauthor=Y.+Chenauthor=J.+Gengauthor=H.+Robinsonauthor=M.+D.+Houslayauthor=I.+Caiauthor=H.+Ke&title=Structures+of+the+four+subfamilies+of+phosphodiesterase-4+provide+insight+into+the+selectivity+of+their+inhibitors&doi=10.1042%2FBJ20070970"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1042%2FBJ20070970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070970%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DM.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DCai%26aufirst%3DI.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DStructures%2520of%2520the%2520four%2520subfamilies%2520of%2520phosphodiesterase-4%2520provide%2520insight%2520into%2520the%2520selectivity%2520of%2520their%2520inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D408%26spage%3D193%26epage%3D201%26doi%3D10.1042%2FBJ20070970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the design of selective phosphodiesterase</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2013.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.cellsig.2013.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=24361374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=657-663&author=D.+Foxauthor=A.+B.+Burginauthor=M.+E.+Gurney&title=Structural+basis+for+the+design+of+selective+phosphodiesterase&doi=10.1016%2Fj.cellsig.2013.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the design of selective phosphodiesterase 4B inhibitors</span></div><div class="casAuthors">Fox, David, III; Burgin, Alex B.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">657-663</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Phosphodiesterase-4B (PDE4B) regulates the pro-inflammatory Toll Receptor -Tumor Necrosis Factor α (TNFα) pathway in monocytes, macrophages and microglial cells.  As such, it is an important, although under-exploited mol. target for anti-inflammatory drugs.  This is due in part to the difficulty of developing selective PDE4B inhibitors as the amino acid sequence of the PDE4 active site is identical in all PDE4 subtypes (PDE4A-D).  We show that highly selective PDE4B inhibitors can be designed by exploiting sequence differences outside the active site.  Specifically, PDE4B selectivity can be achieved by capture of a C-terminal regulatory helix, now termed CR3 (Control Region 3), across the active site in a conformation that closes access by cAMP.  PDE4B selectivity is driven by a single amino acid polymorphism in CR3 (Leu674 in PDE4B1 vs. Gln594 in PDE4D).  The reciprocal mutations in PDE4B and PDE4D cause a 70-80 fold shift in selectivity.  Our structural studies show that CR3 is flexible and can adopt multiple orientations and multiple registries in the closed conformation.  The new co-crystal structure with bound ligand provides a guide map for the design of PDE4B selective anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKu3hgg1Kl7Vg90H21EOLACvtfcHk0lhBd6cmnqFjBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D&md5=ab8e72afbfeadffeae27950206402bd9</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2013.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2013.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DD.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DStructural%2520basis%2520for%2520the%2520design%2520of%2520selective%2520phosphodiesterase%26jtitle%3DCell.%2520Signalling%26date%3D2014%26volume%3D26%26spage%3D657%26epage%3D663%26doi%3D10.1016%2Fj.cellsig.2013.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naganuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maekawara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagumo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsuka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawanishi, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective PDE4B inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3174</span>– <span class="NLM_lpage">3176</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.bmcl.2009.04.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=19447034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1eks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3174-3176&author=K.+Naganumaauthor=A.+Omuraauthor=N.+Maekawaraauthor=M.+Saitohauthor=N.+Ohkawaauthor=T.+Kubotaauthor=H.+Nagumoauthor=T.+Kodamaauthor=M.+Takemuraauthor=Y.+Ohtsukaauthor=J.+Nakamuraauthor=R.+Tsujitaauthor=K.+Kawasakiauthor=H.+Yokoiauthor=M.+Kawanishi&title=Discovery+of+selective+PDE4B+inhibitors&doi=10.1016%2Fj.bmcl.2009.04.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective PDE4B inhibitors</span></div><div class="casAuthors">Naganuma, Kenji; Omura, Akifumi; Maekawara, Naomi; Saitoh, Masahiro; Ohkawa, Naoto; Kubota, Takashi; Nagumo, Hiromitsu; Kodama, Toshiyuki; Takemura, Masayoshi; Ohtsuka, Yuji; Nakamura, Junji; Tsujita, Ryuichi; Kawasaki, Koh; Yokoi, Hirotsugu; Kawanishi, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3174-3176</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study the first PDE4B selective inhibitor is described.  Optimization of lead 2-arylpyrimidine derivs. afforded a series of potent PDE4B inhibitors I (R1 = Me, Et, H2C:CHCH2, CN, CHO, etc.; R2 = Me, Et, n-Pr; R3 = Ph, 4-MeC6H4, 2-thienyl, 2-pyridyl, etc.; R4 = H, F; R5 = CO2H, CH2CO2H) with >100-fold selectivity over the PDE4D isoenzyme.  With a good pharmacokinetic profile, a selected compd. I (R1 = Et; R2 = Me; R3 = 5-chloro-2-thienyl; R4 = H; R5 = CH2CO2H) exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOGQ4ols6Z1rVg90H21EOLACvtfcHk0lhFaMntPMrnsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1eks7w%253D&md5=aca08592557e5d34da5b02835b0e49d8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.121%26sid%3Dliteratum%253Aachs%26aulast%3DNaganuma%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DA.%26aulast%3DMaekawara%26aufirst%3DN.%26aulast%3DSaitoh%26aufirst%3DM.%26aulast%3DOhkawa%26aufirst%3DN.%26aulast%3DKubota%26aufirst%3DT.%26aulast%3DNagumo%26aufirst%3DH.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DTakemura%26aufirst%3DM.%26aulast%3DOhtsuka%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DTsujita%26aufirst%3DR.%26aulast%3DKawasaki%26aufirst%3DK.%26aulast%3DYokoi%26aufirst%3DH.%26aulast%3DKawanishi%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520selective%2520PDE4B%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3174%26epage%3D3176%26doi%3D10.1016%2Fj.bmcl.2009.04.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="note"><p class="first last">For recent examples of inhaled PDE4 inhibitors, see:</p></div><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonough, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmour, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearman, M. S.</span></span> <span> </span><span class="NLM_article-title">Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4661</span>– <span class="NLM_lpage">4676</span>, <span class="refDoi"> DOI: 10.1021/jm5001216</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5001216" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4661-4676&author=C.+De+Saviauthor=R.+J.+Coxauthor=D.+J.+Warnerauthor=A.+R.+Cookauthor=M.+R.+Dickinsonauthor=A.+McDonoughauthor=L.+C.+Morrillauthor=B.+Parkerauthor=G.+Andrewsauthor=S.+S.+Youngauthor=P.+S.+Gilmourauthor=R.+Rileyauthor=M.+S.+Dearman&title=Efficacious+inhaled+PDE4+inhibitors+with+low+emetic+potential+and+long+duration+of+action+for+the+treatment+of+COPD&doi=10.1021%2Fjm5001216"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Fjm5001216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5001216%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26aulast%3DCook%26aufirst%3DA.%2BR.%26aulast%3DDickinson%26aufirst%3DM.%2BR.%26aulast%3DMcDonough%26aufirst%3DA.%26aulast%3DMorrill%26aufirst%3DL.%2BC.%26aulast%3DParker%26aufirst%3DB.%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DS.%2BS.%26aulast%3DGilmour%26aufirst%3DP.%2BS.%26aulast%3DRiley%26aufirst%3DR.%26aulast%3DDearman%26aufirst%3DM.%2BS.%26atitle%3DEfficacious%2520inhaled%2520PDE4%2520inhibitors%2520with%2520low%2520emetic%2520potential%2520and%2520long%2520duration%2520of%2520action%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4661%26epage%3D4676%26doi%3D10.1021%2Fjm5001216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashimoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokomizo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span> <span> </span><span class="NLM_article-title">An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>768</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.ejphar.2015.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=26455478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslaktb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=768&publication_year=2015&pages=41-48&author=S.+Kubotaauthor=M.+Watanabeauthor=M.+Shiratoauthor=T.+Okunoauthor=I.+Higashimotoauthor=K.+Machidaauthor=T.+Yokomizoauthor=H.+Inoue&title=An+inhaled+phosphodiesterase+4+inhibitor+E6005+suppresses+pulmonary+inflammation+in+mice&doi=10.1016%2Fj.ejphar.2015.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice</span></div><div class="casAuthors">Kubota, Shingo; Watanabe, Masaki; Shirato, Manabu; Okuno, Toshiaki; Higashimoto, Ikkou; Machida, Kentaro; Yokomizo, Takehiko; Inoue, Hiromasa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">768</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is a progressive lung disease assocd. with significant morbidity and mortality.  Although several oral phosphodiesterase 4 (PDE4) inhibitors have been developed for the treatment of COPD, their use has been restricted because of side effects including nausea and emesis.  We hypothesized that delivery of a dry powd. PDE4 inhibitor by inhalation would minimize systemic absorption and enable local PDE4 inhibition to suppress inflammation within the lung.  Neutrophilic pulmonary inflammation was induced in mice by intratracheal administration of lipopolysaccharide.  Mice were treated intratracheally with a new dry powder PDE4 inhibitor, E6005 (Me 4-[({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}amino) carbonyl] benzoate).  The pharmacokinetics, cell profiles and levels of cytokines, chemokines, and lipid mediators in bronchoalveolar lavage fluid (BALF), and lung histol. were assessed.  Intratracheal administration of E6005 to mice resulted in high concns. of the compd. in the lungs.  Histol. anal. of E6005-treated mice demonstrated reduced inflammation of lung tissue that correlated with a decrease in BALF levels of neutrophils, proinflammatory cytokines, chemokines, and cysteinyl leukotrienes.  Thus, intratracheal administration of E6005 effectively suppresses neutrophilic pulmonary inflammation, suggesting that the new inhaled dry powder PDE4 inhibitor represents an alternative to the conventional oral formulation for treating COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCroPjN3zdrVg90H21EOLACvtfcHk0lh_QTeQYp9UzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslaktb7M&md5=c9b32400cdd79ee002234c8542122163</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DKubota%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DShirato%26aufirst%3DM.%26aulast%3DOkuno%26aufirst%3DT.%26aulast%3DHigashimoto%26aufirst%3DI.%26aulast%3DMachida%26aufirst%3DK.%26aulast%3DYokomizo%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DH.%26atitle%3DAn%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520E6005%2520suppresses%2520pulmonary%2520inflammation%2520in%2520mice%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D768%26spage%3D41%26epage%3D48%26doi%3D10.1016%2Fj.ejphar.2015.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carzaniga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccellati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patacchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span> <span> </span><span class="NLM_article-title">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1124%2Fjpet.114.220541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=25576075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=559-567&author=N.+Morettoauthor=P.+Carusoauthor=R.+Boscoauthor=G.+Marchiniauthor=F.+Pastoreauthor=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=E.+Ghidiniauthor=R.+De+Fantiauthor=C.+Capaldiauthor=L.+Carzanigaauthor=E.+Hirschauthor=C.+Buccellatiauthor=A.+Salaauthor=C.+Carniniauthor=R.+Patacchiniauthor=M.+Delcanaleauthor=M.+Civelliauthor=G.+Villettiauthor=F.+Facchinetti&title=CHF6001+I%3A+a+novel+highly+potent+and+selective+phosphodiesterase+4+inhibitor+with+robust+anti-inflammatory+activity+and+suitable+for+topical+pulmonary+administration&doi=10.1124%2Fjpet.114.220541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span></div><div class="casAuthors">Moretto, Nadia; Caruso, Paola; Bosco, Raffaella; Marchini, Gessica; Pastore, Fiorella; Armani, Elisabetta; Amari, Gabriele; Rizzi, Andrea; Ghidini, Eleonora; De Fanti, Renato; Capaldi, Carmelida; Carzaniga, Laura; Hirsch, Emilio; Buccellati, Carola; Sala, Angelo; Carnini, Chiara; Patacchini, Riccardo; Delcanale, Maurizio; Civelli, Maurizio; Villetti, Gino; Facchinetti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">559-567, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study examd. the pharmacol. characterization of CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide], a novel phosphodiesterase (PDE)4 inhibitor designed for treating pulmonary inflammatory diseases via inhaled administration.  CHF6001 was 7- and 923-fold more potent than roflumilast and cilomilast, resp., in inhibiting PDE4 enzymic activity (IC50 = 0.026 ± 0.006 nM).  CHF6001 inhibited PDE4 isoforms A-D with equal potency, showed an elevated ratio of high-affinity rolipram binding site vs. low-affinity rolipram binding site (i.e., >40) and displayed >20,000-fold selectivity vs. PDE4 compared with a panel of PDEs.  CHF6001 effectively inhibited (subnanomolar IC50 values) the release of tumor necrosis factor-α from human peripheral blood mononuclear cells, human acute monocytic leukemia cell line macrophages (THP-1), and rodent macrophages (RAW264.7 and NR8383).  Moreover, CHF6001 potently inhibited the activation of oxidative burst in neutrophils and eosinophils, neutrophil chemotaxis, and the release of interferon-γ from CD4+ T cells.  In all these functional assays, CHF6001 was more potent than previously described PDE4 inhibitors, including roflumilast, UK-500,001 [2-(3,4-difluorophenoxy)-5-fluoro-N-((1S,4S)-4-(2-hydroxy-5-methylbenzamido)cyclohexyl)nicotinamide], and cilomilast, and it was comparable to GSK256066 [6-((3-(dimethylcarbamoyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide].  When administered intratracheally to rats as a micronized dry powder, CHF6001 inhibited liposaccharide-induced pulmonary neutrophilia (ED50 = 0.205 μmol/kg) and leukocyte infiltration (ED50 = 0.188 μmol/kg) with an efficacy comparable to a high dose of budesonide (1 μmol/kg i.p.).  In sum, CHF6001 has the potential to be an effective topical treatment of conditions assocd. with pulmonary inflammation, including asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYb2WLQC5SbVg90H21EOLACvtfcHk0lh_QTeQYp9UzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D&md5=2be98d624fe49f7aba8673fa8aea8688</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220541%26sid%3Dliteratum%253Aachs%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DBosco%26aufirst%3DR.%26aulast%3DMarchini%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DBuccellati%26aufirst%3DC.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DFacchinetti%26aufirst%3DF.%26atitle%3DCHF6001%2520I%253A%2520a%2520novel%2520highly%2520potent%2520and%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520with%2520robust%2520anti-inflammatory%2520activity%2520and%2520suitable%2520for%2520topical%2520pulmonary%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D559%26epage%3D567%26doi%3D10.1124%2Fjpet.114.220541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leaker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandeuil, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collarini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariotti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2016.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.pupt.2016.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=27373438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eisLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=1-6&author=D.+Singhauthor=B.+Leakerauthor=M.+Boyceauthor=M.+A.+Nandeuilauthor=S.+Collariniauthor=F.+Mariottiauthor=D.+Santoroauthor=P.+J.+Barnes&title=A+novel+inhaled+phosphodiesterase+4+inhibitor+%28CHF6001%29+reduces+the+allergen+challenge+response+in+asthmatic+patients&doi=10.1016%2Fj.pupt.2016.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19dR"><div class="casContent"><span class="casTitleNuber">19d</span><div class="casTitle"><span class="NLM_cas:atitle">A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients</span></div><div class="casAuthors">Singh, D.; Leaker, B.; Boyce, M.; Nandeuil, M. A.; Collarini, S.; Mariotti, F.; Santoro, D.; Barnes, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of obstructive lung diseases.  The efficacy and safety of CHF6001 were investigated in a double blind, placebo controlled, 3-way cross-over study using the allergen challenge model.  Thirty-six atopic asthmatics who were not taking inhaled corticosteroids and who demonstrated a late asthmatic response (LAR) to inhaled allergen at screening were randomized to receive CHF6001 400 μg or 1200 μg or placebo administered once a day using a dry powder inhaler.  The three treatment periods were 9 days; allergen challenges were performed on day 9 and induced sputum was obtained after 10 h from challenge.  Washout periods between treatments were up to 5 wk.  Both CHF6001 doses significantly attenuated the LAR; the primary endpoint anal. showed that CHF6001 400 μg and 1200 μg caused redns. of 19.7% (p = 0.015) and 28.2% (p < 0.001) resp. of the weighted FEV1 AUC4-10h compared with placebo.  The difference between the CHF6001 doses was not statistically significant (p = 0.223).  Compared with placebo, CHF6001 caused greater redn. in sputum eosinophil counts, although these changes were not statistically significant.  CHF6001 was well tolerated, with similar nos. of adverse events in each treatment period.  This inhaled PDE4 inhibitor has the potential to provide clin. benefits in patients with atopic asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFxltgVfb-QrVg90H21EOLACvtfcHk0lhGhlj66EQL0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eisLzI&md5=cb8064827c2d80be4ae9b9d5f591c514</span></div><a href="/servlet/linkout?suffix=cit19d&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2016.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2016.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DLeaker%26aufirst%3DB.%26aulast%3DBoyce%26aufirst%3DM.%26aulast%3DNandeuil%26aufirst%3DM.%2BA.%26aulast%3DCollarini%26aufirst%3DS.%26aulast%3DMariotti%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DD.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DA%2520novel%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520%2528CHF6001%2529%2520reduces%2520the%2520allergen%2520challenge%2520response%2520in%2520asthmatic%2520patients%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D40%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.pupt.2016.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, D.</span></span> <span> </span><span class="NLM_article-title">Optimisation of DMPK by the inhaled route: challenges and approaches</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.2174/138920012800166571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.2174%2F138920012800166571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=22299825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=457-473&author=A.+E.+Cooperauthor=D.+Fergusonauthor=D.+Grime&title=Optimisation+of+DMPK+by+the+inhaled+route%3A+challenges+and+approaches&doi=10.2174%2F138920012800166571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimisation of DMPK by the inhaled route: challenges and approaches</span></div><div class="casAuthors">Cooper, Anne E.; Ferguson, Douglas; Grime, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-473</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics.  Historically optimization of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung.  Recent efforts have led to an increased understanding of lung concns. and how to maximize exposure to achieve the desired pharmacol. response at a dose consistent with development of an inhaled product.  Although there is a prerequisite for excellent potency in inhalation delivery, it is essential that this be combined with pharmacokinetic properties that allow sufficient free concn. at the effect site in lung to exert the pharmacol. response for an appropriate dosing interval.  Increases in basicity, polarity and/or decreases in aq. soly. can extend pharmacokinetic duration and assist in finding the right balance between lung and systemic exposure.  Current evidence suggests there are similarities in lung retention in rat and dog and that animal lung concn. data can enable pharmacokinetic-pharmacodynamic relationships to be derived thus providing more confidence in the requirements for man.  Although inhaled delivery is challenging from a pharmacokinetic point of view, direct evaluation of exposure in the target organ has enabled further understanding of the drivers for drug disposition and highlighted the need for further development of predictive lung pharmacokinetic tools in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxztkVtHyCeLVg90H21EOLACvtfcHk0lhGhlj66EQL0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D&md5=1dec4f52aeda55fe6ea888c289216d94</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.2174%2F138920012800166571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012800166571%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGrime%26aufirst%3DD.%26atitle%3DOptimisation%2520of%2520DMPK%2520by%2520the%2520inhaled%2520route%253A%2520challenges%2520and%2520approaches%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D457%26epage%3D473%26doi%3D10.2174%2F138920012800166571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A. D.</span></span> <span> </span><span class="NLM_article-title">Inhalation by design</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1563</span>– <span class="NLM_lpage">1565</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.4155%2Ffmc.11.132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=21942245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1563-1565&author=L.+J.+Jonesauthor=A.+D.+Hughes&title=Inhalation+by+design&doi=10.4155%2Ffmc.11.132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhalation by design</span></div><div class="casAuthors">Jones, Lyn H.; Hughes, Adam D.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1563-1565</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcRzo0BxXXfLVg90H21EOLACvtfcHk0lhGhlj66EQL0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvF&md5=fe2e7db8a6fa8ea5575f7d0e6b331eb9</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.132%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BJ.%26aulast%3DHughes%26aufirst%3DA.%2BD.%26atitle%3DInhalation%2520by%2520design%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1563%26epage%3D1565%26doi%3D10.4155%2Ffmc.11.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tayab, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic/pharmacodynamics evaluation of inhalation drugs: application to targeted pulmonary delivery systems</span>. <i>Expert Opin. Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1517/17425247.2.3.519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F17425247.2.3.519" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=519-532&author=Z.+R.+Tayabauthor=G.+Hochhaus&title=Pharmacokinetic%2Fpharmacodynamics+evaluation+of+inhalation+drugs%3A+application+to+targeted+pulmonary+delivery+systems&doi=10.1517%2F17425247.2.3.519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1517%2F17425247.2.3.519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425247.2.3.519%26sid%3Dliteratum%253Aachs%26aulast%3DTayab%26aufirst%3DZ.%2BR.%26aulast%3DHochhaus%26aufirst%3DG.%26atitle%3DPharmacokinetic%252Fpharmacodynamics%2520evaluation%2520of%2520inhalation%2520drugs%253A%2520application%2520to%2520targeted%2520pulmonary%2520delivery%2520systems%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2005%26volume%3D2%26spage%3D519%26epage%3D532%26doi%3D10.1517%2F17425247.2.3.519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. O.,  III</span></span> <span> </span><span class="NLM_article-title">Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilisation on pharmacokinetic properties</span>. <i>Drug Dev. Ind. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3109/03639040903092319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.3109%2F03639040903092319" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2010&pages=1-30&author=J.+A.+Tolmanauthor=R.+O.+Williams&title=Advances+in+the+pulmonary+delivery+of+poorly+water-soluble+drugs%3A+influence+of+solubilisation+on+pharmacokinetic+properties&doi=10.3109%2F03639040903092319"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3109%2F03639040903092319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03639040903092319%26sid%3Dliteratum%253Aachs%26aulast%3DTolman%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BO.%26atitle%3DAdvances%2520in%2520the%2520pulmonary%2520delivery%2520of%2520poorly%2520water-soluble%2520drugs%253A%2520influence%2520of%2520solubilisation%2520on%2520pharmacokinetic%2520properties%26jtitle%3DDrug%2520Dev.%2520Ind.%2520Pharm.%26date%3D2010%26volume%3D36%26spage%3D1%26epage%3D30%26doi%3D10.3109%2F03639040903092319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. O.,  III</span></span> <span> </span><span class="NLM_article-title">Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilisation o pharmacokinetic properties</span>. <i>Drug Dev. Ind. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3109/03639040903092319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.3109%2F03639040903092319" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2010&pages=1-30&author=J.+A.+Tolmanauthor=R.+O.+Williams&title=Advances+in+the+pulmonary+delivery+of+poorly+water-soluble+drugs%3A+influence+of+solubilisation+o+pharmacokinetic+properties&doi=10.3109%2F03639040903092319"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3109%2F03639040903092319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03639040903092319%26sid%3Dliteratum%253Aachs%26aulast%3DTolman%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BO.%26atitle%3DAdvances%2520in%2520the%2520pulmonary%2520delivery%2520of%2520poorly%2520water-soluble%2520drugs%253A%2520influence%2520of%2520solubilisation%2520o%2520pharmacokinetic%2520properties%26jtitle%3DDrug%2520Dev.%2520Ind.%2520Pharm.%26date%3D2010%26volume%3D36%26spage%3D1%26epage%3D30%26doi%3D10.3109%2F03639040903092319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span> <span> </span><span class="NLM_article-title">Optimisation of DMPK by the inhaled route: challenges and approaches</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.2174/138920012800166571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.2174%2F138920012800166571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=22299825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=457-473&author=A.+E.+Cooperauthor=D.+Fergusonauthor=K.+Grime&title=Optimisation+of+DMPK+by+the+inhaled+route%3A+challenges+and+approaches&doi=10.2174%2F138920012800166571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Optimisation of DMPK by the inhaled route: challenges and approaches</span></div><div class="casAuthors">Cooper, Anne E.; Ferguson, Douglas; Grime, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-473</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics.  Historically optimization of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung.  Recent efforts have led to an increased understanding of lung concns. and how to maximize exposure to achieve the desired pharmacol. response at a dose consistent with development of an inhaled product.  Although there is a prerequisite for excellent potency in inhalation delivery, it is essential that this be combined with pharmacokinetic properties that allow sufficient free concn. at the effect site in lung to exert the pharmacol. response for an appropriate dosing interval.  Increases in basicity, polarity and/or decreases in aq. soly. can extend pharmacokinetic duration and assist in finding the right balance between lung and systemic exposure.  Current evidence suggests there are similarities in lung retention in rat and dog and that animal lung concn. data can enable pharmacokinetic-pharmacodynamic relationships to be derived thus providing more confidence in the requirements for man.  Although inhaled delivery is challenging from a pharmacokinetic point of view, direct evaluation of exposure in the target organ has enabled further understanding of the drivers for drug disposition and highlighted the need for further development of predictive lung pharmacokinetic tools in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxztkVtHyCeLVg90H21EOLACvtfcHk0lgqzgFqjFk3zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D&md5=1dec4f52aeda55fe6ea888c289216d94</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F138920012800166571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012800166571%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGrime%26aufirst%3DK.%26atitle%3DOptimisation%2520of%2520DMPK%2520by%2520the%2520inhaled%2520route%253A%2520challenges%2520and%2520approaches%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D457%26epage%3D473%26doi%3D10.2174%2F138920012800166571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Felding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Refer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladefoged, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thormann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinggaard, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Søhoel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO29102), a soft-drug Inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5893</span>– <span class="NLM_lpage">5903</span>, <span class="refDoi"> DOI: 10.1021/jm500378a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500378a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5893-5903&author=F.+Feldingauthor=M.+D.+S%C3%B8rensenauthor=T.+D.+Poulsenauthor=J.+Larsenauthor=C.+Anderssonauthor=P.+Referauthor=K.+Engellauthor=L.+G.+Ladefogedauthor=T.+Thormannauthor=A.+M.+Vinggaardauthor=P.+Hegardtauthor=A.+S%C3%B8hoelauthor=S.+F.+Nielsen&title=Discovery+and+early+clinical+development+of+2-%7B6-%5B2-%283%2C5-dichloro-4-pyridyl%29acetyl%5D-2%2C3-dimethoxyphenoxy%7D-N-propylacetamide+%28LEO29102%29%2C+a+soft-drug+Inhibitor+of+phosphodiesterase+4+for+topical+treatment+of+atopic+dermatitis&doi=10.1021%2Fjm500378a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1021%2Fjm500378a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500378a%26sid%3Dliteratum%253Aachs%26aulast%3DFelding%26aufirst%3DF.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DM.%2BD.%26aulast%3DPoulsen%26aufirst%3DT.%2BD.%26aulast%3DLarsen%26aufirst%3DJ.%26aulast%3DAndersson%26aufirst%3DC.%26aulast%3DRefer%26aufirst%3DP.%26aulast%3DEngell%26aufirst%3DK.%26aulast%3DLadefoged%26aufirst%3DL.%2BG.%26aulast%3DThormann%26aufirst%3DT.%26aulast%3DVinggaard%26aufirst%3DA.%2BM.%26aulast%3DHegardt%26aufirst%3DP.%26aulast%3DS%25C3%25B8hoel%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520development%2520of%25202-%257B6-%255B2-%25283%252C5-dichloro-4-pyridyl%2529acetyl%255D-2%252C3-dimethoxyphenoxy%257D-N-propylacetamide%2520%2528LEO29102%2529%252C%2520a%2520soft-drug%2520Inhibitor%2520of%2520phosphodiesterase%25204%2520for%2520topical%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5893%26epage%3D5903%26doi%3D10.1021%2Fjm500378a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bodor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, P.</span></span> <span> </span><span class="NLM_article-title">Soft drug design: general principles and recent applications</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10608921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=58-101&author=N.+Bodorauthor=P.+Buchwald&title=Soft+drug+design%3A+general+principles+and+recent+applications&doi=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Soft drug design: general principles and recent applications</span></div><div class="casAuthors">Bodor, Nicholas; Buchwald, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-101</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review with 208 refs.  Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metab. considerations into the drug design process.  Soft drugs are new therapeutic agents that undergo predictable metab. to inactive metabolites after exerting their therapeutic effect.  Hence, they are obtained by building into the mol., in addn. to the activity, the most desired way in which the mol. is to be deactivated and detoxified.  In an attempt to systematize and summarize the related work done in a no. of labs., including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts.  A no. of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles.  Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, β-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others.  Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compds. used in the same field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphV1vhXwTl8LVg90H21EOLACvtfcHk0lhGEsFNa62JsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D&md5=e0ca493ba31d001e62a759be0fc4bcc8</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-1128%2528200001%252920%253A1%253C58%253A%253AAID-MED3%253E3.0.CO%253B2-X%26sid%3Dliteratum%253Aachs%26aulast%3DBodor%26aufirst%3DN.%26aulast%3DBuchwald%26aufirst%3DP.%26atitle%3DSoft%2520drug%2520design%253A%2520general%2520principles%2520and%2520recent%2520applications%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2000%26volume%3D20%26spage%3D58%26epage%3D101%26doi%3D10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerud, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and the drug–target residence time concept</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.drudis.2013.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=23500610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=697-707&author=G.+Dahlauthor=T.+Akerud&title=Pharmacokinetics+and+the+drug%E2%80%93target+residence+time+concept&doi=10.1016%2Fj.drudis.2013.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and the drug-target residence time concept</span></div><div class="casAuthors">Dahl, Goeran; Akerud, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">697-707</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The concept of drug-target residence time has been in focus in recent drug discovery literature.  However, few studies consider the combined effect of pharmacokinetics (PK) and binding kinetics (BK) on the duration of effect of a drug.  Using a simple model that takes both PK and BK into account, we found that prolongation of binding owing to a long drug-target residence time can only occur when the binding dissocn. is slower than the PK elimination.  Data for several drugs and/or drug candidates in the literature indicate that the opposite is obsd., i.e., they have a slower elimination compared with dissocn.  These observations greatly reduce the usability of drug-target residence times for estg. the duration of effect of a drug in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon2xZ9fJkTybVg90H21EOLACvtfcHk0lhj6qsabVW6qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D&md5=73b190a44d359f55ee19af9099846505</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DAkerud%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520the%2520drug%25E2%2580%2593target%2520residence%2520time%2520concept%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D697%26epage%3D707%26doi%3D10.1016%2Fj.drudis.2013.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Liefde, I.</span></span> <span> </span><span class="NLM_article-title">Slow antagonist dissociation and long-lasting in vivo receptor protection</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2006.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.tips.2006.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsFSmu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=355-359&author=G.+Vauquelinauthor=I.+Van+Liefde&title=Slow+antagonist+dissociation+and+long-lasting+in+vivo+receptor+protection&doi=10.1016%2Fj.tips.2006.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Slow antagonist dissociation and long-lasting in vivo receptor protection</span></div><div class="casAuthors">Vauquelin, Georges; Van Liefde, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">355-359</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The ability of antagonists to form slowly dissocg. complexes with their cognate receptors has repeatedly been proposed to contribute to their long-lasting clin. actions.  Yet specific conditions seem to be necessary for this to take place.  The elimination rate of the free antagonist and the variation of agonist concn. with time have important roles.  Slowly dissocg. antagonists are likely to exert longer efficient receptor protection in vivo than are fast-dissocg. antagonists when the half-life of the antagonist-receptor complex exceeds that of the free antagonist.  However, when the half-life of the free antagonist prevails, longer effective protection by slowly dissocg. antagonists occurs only if the receptor is exposed to rapid fluctuations in free agonist concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCVnyLMr2SRbVg90H21EOLACvtfcHk0lhj6qsabVW6qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsFSmu7o%253D&md5=cb7f4428b23136b31523a233d9b11dcf</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2006.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2006.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26aulast%3DVan%2BLiefde%26aufirst%3DI.%26atitle%3DSlow%2520antagonist%2520dissociation%2520and%2520long-lasting%2520in%2520vivo%2520receptor%2520protection%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D355%26epage%3D359%26doi%3D10.1016%2Fj.tips.2006.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">The Role of target binding kinetics in drug discovery</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1796</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1002%2Fcmdc.201500310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=26506404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1793-1796&author=D.+Guoauthor=L.+H.+Heitmanauthor=A.+P.+IJzerman&title=The+Role+of+target+binding+kinetics+in+drug+discovery&doi=10.1002%2Fcmdc.201500310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25cR"><div class="casContent"><span class="casTitleNuber">25c</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Target Binding Kinetics in Drug Discovery</span></div><div class="casAuthors">Guo, Dong; Heitman, Laura H.; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1793-1796</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Traditionally structure-activity/affinity relationships (SAR) have dominated research in medicinal chem.  However, structure-kinetics relationships (SKR) can be very informative too.  In this viewpoint we explore the mol. determinants of binding kinetics and discuss challenges for future binding kinetics studies.  A scheme for future kinetics-directed drug design and discovery is also proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiX7v30ryLZLVg90H21EOLACvtfcHk0lhj6qsabVW6qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjurfF&md5=8442ba4d4ec014762ed470f7f6131d09</span></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500310%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26atitle%3DThe%2520Role%2520of%2520target%2520binding%2520kinetics%2520in%2520drug%2520discovery%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1793%26epage%3D1796%26doi%3D10.1002%2Fcmdc.201500310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">For some recent reviews on the role of residence time, see:</p></div><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Swinney, D. C.</span></span> <span> </span><span class="NLM_article-title">Applications of binding kinetics to drug discovery</span>. <i>Pharm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1007/BF03256679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1007%2FBF03256679" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=23-34&author=D.+C.+Swinney&title=Applications+of+binding+kinetics+to+drug+discovery&doi=10.1007%2FBF03256679"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1007%2FBF03256679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03256679%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DApplications%2520of%2520binding%2520kinetics%2520to%2520drug%2520discovery%26jtitle%3DPharm.%2520Med.%26date%3D2008%26volume%3D22%26spage%3D23%26epage%3D34%26doi%3D10.1007%2FBF03256679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Swinney, D. C.</span></span> <span> </span><span class="NLM_article-title">The role of binding kinetics in therapeutically useful drug action</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=19152211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt12ltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=31-39&author=D.+C.+Swinney&title=The+role+of+binding+kinetics+in+therapeutically+useful+drug+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">The role of binding kinetics in therapeutically useful drug action</span></div><div class="casAuthors">Swinney, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">2040-3437</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Binding kinetics help define how a medicine will communicate with physiol. to produce a desired therapeutic response.  Clin. efficacy, duration of action, clin. differentiation and safety may all be influenced by binding kinetics.  The optimization of binding kinetics can be used to maximize a drug's therapeutic index and thereby decrease drug attrition.  The gap between basic scientific principles and the potential medical value of a drug is currently bridged by the use of empirical assays.  The value of binding kinetics to drug discovery will be increased through an improved ability to identify optimal kinetic mechanisms and define kinetic structure activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8IoReBfGAabVg90H21EOLACvtfcHk0lh78H6rrMDA5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt12ltrk%253D&md5=129948a7fb0a60f3b9995e5aedb700a4</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DThe%2520role%2520of%2520binding%2520kinetics%2520in%2520therapeutically%2520useful%2520drug%2520action%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2009%26volume%3D12%26spage%3D31%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <span> </span><span class="NLM_article-title">The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1517/17460441003677725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F17460441003677725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=22823083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFSgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=305-309&author=R.+A.+Copeland&title=The+dynamics+of+drug-target+interactions%3A+drug-target+residence+time+and+its+impact+on+efficacy+and+safety&doi=10.1517%2F17460441003677725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26cR"><div class="casContent"><span class="casTitleNuber">26c</span><div class="casTitle"><span class="NLM_cas:atitle">The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety</span></div><div class="casAuthors">Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-310</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The extent and duration of pharmacol. action is detd. by the lifetime of drug occupancy on a mol. target.  This lifetime is defined by dynamic processes that control the rates of drug assocn. and dissocn. from the target.  Recently, the term residence time has been coined to describe exptl. measurements that can be related to the lifetime of the binary drug-target complex, and this in turn to durable, pharmacodynamic activity.  The residence time concept and its impact on drug optimization are reviewed here.  Examples are provided that demonstrate how a long residence time can improve drug efficacy in vivo.  Addnl., optimization of drug-target residence time can help to mitigate off-target mediated toxicity, hence, improving drug safety and tolerability.  Recent applications of the residence time concept to both drug discovery and development are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyt3KrIYdRjbVg90H21EOLACvtfcHk0lh78H6rrMDA5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFSgsbo%253D&md5=aca925e00abefddf6e92d83b470d96f1</span></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=10.1517%2F17460441003677725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441003677725%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DThe%2520dynamics%2520of%2520drug-target%2520interactions%253A%2520drug-target%2520residence%2520time%2520and%2520its%2520impact%2520on%2520efficacy%2520and%2520safety%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2010%26volume%3D5%26spage%3D305%26epage%3D309%26doi%3D10.1517%2F17460441003677725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monsma, F.</span></span> <span> </span><span class="NLM_article-title">Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1517/17460441.2010.520700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1517%2F17460441.2010.520700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=22827742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlaiu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1023-1029&author=R.+Zhangauthor=F.+Monsma&title=Binding+kinetics+and+mechanism+of+action%3A+toward+the+discovery+and+development+of+better+and+best+in+class+drugs&doi=10.1517%2F17460441.2010.520700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26dR"><div class="casContent"><span class="casTitleNuber">26d</span><div class="casTitle"><span class="NLM_cas:atitle">Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs</span></div><div class="casAuthors">Zhang, Rumin; Monsma, Frederick</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1023-1029</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Binding kinetics (BK), an often overlooked key aspect of the broader concept of drug mechanism of action (MOA), is increasingly recognized as a springboard from pharmacokinetics (PK) to pharmacodynamics, and as a crit. differentiator and predictor for drug efficacy and safety.  Just as greater attention to PK issues has helped reduce the attrition of drugs tested in clin. trials, the emerging paradigm shift from primarily affinity/potency-emphasized to a more holistic BK-perceptive and MOA-informed approach is expected to further enhance the success of drug discovery and development.  This perspective attempts to envision what this new approach looks like when proper emphasis is placed on BK and MOA in designing better and best in class drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7O7ymOCyIe7Vg90H21EOLACvtfcHk0lillT6UrL4X-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlaiu77O&md5=9b3efefdf67fd2c9303537a15dcc8d98</span></div><a href="/servlet/linkout?suffix=cit26d&amp;dbid=16384&amp;doi=10.1517%2F17460441.2010.520700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2010.520700%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DMonsma%26aufirst%3DF.%26atitle%3DBinding%2520kinetics%2520and%2520mechanism%2520of%2520action%253A%2520toward%2520the%2520discovery%2520and%2520development%2520of%2520better%2520and%2520best%2520in%2520class%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2010%26volume%3D5%26spage%3D1023%26epage%3D1029%26doi%3D10.1517%2F17460441.2010.520700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeadon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevethick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agoram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entwistle, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, F. J.</span></span> <span> </span><span class="NLM_article-title">Inhalation by design: novel tertiary amine muscarinic M<sub>3</sub> receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6888</span>– <span class="NLM_lpage">6904</span>, <span class="refDoi"> DOI: 10.1021/jm200884j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200884j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SltbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6888-6904&author=P.%0AA.+Glossopauthor=C.+A.+Watsonauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=D.+S.+Middletonauthor=A.+Woodauthor=K.+Jamesauthor=D.+Robertsauthor=R.+S.+Strangauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=N.+P.+Clarkeauthor=M.+A.+Trevethickauthor=I.+Machinauthor=E.+F.+Stuartauthor=S.+M.+Evansauthor=A.+C.+Harrisonauthor=D.+A.+Fairmanauthor=B.+Agoramauthor=J.+L.+Burrowsauthor=N.+Feederauthor=C.+K.+Fultonauthor=B.+R.+Dillonauthor=D.+A.+Entwistleauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+tertiary+amine+muscarinic+M3+receptor+antagonists+with+slow+off-rate+binding+kinetics+for+inhaled+once-daily+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1021%2Fjm200884j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhalation by Design: Novel Tertiary Amine Muscarinic M3 Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Glossop, Paul A.; Watson, Christine A. L.; Price, David A.; Bunnage, Mark E.; Middleton, Donald S.; Wood, Anthony; James, Kim; Roberts, Dannielle; Strang, Ross S.; Yeadon, Michael; Perros-Huguet, Christelle; Clarke, Nicholas P.; Trevethick, Michael A.; Machin, Ian; Stuart, Emilio F.; Evans, Steven M.; Harrison, Anthony C.; Fairman, David A.; Agoram, Balaji; Burrows, Jane L.; Feeder, Neil; Fulton, Craig K.; Dillon, Barry R.; Entwistle, David A.; Spence, Fiona J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6888-6904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel tertiary amine series of potent muscarinic M3 receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease.  Geminal di-Me functionality present in this series of compds. confers very long dissociative half-life (slow off-rate) from the M3 receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips.  Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation.  Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug-drug interactions, and reduce systemically mediated adverse events.  Compd. 47 (PF-3635659) is identified as a Phase II clin. candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs8Q4T5oR53bVg90H21EOLACvtfcHk0lillT6UrL4X-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SltbzM&md5=ca9b632b4c7982fb44c0d5dd17a056bf</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1021%2Fjm200884j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200884j%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DWatson%26aufirst%3DC.%2BA.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DMiddleton%26aufirst%3DD.%2BS.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DD.%26aulast%3DStrang%26aufirst%3DR.%2BS.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DMachin%26aufirst%3DI.%26aulast%3DStuart%26aufirst%3DE.%2BF.%26aulast%3DEvans%26aufirst%3DS.%2BM.%26aulast%3DHarrison%26aufirst%3DA.%2BC.%26aulast%3DFairman%26aufirst%3DD.%2BA.%26aulast%3DAgoram%26aufirst%3DB.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DFulton%26aufirst%3DC.%2BK.%26aulast%3DDillon%26aufirst%3DB.%2BR.%26aulast%3DEntwistle%26aufirst%3DD.%2BA.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520tertiary%2520amine%2520muscarinic%2520M3%2520receptor%2520antagonists%2520with%2520slow%2520off-rate%2520binding%2520kinetics%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6888%26epage%3D6904%26doi%3D10.1021%2Fjm200884j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewthwaite, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeadon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevethick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, F. J.</span></span> <span> </span><span class="NLM_article-title">Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6640</span>– <span class="NLM_lpage">6652</span>, <span class="refDoi"> DOI: 10.1021/jm1005989</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&author=P.+A.+Glossopauthor=C.+A.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+ultra-long-acting+%CE%B2%282%29-adrenoreceptor+agonists+for+inhaled+once-daily+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease+that+utilize+a+sulfonamide+agonist+headgroup&doi=10.1021%2Fjm1005989"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520ultra-long-acting%2520%25CE%25B2%25282%2529-adrenoreceptor%2520agonists%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520that%2520utilize%2520a%2520sulfonamide%2520agonist%2520headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6640%26epage%3D6652%26doi%3D10.1021%2Fjm1005989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Claus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiewe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friess, W.</span></span> <span> </span><span class="NLM_article-title">How can we bring high drug doses to the lung?</span>. <i>Eur. J. Pharm. Biopharm.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.ejpb.2013.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.ejpb.2013.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=24300444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVSgsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=1-6&author=S.+Clausauthor=C.+Weilerauthor=J.+Schieweauthor=W.+Friess&title=How+can+we+bring+high+drug+doses+to+the+lung%3F&doi=10.1016%2Fj.ejpb.2013.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">How can we bring high drug doses to the lung?</span></div><div class="casAuthors">Claus, Sarah; Weiler, Claudius; Schiewe, Joerg; Friess, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the last decades, dry powder inhalation has become a very attractive option for pulmonary drug delivery to treat lung diseases like cystic fibroses and lung infections.  In contrast to the traditional pulmonary application of drugs for asthma and chronic obstructive pulmonary disease, these therapies require higher lung doses to be administered.  The developments and improvements toward high dose powder pulmonary drug delivery are summarized and discussed in this chapter.  These include the invention and improvement of novel inhaler devices as well as the further development of formulation principles and new powder engineering methods.  The implementation of these strategies is subsequently described for some prototypes and formulations in research and development stage as well as for already marketed dry powder products.  Finally, possible adverse effects that can occur after inhalation of high powder doses are shortly addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV5Llh5PaWsrVg90H21EOLACvtfcHk0liWfQSEiQe5GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVSgsrzN&md5=a0bd5801e0c672b787282b3c2636a1df</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2013.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2013.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DClaus%26aufirst%3DS.%26aulast%3DWeiler%26aufirst%3DC.%26aulast%3DSchiewe%26aufirst%3DJ.%26aulast%3DFriess%26aufirst%3DW.%26atitle%3DHow%2520can%2520we%2520bring%2520high%2520drug%2520doses%2520to%2520the%2520lung%253F%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2014%26volume%3D86%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.ejpb.2013.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petavy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, A. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-11-26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1186%2F1465-9921-11-26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=20193079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=26-34&author=D.+Singhauthor=F.+Petavyauthor=A.+J.+Macdonald&title=The+inhaled+phosphodiesterase+4+inhibitor+GSK256066+reduces+allergen+challenge+responses+in+asthma&doi=10.1186%2F1465-9921-11-26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span></div><div class="casAuthors">Singh Dave; Petavy Frank; Macdonald Alex J; Lazaar Aili L; O'Connor Brian J</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects.  We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild asthmatics.  METHODS:  In a randomised, double blind, cross-over study, 24 steroid naive atopic asthmatics with both early (EAR) and late (LAR) responses to inhaled allergen received inhaled GSK256066 87.5 mcg once per day and placebo for 7 days, followed by allergen challenge.  Methacholine reactivity was measured 24 h post-allergen.  Plasma pharmacokinetics were measured.  The primary endpoint was the effect on LAR.  RESULTS:  GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo.  GSK256066 significantly reduced the EAR, inhibiting the fall in minimum and weighted mean FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014) respectively compared to placebo.  There was no effect on pre-allergen FEV1 or methacholine reactivity post allergen.  GSK256066 was well tolerated, with low systemic exposure; plasma levels were not measurable after 4 hours in the majority of subjects.  CONCLUSIONS:  GSK256066 demonstrated a protective effect on the EAR and LAR.  This is the first inhaled PDE4 inhibitor to show therapeutic potential in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6sWKb5nMe2ROk4JA3soTqfW6udTcc2eYIZZSkkQvtbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D&md5=88d976c3aa2d963dc83c5fa8e32e4f62</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-26%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DPetavy%26aufirst%3DF.%26aulast%3DMacdonald%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520GSK256066%2520reduces%2520allergen%2520challenge%2520responses%2520in%2520asthma%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D26%26epage%3D34%26doi%3D10.1186%2F1465-9921-11-26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballantine, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindvaal, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranshaw, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanke, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, J. O.</span></span> <span> </span><span class="NLM_article-title">Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5261</span>– <span class="NLM_lpage">5265</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.bmcl.2009.04.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5261-5265&author=M.+D.+Woodrowauthor=S.+P.+Ballantineauthor=M.+D.+Barkerauthor=B.+J.+Clarkeauthor=J.+Dawsonauthor=T.+W.+Deanauthor=C.+J.+Delvesauthor=B.+Evansauthor=S.+L.+Goughauthor=S.+B.+Guntripauthor=S.+Holmanauthor=D.+S.+Holmesauthor=M.+Kranzauthor=M.+K.+Lindvaalauthor=F.+S.+Lucasauthor=M.+Neuauthor=L.+E.+Ranshawauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=P.+Wardauthor=J.+O.+Wiseman&title=Quinolines+as+a+novel+structural+class+of+potent+and+selective+PDE4+inhibitors.+Optimisation+for+inhaled+administration&doi=10.1016%2Fj.bmcl.2009.04.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DWoodrow%26aufirst%3DM.%2BD.%26aulast%3DBallantine%26aufirst%3DS.%2BP.%26aulast%3DBarker%26aufirst%3DM.%2BD.%26aulast%3DClarke%26aufirst%3DB.%2BJ.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DDean%26aufirst%3DT.%2BW.%26aulast%3DDelves%26aufirst%3DC.%2BJ.%26aulast%3DEvans%26aufirst%3DB.%26aulast%3DGough%26aufirst%3DS.%2BL.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHolman%26aufirst%3DS.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DLindvaal%26aufirst%3DM.%2BK.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DQuinolines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520and%2520selective%2520PDE4%2520inhibitors.%2520Optimisation%2520for%2520inhaled%2520administration%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5261%26epage%3D5265%26doi%3D10.1016%2Fj.bmcl.2009.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gràcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buil, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segarra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagès, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Biphenyl pyridazinone derivatives as inhaled PDE4 inhibitors: structural biology and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10479</span>– <span class="NLM_lpage">10497</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10479-10497&author=J.+Gr%C3%A0ciaauthor=M.+A.+Builauthor=J.+Castroauthor=P.+Eichhornauthor=M.+Ferrerauthor=A.+Gavald%C3%A0author=B.+Hern%C3%A1ndezauthor=V.+Segarraauthor=M.+D.+Lehnerauthor=I.+Morenoauthor=L.+Pag%C3%A8sauthor=R.+S.+Robertsauthor=J.+Serratauthor=S.+Sevillaauthor=J.+Taltavullauthor=M.+Andr%C3%A9sauthor=J.+Cabedoauthor=D.+Vilellaauthor=E.+Calamaauthor=C.+Carcasonaauthor=M.+Miralpeix&title=Biphenyl+pyridazinone+derivatives+as+inhaled+PDE4+inhibitors%3A+structural+biology+and+structure-activity+relationships&doi=10.1021%2Facs.jmedchem.6b00829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships</span></div><div class="casAuthors">Gracia, Jordi; Buil, Maria Antonia; Castro, Jordi; Eichhorn, Peter; Ferrer, Manel; Gavalda, Amadeu; Hernandez, Begona; Segarra, Victor; Lehner, Martin D.; Moreno, Imma; Pages, Lluis; Roberts, Richard S.; Serrat, Jordi; Sevilla, Sara; Taltavull, Joan; Andres, Miriam; Cabedo, Judit; Vilella, Dolors; Calama, Elena; Carcasona, Carla; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10479-10497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclic nucleotide cAMP is an ubiquitous second messenger involved in a plethora of cellular responses to biol. agents involving activation of adenylyl cyclase.  Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs.  In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD.  Here the authors describe efforts to discover novel, highly potent inhaled inhibitors of PDE4.  Through structure based design, with the intervention of a wide variety of functional groups and physichochem. profiles to occupy the solvent-filled pocket of the PDE4 enzyme, the authors modified the structure of the authors' oral PDE4 inhibitors to reach compds. up to picomolar enzymic potencies.  In vitro potencies were demonstrated in a rat lung neutrophilia model by suspension microspray administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCrwH5GRUxx7Vg90H21EOLACvtfcHk0liYKsTRy1fD5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE&md5=13709b5d62c06b553655f88f65ff3bdf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00829%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25A0cia%26aufirst%3DJ.%26aulast%3DBuil%26aufirst%3DM.%2BA.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DEichhorn%26aufirst%3DP.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DMoreno%26aufirst%3DI.%26aulast%3DPag%25C3%25A8s%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26aulast%3DSerrat%26aufirst%3DJ.%26aulast%3DSevilla%26aufirst%3DS.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DBiphenyl%2520pyridazinone%2520derivatives%2520as%2520inhaled%2520PDE4%2520inhibitors%253A%2520structural%2520biology%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10479%26epage%3D10497%26doi%3D10.1021%2Facs.jmedchem.6b00829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2004.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.molcel.2004.07.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=279-286&author=K.+Y.+Zhangauthor=G.+L.+Cardauthor=Y.+Suzukiauthor=D.+R.+Artisauthor=D.+Fongauthor=S.+Gilletteauthor=D.+Hsiehauthor=J.+Neimanauthor=B.+L.+Westauthor=C.+Zhangauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=G.+Bollag&title=A+glutamine+switch+mechanism+for+nucleotide+selectivity+by+phosphodiesterases&doi=10.1016%2Fj.molcel.2004.07.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DNeiman%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DA%2520glutamine%2520switch%2520mechanism%2520for%2520nucleotide%2520selectivity%2520by%2520phosphodiesterases%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D23%26spage%3D279%26epage%3D286%26doi%3D10.1016%2Fj.molcel.2004.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="note"><p class="first last">Erratum in:</p></div><div class="NLM_citation" id="rightTab-cit32a1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">659</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2004.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.molcel.2004.08.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Zhang%2C+K.+Y.%3B+Card%2C+G.+L.%3B+Suzuki%2C+Y.%3B+Artis%2C+D.+R.%3B+Fong%2C+D.%3B+Gillette%2C+S.%3B+Hsieh%2C+D.%3B+Neiman%2C+J.%3B+West%2C+B.+L.%3B+Zhang%2C+C.%3B+Milburn%2C+M.+V.%3B+Kim%2C+S.+H.%3B+Schlessinger%2C+J.%3B+Bollag%2C+G.+Mol.+Cell+2004%2C+27%2C+659%2C+10.1016%2Fj.molcel.2004.08.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a1&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DNeiman%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DBollag%26aufirst%3DG.%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D27%26spage%3D659%26doi%3D10.1016%2Fj.molcel.2004.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrafnsdottir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1038/nbt.1598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1038%2Fnbt.1598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=20037581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=63-72&author=A.+B.+Burginauthor=O.+T.+Magnussonauthor=J.+Singhauthor=P.+Witteauthor=B.+L.+Stakerauthor=J.+M.+Bjornssonauthor=M.+Thorsteinsdottirauthor=S.+Hrafnsdottirauthor=T.+Hagenauthor=A.+S.+Kiselyovauthor=L.+J.+Stewartauthor=M.+E.+Gurney&title=Design+of+phosphodiesterase+4D+%28PDE4D%29+allosteric+modulators+for+enhancing+cognition+with+improved+safety&doi=10.1038%2Fnbt.1598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span></div><div class="casAuthors">Burgin, Alex B.; Magnusson, Olafur T.; Singh, Jasbir; Witte, Pam; Staker, Bart L.; Bjornsson, Jon M.; Thorsteinsdottir, Margret; Hrafnsdottir, Sigrun; Hagen, Timothy; Kiselyov, Alex S.; Stewart, Lance J.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions.  Here we present seven co-crystal structures of PDE4 and bound inhibitors that show the regulatory domain closed across the active site, thereby revealing the structural basis of PDE4 regulation.  This structural insight, together with supporting mutagenesis and kinetic studies, allowed us to design small-mol. allosteric modulators of PDE4D that do not completely inhibit enzymic activity (Imax ∼ 80-90%).  These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biol. activity in cellular and in vivo models.  Our results may facilitate the design of CNS therapeutics modulating cAMP signaling for the treatment of Alzheimer's disease, Huntington's disease, schizophrenia and depression, where brain distribution is desired for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr18KdQE2oVsbVg90H21EOLACvtfcHk0lh-gAYNAe2aiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ&md5=1e8651a7116206eefddb9fa6b79d5112</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1598%26sid%3Dliteratum%253Aachs%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DP.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DBjornsson%26aufirst%3DJ.%2BM.%26aulast%3DThorsteinsdottir%26aufirst%3DM.%26aulast%3DHrafnsdottir%26aufirst%3DS.%26aulast%3DHagen%26aufirst%3DT.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDesign%2520of%2520phosphodiesterase%25204D%2520%2528PDE4D%2529%2520allosteric%2520modulators%2520for%2520enhancing%2520cognition%2520with%2520improved%2520safety%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D63%26epage%3D72%26doi%3D10.1038%2Fnbt.1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevilla, S.</span></span> <span> </span><span class="NLM_article-title">A modular synthesis of novel 4-amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as PDE4 inhibitors</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4821</span>– <span class="NLM_lpage">4825</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2013.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.tetlet.2013.06.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=4821-4825&author=M.+Ferrerauthor=R.+S.+Robertsauthor=S.+Sevilla&title=A+modular+synthesis+of+novel+4-amino-7%2C8-dihydro-1%2C6-naphthyridin-5%286H%29-ones+as+PDE4+inhibitors&doi=10.1016%2Fj.tetlet.2013.06.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2013.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2013.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26aulast%3DSevilla%26aufirst%3DS.%26atitle%3DA%2520modular%2520synthesis%2520of%2520novel%25204-amino-7%252C8-dihydro-1%252C6-naphthyridin-5%25286H%2529-ones%2520as%2520PDE4%2520inhibitors%26jtitle%3DTetrahedron%2520Lett.%26date%3D2013%26volume%3D54%26spage%3D4821%26epage%3D4825%26doi%3D10.1016%2Fj.tetlet.2013.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alex, A.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eZn4QNk4F8Mb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkaichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7037</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.bmc.2013.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=24094436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGnsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=7025-7037&author=T.+Gotoauthor=A.+Shiinaauthor=T.+Yoshinoauthor=K.+Mizukamiauthor=K.+Hiraharaauthor=O.+Suzukiauthor=Y.+Sogawaauthor=T.+Takahashiauthor=T.+Mikkaichiauthor=N.+Nakaoauthor=M.+Takahashiauthor=M.+Hasegawaauthor=S.+Sasaki&title=Synthesis+and+biological+evaluation+of+5-carbamoyl-2-phenylpyrimidine+derivatives+as+novel+and+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmc.2013.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors</span></div><div class="casAuthors">Goto, Taiji; Shiina, Akiko; Yoshino, Toshiharu; Mizukami, Kiyoshi; Hirahara, Kazuki; Suzuki, Osamu; Sogawa, Yoshitaka; Takahashi, Tomoko; Mikkaichi, Tsuyoshi; Nakao, Naoki; Takahashi, Mizuki; Hasegawa, Masashi; Sasaki, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7025-7037</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">5-Carbamoyl-2-phenylpyrimidine deriv. has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM).  Modification of the carboxylic acid moiety of the deriv. gave N-neopentylacetamide deriv., which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia in mice (ID50 = 16 mg/kg, i.p.).  Furthermore, based on the x-ray crystallog. of N-neopentylacetamide deriv. bound to the human PDE4B catalytic domain, the authors designed 7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one deriv. I, which has a fused bicyclic lactam scaffold.  Compd. I exhibited excellent inhibitory activity against LPS-induced tumor necrosis factor alpha (TNF-α) prodn. in mouse splenocytes (IC50 = 0.21 nM) and in vivo anti-inflammatory activity against LPS-induced pulmonary neutrophilia in mice (41% inhibition at a dose of 1.0 mg/kg, i.t.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo66taMP2rurVg90H21EOLACvtfcHk0liGGh0S8nU5oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGnsL%252FN&md5=53de746f90ef183a3c89b36895c3fe2b</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DShiina%26aufirst%3DA.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DMizukami%26aufirst%3DK.%26aulast%3DHirahara%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DO.%26aulast%3DSogawa%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DMikkaichi%26aufirst%3DT.%26aulast%3DNakao%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25205-carbamoyl-2-phenylpyrimidine%2520derivatives%2520as%2520novel%2520and%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D7025%26epage%3D7037%26doi%3D10.1016%2Fj.bmc.2013.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkaichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span> <span> </span><span class="NLM_article-title">Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3325</span>– <span class="NLM_lpage">3328</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.03.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.bmcl.2013.03.104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3325-3328&author=T.+Gotoauthor=A.+Shiinaauthor=T.+Yoshinoauthor=K.+Mizukamiauthor=K.+Hiraharaauthor=O.+Suzukiauthor=Y.+Sogawaauthor=T.+Takahashiauthor=T.+Mikkaichiauthor=N.+Nakaoauthor=M.+Takahashiauthor=M.+Hasegawaauthor=S.+Sasaki&title=Identification+of+the+fused+bicyclic+4-amino-2-phenylpyrimidine+derivatives+as+novel+and+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2013.03.104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.104%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DShiina%26aufirst%3DA.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DMizukami%26aufirst%3DK.%26aulast%3DHirahara%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DO.%26aulast%3DSogawa%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DMikkaichi%26aufirst%3DT.%26aulast%3DNakao%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520the%2520fused%2520bicyclic%25204-amino-2-phenylpyrimidine%2520derivatives%2520as%2520novel%2520and%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3325%26epage%3D3328%26doi%3D10.1016%2Fj.bmcl.2013.03.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leriche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamiot-Clerc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feutrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derimay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grépin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1016%2Fj.bmcl.2015.11.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=26681511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=454-459&author=J.+Le+Rouxauthor=C.+Lericheauthor=P.+Chamiot-Clercauthor=J.+Feutrillauthor=F.+Halleyauthor=D.+Papinauthor=N.+Derimayauthor=C.+Muglerauthor=C.+Gr%C3%A9pinauthor=L.+Schio&title=Preparation+and+optimization+of+pyrazolo%5B1%2C5-a%5Dpyrimidines+as+new+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2015.11.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors</span></div><div class="casAuthors">Le Roux, Jacques; Leriche, Caroline; Chamiot-Clerc, Philippe; Feutrill, John; Halley, Frank; Papin, David; Derimay, Nathalie; Mugler, Christelle; Grepin, Claudine; Schio, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">454-459</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of pyrazolo[1,5-a]pyrimidines exemplified by compd. I, has been identified with moderate activity (IC50 = 165 nM), following GSK256066 rescaffolding.  Compd. I optimization at positions 2, 3, 6 and 7 gave compd. II with high in vitro activity (IC50 = 0.7 nM).  Modeling studies based on the PDB structure 3GWT with compd. III showed the expected overlay with the carboxamide, the aryl moiety and the sulfone.  Cyclization of the primary amide to the 5 position of the pyrazolo[1,5-a]pyrimidines scaffold afforded compds. IV [R = 3-MeO, 3,5-Cl] with 200-fold enhancement in activity and cellular potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmgso9aPgRr7Vg90H21EOLACvtfcHk0liPqNiDdKyGWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ&md5=962985b2b1ff0cb57e104018b75d23fa</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.093%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRoux%26aufirst%3DJ.%26aulast%3DLeriche%26aufirst%3DC.%26aulast%3DChamiot-Clerc%26aufirst%3DP.%26aulast%3DFeutrill%26aufirst%3DJ.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DPapin%26aufirst%3DD.%26aulast%3DDerimay%26aufirst%3DN.%26aulast%3DMugler%26aufirst%3DC.%26aulast%3DGr%25C3%25A9pin%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DPreparation%2520and%2520optimization%2520of%2520pyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520new%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D454%26epage%3D459%26doi%3D10.1016%2Fj.bmcl.2015.11.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amadasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surface, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyrakis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozzarelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellogg, G. E.</span></span> <span> </span><span class="NLM_article-title">Robust classification of “relevant” water molecules in putative protein binding sites</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1063</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1021/jm701023h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701023h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1063-1067&author=A.+Amadasiauthor=J.+A.+Surfaceauthor=F.+Spyrakisauthor=P.+Cozziniauthor=A.+Mozzarelliauthor=G.+E.+Kellogg&title=Robust+classification+of+%E2%80%9Crelevant%E2%80%9D+water+molecules+in+putative+protein+binding+sites&doi=10.1021%2Fjm701023h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm701023h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701023h%26sid%3Dliteratum%253Aachs%26aulast%3DAmadasi%26aufirst%3DA.%26aulast%3DSurface%26aufirst%3DJ.%2BA.%26aulast%3DSpyrakis%26aufirst%3DF.%26aulast%3DCozzini%26aufirst%3DP.%26aulast%3DMozzarelli%26aufirst%3DA.%26aulast%3DKellogg%26aufirst%3DG.%2BE.%26atitle%3DRobust%2520classification%2520of%2520%25E2%2580%259Crelevant%25E2%2580%259D%2520water%2520molecules%2520in%2520putative%2520protein%2520binding%2520sites%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1063%26epage%3D1067%26doi%3D10.1021%2Fjm701023h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span>Roflumilast. <a href="https://www.drugbank.ca/drugs/DB01656" class="extLink">https://www.drugbank.ca/drugs/DB01656</a> (accessed Jan 25, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Roflumilast.+https%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01656+%28accessed+Jan+25%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Percival, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falgueyret, J. P.</span></span> <span> </span><span class="NLM_article-title">Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A)</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>241</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1997.7542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;key=10.1006%2Fbbrc.1997.7542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=1997&pages=175-180&author=M.+D.+Percivalauthor=B.+Yehauthor=J.+P.+Falgueyret&title=Zinc+dependent+activation+of+cAMP-specific+phosphodiesterase+%28PDE4A%29&doi=10.1006%2Fbbrc.1997.7542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1997.7542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1997.7542%26sid%3Dliteratum%253Aachs%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DYeh%26aufirst%3DB.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26atitle%3DZinc%2520dependent%2520activation%2520of%2520cAMP-specific%2520phosphodiesterase%2520%2528PDE4A%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1997%26volume%3D241%26spage%3D175%26epage%3D180%26doi%3D10.1006%2Fbbrc.1997.7542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwt" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwt','PDB','3gwt'); return false;">PDB: 3gwt</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k1i" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k1i','PDB','5k1i'); return false;">PDB: 5k1i</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5kli" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5kli','PDB','5kli'); return false;">PDB: 5kli</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k32" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k32','PDB','5k32'); return false;">PDB: 5k32</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i90"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01751">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_55216"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01751">10.1021/acs.jmedchem.7b01751</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">PDE selectivity panel for compound <b>72</b>; kinase selectivity panel for compound <b>72</b>; single dose inhibition of LPS-induced lung neutrophilia in rats (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01751/suppl_file/jm7b01751_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01751/suppl_file/jm7b01751_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01751/suppl_file/jm7b01751_si_001.pdf">jm7b01751_si_001.pdf (118.43 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01751/suppl_file/jm7b01751_si_002.csv">jm7b01751_si_002.csv (6.33 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PBD ID codes: <b>3</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwt">3gwt</a>; <b>4</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k1i">5k1i</a>; <b>21</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5k32">5k32</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01751%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-6%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01751" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994e2bdaa43c04","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
